6. パーキンソン病 Disease details / Clinical trials / Drug dev / DR info

0 MG tropicamide
   NeuroHealing Pharmaceuticals Inc.
      2008   Phase 2   NCT00761137   Argentina
0.04 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.08 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.2 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.3 MG tropicamide
   NeuroHealing Pharmaceuticals Inc.
      2008   Phase 2   NCT00761137   Argentina
0.4 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.6 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.8 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
0.9% saline
   Beijing Tiantan Hospital
      2023   -   NCT05197439   China
0.9% sodium chloride
   Asubio Pharmaceuticals, Inc.
      2007   Phase 2   NCT00623363   Guatemala;Romania;United States
   Jee-Young Lee
      2011   Phase 4   NCT01313845   Korea, Republic of
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China
009-0
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-1
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-2
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-3
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-4
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-5
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
009-A0
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands
009-A1
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands
009-A2
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands
009-A3
   Alexza Pharmaceuticals, Inc.
      2019   Phase 1   NCT04157933   Netherlands
1 MG QD TO 15 MG QD PF-06649751
   Pfizer
      2017   Phase 2   NCT03185481   United States
1 MG tropicamide
   NeuroHealing Pharmaceuticals Inc.
      2008   Phase 2   NCT00761137   Argentina
1.0 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
1.0 MG rasagiline mesylate
   Teva Pharmaceutical Industries
      2000   Phase 3   NCT00203034   United States
1.2 MG LU AE04621
   H. Lundbeck A/S
      2016   Phase 1   NCT02649608   United States
11C-MC1
   National Institute of Mental Health (NIMH)
      2021   Phase 1   NCT04396873   United States
11C-PBR28
   Columbia University
      2015   Phase 2   NCT02702102   United States
11C-PIB
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
      2019   -   JPRN-UMIN000036908   Japan
   Oriental Neurosurgery Evidence-Based-Study Team
      2017   Phase 2   NCT03555292   China
11C-PS13
   National Institute of Mental Health (NIMH)
      2021   Phase 1   NCT04396873   United States
11C-raclopride
   Institute of Biomedical Research and Innovation
      2015   -   JPRN-UMIN000016485   Japan
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036952   Japan
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
11C-UCB-J
   Yale University
      2024   Phase 2   NCT06402955   United States
13N-ammonia
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
      2009   -   NCT00775853   United States
15 MG QD DE-escalated TO 7 MG QD PF-06649751 IN parent study remain AT 7 MG QD
   Pfizer
      2017   Phase 2   NCT03185481   United States
15-0 H20
   National Human Genome Research Institute (NHGRI)
      2006   -   NCT00302146   United States
150% OF their routine home dopaminergic medications dose right IN THE clinic
   Stardots AB
      2025   -   NCT06586320   United States
15O H2O
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden
18-fdtbz
   Chang Gung Memorial Hospital
      2015   Phase 2   NCT02599753   Taiwan
18F florbetaben
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain
18F- dtbz
   Chang Gung Memorial Hospital
      2012   Phase 2   NCT02039024   Taiwan
18F-AV-133
   Avid Radiopharmaceuticals
      2012   Phase 2/Phase 3   NCT01550484   Australia;United States
      2010   Phase 1/Phase 2   NCT01503944   United States
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China
18F-AV-45
   Avid Radiopharmaceuticals
      2010   Phase 1/Phase 2   NCT01503944   United States
18F-dopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
   University of Alberta
      2021   Phase 3   NCT04706910   Canada
      2017   Phase 3   NCT03042416   Canada
18F-dopa PET
   National Taiwan University Hospital
      2017   -   NCT03973502   Taiwan
18F-dopamine
   National Institute of Neurological Disorders and Stroke (NINDS)
      2018   -   NCT03648905   United States
18F-dtbz
   Chang Gung Memorial Hospital
      2013   Phase 2   NCT02059733   Taiwan
      2011   Phase 2   NCT01759888   Taiwan
      2010   Phase 2   NCT01283347   Taiwan
18F-dtbz AV-133
   Chang Gung Memorial Hospital
      2011   Phase 2   NCT01556100   -
18F-FDG
   Chang Gung Memorial Hospital
      2010   Phase 2   NCT01824056   Taiwan
   Huashan Hospital Affiliated to Fudan University
      2020   Phase 0   ChiCTR2000037856   China
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036908   Japan
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China
18F-florbetaben
   National Institute of Mental Health (NIMH)
      2021   Phase 1   NCT04396873   United States
18F-fluoro-L-dopa
   National Institute of Mental Health (NIMH)
      2002   -   NCT00024622   United States
18F-OP-801
   Ashvattha Therapeutics, Inc.
      2023   Phase 1/Phase 2   NCT05395624   United States
18F-SMBT-1
   Anhui Provincial Hospital
      2022   -   NCT06010290   China
   Cyclotron and Radioisotope Center, Tohoku University
      2022   -   JPRN-UMIN000049442   Japan
1[(6- allyl- 8ß- ERG
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
1[(6- allyl- 8ß- ergolinyl)carbonyl]- 1- [3- (dimethylamino)propyl]- 3- ethylurea
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
2 MG perampanel
   Eisai Inc.
      2006   Phase 3   NCT00368108   Canada;United States
2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-YL)-4,6-dimethylpyridine-1-oxide
   BIAL Portela & Cª, S.A.
      2011   Phase 3   EUCTR2010-022366-27-GB   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom
      2011   -   EUCTR2010-022366-27-CZ   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom
      2011   Phase 3   EUCTR2010-022366-27-BE   Belgium;Czech Republic;Estonia;United Kingdom
      2010   -   EUCTR2010-022366-27-EE   Belgium;Czech Republic;Estonia;United Kingdom
2-[[[(2R)-1-[1-[(4-chloro-3-methylphenyl)methyl]-4- piperidinyl]-5-OXO-2-pyrrolidinyl]carbonyl]amino]- N,N,6-trimethyl-4-pyridinecarboxamide,dihydrochloride
   Alkahest, Inc.
      2020   Phase 2   EUCTR2019-001657-42-SK   Estonia;Germany;Hungary;Poland;Slovakia;United States
      2019   Phase 2   EUCTR2019-001657-42-DE   Estonia;Germany;Hungary;Poland;Slovakia;United States
200 MG BIA 6-512
   Bial - Portela C S.A.
      2006   Phase 1   NCT03095105   Germany
207-3120
   Aston University
      2018   Phase 2   EUCTR2017-004297-34-GB   United Kingdom
240MG amantadine HCL ER tablets
   Adamas Pharmaceuticals, Inc.
      2014   Phase 3   NCT02153645   Canada;France;Germany;Spain;United States
25 MG BIA9 1067
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom
25 MG ongentys
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom
3 MG QD TO 15 MG QD PF-06649751
   Pfizer
      2017   Phase 2   NCT03185481   United States
3- (9,10- didehydro- 6- methyl- 8?- ergolinyl)-1,1- diethylurea hydrogenmaleate
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
3-(3,4-dihydroxyphenyl)-L-alanine
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
320MG amantadine HCL ER tablets
   Adamas Pharmaceuticals, Inc.
      2014   Phase 3   NCT02153645   Canada;France;Germany;Spain;United States
4 MG perampanel
   Eisai Inc.
      2006   Phase 3   NCT00368108   Canada;United States
5-year follow-UP DPA-714-PET/MRI
   University of Alabama at Birmingham
      2018   Phase 1/Phase 2   NCT03457493   United States
50 MG BIA 9 1067
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom
50 MG ongentys
   Bial - Portela C S.A.
      2018   Phase 1   NCT04265027   United Kingdom
6-[18F]fluorodopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2009   -   NCT00775853   United States
6-[18F]fluorodopamine
   National Institute of Neurological Disorders and Stroke (NINDS)
      2009   -   NCT00775853   United States
6Aß - apomorphine-10,11-diol hydrochloride hemihydrate
   Britannia Pharmaceuticals Limited
      2006   Phase 3   EUCTR2006-000391-32-NL   Germany;Netherlands;United Kingdom
      2006   Phase 3   EUCTR2006-000391-32-GB   Germany;Netherlands;United Kingdom
      2006   -   EUCTR2006-000391-32-DE   Germany;Netherlands;United Kingdom
7 MG QD TO 15 MG QD PF-06649751
   Pfizer
      2017   Phase 2   NCT03185481   United States
7-BETA-hydroxyepiandrosterone
   Hunter-Fleming Ltd
      2007   -   EUCTR2005-005791-32-SE   Sweden;United Kingdom
      2006   Phase 2   EUCTR2005-005791-32-GB   Sweden;United Kingdom
8-ohdg
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000019082   Japan
A-dopamine
   InBrain Pharma SAS
      2020   Phase 1;Phase 2   EUCTR2020-000155-12-FR   France
   University Hospital, Lille
      2020   Phase 1/Phase 2   NCT04332276   France
Aadipose-derived mesenchymal stem cells
   Taiwan Mitochondrion Applied Technology Co., Ltd.
      2026   Phase 1   NCT05094011   -
AAV-GAD
   MeiraGTx, LLC
      2023   Phase 1/Phase 2   NCT05894343   United States
AAV-GAD dose 1
   MeiraGTx, LLC
      2022   Phase 1/Phase 2   NCT05603312   United States
AAV-GAD dose 2
   MeiraGTx, LLC
      2022   Phase 1/Phase 2   NCT05603312   United States
AAV-haadc-2
   Genzyme, a Sanofi Company
      2004   Phase 1   NCT00229736   United States
AAV2-gdnf
   Brain Neurotherapy Bio, Inc.
      2020   Phase 1   NCT04167540   United States
AAV2-gdnf gene therapy
   AskBio Inc
      2024   Phase 2   NCT06285643   Germany;Poland;United Kingdom;United States
AB1010
   AB Science
      2015   Phase 2   EUCTR2010-024424-26-SK   Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States
ABBV-0805
   AbbVie
      2020   Phase 1   NCT04127695   Puerto Rico;United States
ABBV-951
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AbbVie
      2022   Phase 1   NCT05094050   United States
      2021   Phase 3   NCT04750226   Australia;United States
      2020   Phase 3   NCT04380142   Australia;United States
      2020   Phase 3   NCT04379050   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2019   Phase 3   NCT03781167   Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States
      2018   Phase 1   NCT03374917   United States
      2017   Phase 1   NCT03033498   United States
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
ABC
   Oregon Health and Science University
      2022   -   NCT05680597   United States
Abdominal compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
ABT-SLV187
   AbbVie
      2014   Phase 3   NCT02082249   Japan;Korea, Republic of;Taiwan
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan
   Abbott Japan Co., Ltd.
      2011   Phase 2   JPRN-jRCT2080221657   -
Acamprosate
   Baylor College of Medicine
      2006   -   NCT00640952   United States
Accordion pill carbidopa/levodopa
   Intec Pharma Ltd.
      2018   Phase 2   NCT03576638   -
Accordion pill ¿ carbidopa/levodopa 50/400 MG
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003513-24-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill ¿ carbidopa/levodopa 50/500 MG
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003513-24-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill? carbidopa/levodopa 50/400 MG
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003513-24-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill? carbidopa/levodopa 50/500 MG
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003513-24-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill¿ carbidopa/levodopa
   INTEC PHARMA LTD
      2018   Phase 2   EUCTR2018-001209-95-IT   Italy;Spain
Accordion pill™ carbidopa/levodopa
   Intec Pharma Ltd.
      2016   Phase 3   NCT02615873   Bulgaria;Germany;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   NCT02605434   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill™ carbidopa/levodopa 50/400 MG
   Intec Pharma, Ltd.
      2017   Phase 3   EUCTR2015-003513-24-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-DE   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-BG   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Accordion pill™ carbidopa/levodopa 50/500 MG
   Intec Pharma, Ltd.
      2017   Phase 3   EUCTR2015-003513-24-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-DE   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003513-24-BG   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
ACI-7104.056 AT dose A
   AC Immune SA
      2023   Phase 2   NCT06015841   Germany;Spain;United Kingdom
ACP-103
   ACADIA PHARMACEUTICALS INC.
      2009   -   EUCTR2007-003035-22-IT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
   ACADIA Pharmaceuticals Inc
      2009   Phase 3   EUCTR2007-003035-22-PT   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States
   ACADIA Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-003512-12-FR   France;Portugal;Russian Federation;Serbia
      2008   Phase 3   NCT00658567   Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden;United States
      2008   Phase 3   EUCTR2007-003035-22-GB   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States
      2007   Phase 3   NCT00550238   Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States
      2007   Phase 3   NCT00477672   Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom;United States
      2004   Phase 2   NCT01518309   United States
      2004   Phase 2   NCT00087542   United States
   Acadia Pharmaceuticals Inc
      2009   Phase 2;Phase 3   EUCTR2007-003035-22-AT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   -   EUCTR2007-003051-36-SE   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-PT   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-ES   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-BE   Austria;Belgium;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-AT   Austria;Portugal;Spain;Sweden
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-SE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-FR   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-BE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   -   EUCTR2007-002906-23-BG   Bulgaria;France;United Kingdom
      2007   -   EUCTR2007-002906-23-GB   Bulgaria;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2007-002906-23-FR   Bulgaria;France;United Kingdom
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00086294   United States
ACR325
   NeuroSearch A/S
      2009   Phase 1   NCT01023282   Germany
Actimyo recording
   Institut de Myologie, France
      2016   -   NCT02785978   France
Active comparator
   Alexza Pharmaceuticals, Inc.
      2018   Phase 1   NCT03822364   Netherlands
Active investigational treatment ENT-01
   Enterin Inc.
      2024   Phase 1   NCT03938922   United States
      2020   Phase 2   NCT04483479   United States
      2018   Phase 2   NCT03781791   United States
Active tdcs
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
Active tpcs
   Western University, Canada
      2019   -   NCT04054960   Canada
Active transcranial direct current stimulation
   Universidad Francisco de Vitoria
      2023   -   NCT06214377   Spain
Adaptor: hakko adaptor
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan
Adipose-derived stromal vascular fraction cells
   Samuel Vilchez, PhD
      2021   Phase 1/Phase 2   NCT05699161   Nicaragua
Adjuvant without active component
   Affiris AG
      2015   Phase 1   NCT02758730   Germany
      2014   Phase 1   NCT02267434   Austria
Administration OF carbidopa/levodopa
   Julien Bally
      2025   Phase 1/Phase 2   NCT06831500   Switzerland
ADS-5102
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States
      2014   Phase 3   NCT02274766   Austria;France;Germany;Spain;United States
      2014   Phase 3   NCT02202551   Austria;Canada;France;Germany;Spain;United States
      2014   Phase 3   NCT02136914   Canada;United States
      2011   Phase 2/Phase 3   NCT01397422   United States
ADX48621
   Addex Pharma S.A.
      2011   Phase 2   NCT01336088   Austria;France;Germany;United States
   Addex Pharma SA
      2011   Phase 2   EUCTR2010-022517-25-DE   Austria;France;Germany;United States
      2011   -   EUCTR2010-022517-25-AT   Austria;France;Germany;United States
Affitope® PD01A
   Affiris AG
      2016   Phase 1   NCT02618941   Austria
      2014   Phase 1   NCT02216188   Austria
      2012   Phase 1   NCT01568099   Austria
Affitope® PD01A + adjuvant
   Affiris AG
      2015   Phase 1   NCT02758730   Germany
AFQ056
   NOVARTIS FARMA
      2012   -   EUCTR2011-004378-27-IT   Austria;Canada;Germany;Hungary;Italy;Spain;United States
      2012   -   EUCTR2011-002074-23-IT   Austria;Canada;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2011   -   EUCTR2011-002073-30-IT   Canada;European Union;Germany;Italy;Spain;Switzerland;United States
      2009   -   EUCTR2008-008712-98-IT   Finland;France;Germany;Italy;Spain
   Novartis
      2009   Phase 2   NCT00986414   Australia;Canada;Finland;France;Germany;Italy;Japan;Spain
      2009   Phase 2   NCT00888004   Germany
      2007   Phase 2   NCT00582673   Germany
   Novartis Farmacéutica, S.A.
      2012   -   EUCTR2011-002074-23-ES   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
   Novartis Pharma AG
      2010   -   EUCTR2010-019418-25-FR   Finland;France;Germany;Italy
      2010   -   EUCTR2010-019418-25-FI   Finland;France;Germany;Italy
      2009   -   EUCTR2008-008712-98-FR   Finland;France;Germany;Italy;Spain
      2009   -   EUCTR2008-008712-98-FI   Finland;France;Germany;Italy;Spain
      2009   -   EUCTR2008-008712-98-DE   Finland;France;Germany;Italy;Spain
   Novartis Pharma Services AG
      2012   -   EUCTR2011-004378-27-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-004378-27-HU   Austria;Canada;France;Germany;Hungary;Italy;Spain;United States
      2012   -   EUCTR2011-004378-27-DE   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-004378-27-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-002074-23-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-002074-23-HU   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-002074-23-DE   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-002074-23-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2007   -   EUCTR2007-002900-16-DE   Germany
      -   -   EUCTR2011-002073-30-DE   Canada;France;Germany;Hungary;Italy;Spain;United States
   Novartis Pharma Sevices AG
      2010   -   EUCTR2010-019418-25-DE   Australia;Canada;Finland;France;Germany;Italy;Japan
   Novartis Pharmaceuticals
      2012   Phase 2   NCT01491932   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   Phase 2   NCT01491529   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2011   Phase 2   NCT01385592   Canada;France;Germany;Hungary;Italy;Spain;United States
      2010   Phase 2   NCT01173731   Australia;Canada;Finland;France;Germany;Italy;Spain;United States
AFQ056 with L-dopa
   Novartis
      2010   Phase 2   NCT01092065   United States
AFQ065
   Novartis Pharma AG
      2010   -   EUCTR2010-019418-25-FI   Finland;France;Germany;Italy
   Novartis Pharma Sevices AG
      2010   -   EUCTR2010-019418-25-DE   Australia;Canada;Finland;France;Germany;Italy;Japan
AGB101
   Johns Hopkins University
      2023   Phase 2   NCT05824728   United States
Agomelatine or piacebo
   Second Affiliated Hospital of Soochow University
      2019   Phase 4   NCT03977441   -
AKST4290
   Alkahest, Inc.
      2020   Phase 2   NCT04369430   Estonia;Germany;Hungary;Poland;Slovakia;United States
      2020   Phase 2   EUCTR2019-001657-42-SK   Estonia;Germany;Hungary;Poland;Slovakia;United States
      2019   Phase 2   EUCTR2019-001657-42-DE   Estonia;Germany;Hungary;Poland;Slovakia;United States
Alcoholic drink
   Medical University of Graz
      2024   -   NCT06403280   Austria
Alloex
   The Foundation for Orthopaedics and Regenerative Medicine
      2024   Phase 1   NCT05152394   Antigua and Barbuda
Allogeneic bone marrow-derived mesenchymal stem cells
   Mya Schiess
      2025   -   NCT06798064   United States
Allogeneic embryonic stem CELL-derived ventral midbrain dopaminergic progenitor cells
   Region Skåne – Skåne University Hospital
      2022   Phase 1;Phase 2   EUCTR2021-001366-38-SE   Sweden;United Kingdom
Allogenic embryonic stem CELL-derived A9 dopamine progenitor cell (A9-DPC) high dose
   S.Biomedics Co., Ltd.
      2023   Phase 1/Phase 2   NCT05887466   Korea, Republic of
Allogenic embryonic stem CELL-derived A9 dopamine progenitor cell (A9-DPC) LOW dose
   S.Biomedics Co., Ltd.
      2023   Phase 1/Phase 2   NCT05887466   Korea, Republic of
Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_high dose
   S.Biomedics Co., Ltd.
      2023   -   NCT06477744   Korea, Republic of
Allogenic embryonic stem cellderived A9 dopamine progenitor cell (A9-DPC)_low dose
   S.Biomedics Co., Ltd.
      2023   -   NCT06477744   Korea, Republic of
Allopregnanolone
   Roberta Brinton
      2024   Phase 1   NCT06263010   United States
Allopurinol
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   -
Alovudine
   Kyoto University Hospital
      2018   Phase 3   JPRN-UMIN000033565   Japan
      2018   Phase 1,2   JPRN-UMIN000033564   Japan
Alternating, 10 SEC HIGH-frequency, 10 SEC LOW-frequency stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
Alternating, 10 SEC HIGH-frequency, 50 SEC LOW-frequency stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
Alternating, 50 SEC HIGH-frequency, 10 SEC LOW-frequency stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
Alternating, 50 SEC HIGH-frequency, 50 SEC LOW-frequency stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
Altropane
   Molecular NeuroImaging
      2006   Phase 2   NCT00397228   United States
Altropane (123I) injection
   GE Healthcare
      2023   Phase 2   NCT05636852   United States
Amantadin-ratiopharm 100MG
   CHU de Toulouse
      2010   -   EUCTR2009-016143-19-AT   Austria;France
Amantadine
   Adamas Pharmaceuticals, Inc.
      2011   Phase 2/Phase 3   NCT01397422   United States
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   CHU de Toulouse
      2012   Phase 2   EUCTR2011-005201-75-FR   France
   Department of Neurology, Juntendo University School of Medicine
      2013   -   JPRN-UMIN000010596   Japan
   Northwestern University
      2011   Phase 3   NCT01652534   United States
   Rabin Medical Center
      2010   -   NCT01190553   -
      2008   Phase 2   NCT00600093   Israel
   Rush University Medical Center
      2013   Phase 2   NCT01789047   United States
      2010   Phase 4   NCT01071395   Austria;Canada;France;United States
   University Hospital, Toulouse
      2025   Phase 2   NCT06817200   France
      2012   Phase 2   NCT01538329   France
Amantadine 300 MG
   Oregon Health and Science University
      2009   -   NCT00794313   United States
Amantadine HCL ER
   Adamas Pharmaceuticals, Inc.
      2014   Phase 3   NCT02153632   Canada;France;Germany;Spain;United States
Amantadine HCL extended release
   Osmotica Pharmaceutical Corp.
      2014   -   EUCTR2014-001132-10-FR   Canada;France;Germany;Spain;United States
      2014   Phase 3   EUCTR2014-001132-10-ES   Canada;France;Germany;Spain;United States
      2014   Phase 3   EUCTR2014-001131-36-ES   Canada;France;Germany;Spain;United States
Amantadine HCL extended release capsule
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States
Amantadine hydrochloride
   Adamas Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2014-003739-20-FR   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-DE   Austria;France;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003739-20-AT   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-ES   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-DE   Austria;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-003738-24-AT   Austria;Germany;Spain;United States
   CHU de Toulouse
      2010   -   EUCTR2009-016143-19-AT   Austria;France
   Comprehensive clinical study group concerning diagnosis, treatment, and prevention of the neurological disorders
      2007   -   JPRN-UMIN000000780   Japan
   Osmotica Pharmaceutical Corp.
      2014   -   EUCTR2014-001132-10-FR   Canada;France;Germany;Spain;United States
      2014   Phase 3   EUCTR2014-001132-10-ES   Canada;France;Germany;Spain;United States
      2014   Phase 3   EUCTR2014-001131-36-ES   Canada;France;Germany;Spain;United States
Amantadine sulfate
   Jee-Young Lee
      2011   Phase 4   NCT01313845   Korea, Republic of
Ambrosan 60MG tablets
   Joint Research Office
      2016   Phase 2   EUCTR2015-002571-24-GB   United Kingdom
Ambroxol
   Lawson Health Research Institute
      2015   Phase 2   NCT02914366   Canada
   University College, London
      2016   Phase 2   NCT02941822   United Kingdom
Ambroxol cloridrato
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2022   Phase 2   EUCTR2021-004565-13-IT   Italy
Ambroxol hydrochloride
   Agyany Pharma LTD
      2023   Phase 1/Phase 2   NCT06193421   Israel
   FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
      2022   Phase 2   EUCTR2021-004565-13-IT   Italy
   Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
      2022   Phase 2   NCT05287503   Italy
   Joint Research Office
      2016   Phase 2   EUCTR2015-002571-24-GB   United Kingdom
   University College, London
      2025   Phase 3   NCT05778617   United Kingdom
   University Medical Center Groningen
      2023   Phase 2/Phase 3   NCT05830396   Netherlands
      2023   Phase 2   EUCTR2021-001833-38-NL   Netherlands
AMDX2011P
   Amydis Inc.
      2022   Phase 1/Phase 2   NCT05542576   United States
Amino acid supplement
   UConn Health
      2025   Early Phase 1   NCT06954662   United States
Amino acids
   University of Arkansas
      2025   Phase 1   NCT06604065   -
Ampreloxetine
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Theravance Biopharma
      2019   Phase 3   NCT03829657   Argentina;Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States
Ampreloxetine chydrochloride
   Theravance Biopharma Ireland Limited
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
Ampreloxetine hydrochloride
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
Anavex2-73
   Anavex Life Sciences Corp.
      2018   Phase 2   EUCTR2017-004335-36-ES   Spain
Anhydrous carbidopa
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002234-21-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-IT   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-ES   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-DE   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-CZ   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
   Oslo University Hospital
      2021   Phase 3   EUCTR2021-000541-41-DE   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
ANLE138B
   MODAG GmbH
      2020   Phase 1   NCT04685265   United Kingdom
ANPD001
   Aspen Neuroscience
      2024   Phase 1   NCT06344026   United States
ANTI-parkinson medication
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
ANTI-parkinsonian drugs
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   -
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2014   -   NCT04928079   -
ANVS401
   Annovis Bio, Inc.
      2023   Phase 3   EUCTR2022-001542-38-PL   France;Germany;Hungary;Italy;Poland;Spain;United States
      2023   Phase 3   EUCTR2022-001542-38-IT   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-HU   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-ES   France;Germany;Hungary;Italy;Poland;Spain;United States
AP-CD/LD
   Intec Pharma Ltd.
      2016   Phase 3   NCT02605434   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2012   Phase 2   NCT00947037   Israel
AP09004
   Intec Pharma Ltd.
      2009   Phase 2   NCT00918177   Israel
APL-130277
   SUNOVION PHARMACEUTICALS
      2016   Phase 2   EUCTR2016-001762-29-IT   Italy
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-000637-43-IT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
   Sunovion
      2018   Phase 3   NCT03391882   Austria;France;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   NCT03292016   United States
      2017   Phase 2   NCT03187301   Italy;United States
      2015   Phase 3   NCT02542696   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2015   Phase 3   NCT02469090   Canada;United Kingdom;United States
      2014   Phase 2   NCT02228590   United States
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-000637-43-ES   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-000637-43-AT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000637-43-GB   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
   Sunuvion Pharmaceuticals Inc
      2016   Phase 3   EUCTR2016-000636-18-GB   Canada;United Kingdom;United States
Aplindore
   Ligand Pharmaceuticals
      2008   Phase 2   NCT00623324   United States
Aplindore MR tablets
   Neurogen Corporation
      2008   Phase 2   NCT00809302   United States
APO-GO
   Britannia Pharmaceuticals Limited
      2014   Phase 3   EUCTR2013-000980-10-NL   Austria;Denmark;France;Germany;Netherlands;Spain
      2014   Phase 3   EUCTR2013-000980-10-DK   Austria;Denmark;France;Germany;Netherlands;Spain
      2013   Phase 3   EUCTR2013-000980-10-AT   Austria;Denmark;France;Germany;Netherlands;Spain
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands
   STADA Arzneimittel AG
      2014   Phase 3   EUCTR2013-000980-10-FR   Austria;Denmark;France;Germany;Netherlands;Spain
      2014   Phase 3   EUCTR2013-000980-10-ES   Austria;Denmark;France;Germany;Netherlands;Spain
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Sunovion
      2017   Phase 2   NCT03292016   United States
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
   University Medical Center Groningen
      2016   Phase 2;Phase 3   EUCTR2016-000102-11-NL   Netherlands
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands
Apoe genotype
   Douglas Scharre
      2018   -   NCT03019757   United States
Apokinon
   CHU Rennes
      2021   Phase 4   EUCTR2021-000826-89-FR   France
   CHU Toulouse
      2007   -   EUCTR2006-005318-11-FR   France
   CHU de Rennes
      2016   Phase 3   EUCTR2016-002454-20-FR   France
      2009   Phase 3   EUCTR2008-006045-10-FR   France
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
Apokyn
   MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
      2012   Phase 4   NCT01770145   United States
   Sunovion
      2017   Phase 2   NCT03292016   United States
   US WorldMeds LLC
      2016   Phase 4   NCT02549573   United States
Apomor
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
Apomorfina cloridrato
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-000637-43-IT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
Apomorp
   Sunovion Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
Apomorphine
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
   Clinique Beau Soleil
      2017   Phase 4   NCT02940912   France
   Fondation Ophtalmologique Adolphe de Rothschild
      2016   Phase 4   NCT02688465   France
   Oregon Health and Science University
      2009   Phase 2   NCT00758368   United States
      2005   Phase 2   NCT00472355   United States
   Rennes University Hospital
      2021   Phase 4   NCT04887467   France
      2017   Phase 3   NCT02864004   France
   University Hospital, Toulouse
      2007   -   NCT00524914   France
   University Medical Center Groningen
      2017   Phase 2   NCT02702076   Netherlands
      2016   Phase 2;Phase 3   EUCTR2016-000102-11-NL   Netherlands
      2015   Phase 2   NCT02230930   Netherlands
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands
Apomorphine cartridge
   Alexza Pharmaceuticals, Inc.
      2023   Phase 2   NCT05979415   United States
Apomorphine HCL injection
   Mylan Bertek Pharmaceuticals
      2001   Phase 3   NCT00200525   -
      2001   Phase 3   NCT00145171   -
      1999   Phase 2/Phase 3   NCT00200512   United Kingdom
      1999   Phase 3   NCT00142545   United States
Apomorphine hydrochloride
   Britannia Pharmaceuticals Limited
      2014   Phase 3   EUCTR2013-000980-10-NL   Austria;Denmark;France;Germany;Netherlands;Spain
      2014   Phase 3   EUCTR2013-000980-10-DK   Austria;Denmark;France;Germany;Netherlands;Spain
      2013   Phase 3   EUCTR2013-000980-10-AT   Austria;Denmark;France;Germany;Netherlands;Spain
   Britannia Pharmaceuticals Ltd.
      2014   Phase 3   NCT02006121   Austria;Denmark;France;Germany;Netherlands;Spain;United Kingdom
   Kyowa Kirin Co., Ltd.
      2007   Phase 2   NCT00610103   Japan
   STADA Arzneimittel AG
      2014   Phase 3   EUCTR2013-000980-10-FR   Austria;Denmark;France;Germany;Netherlands;Spain
      2014   Phase 3   EUCTR2013-000980-10-ES   Austria;Denmark;France;Germany;Netherlands;Spain
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-000637-43-IT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-000637-43-ES   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2016-000637-43-AT   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
      2016   Phase 3   EUCTR2016-000637-43-GB   Austria;Canada;France;Germany;Italy;Spain;United Kingdom;United States
   Sunuvion Pharmaceuticals Inc
      2016   Phase 3   EUCTR2016-000636-18-GB   Canada;United Kingdom;United States
   Vectura Group plc
      2006   Phase 2   EUCTR2006-005509-79-GB   United Kingdom
      2006   Phase 2   EUCTR2006-004582-33-GB   United Kingdom
      2005   Phase 2   EUCTR2005-005120-13-GB   United Kingdom
Apomorphine hydrochloride 1.8MG inhalation powder, PRE-dispensed
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom
Apomorphine hydrochloride 2.8MG inhalation powder, PRE-dispensed
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom
Apomorphine hydrochloride 4.0 MG inhalation powder, PRE-dispensed
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom
Apomorphine hydrochloride 5.8 MG inhalation powder, PRE-dispensed
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom
Apomorphine hydrochloride hemihydrate
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands
Apomorphine hydrocloride hemihydrate
   SUNOVION PHARMACEUTICALS
      2016   Phase 2   EUCTR2016-001762-29-IT   Italy
Apomorphine infusion
   MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
      2015   Phase 3   NCT02339064   United States
   University Hospital, Toulouse
      2024   -   NCT06080399   France
Apomorphine injectable solution
   University of Calgary
      2022   Phase 2/Phase 3   NCT04879134   Canada
   University of Texas Southwestern Medical Center
      2022   -   NCT04957095   United States
Apomorphine nasal powder
   Britannia Pharmaceuticals Limited
      2006   Phase 3   EUCTR2006-000391-32-NL   Germany;Netherlands;United Kingdom
      2006   Phase 3   EUCTR2006-000391-32-GB   Germany;Netherlands;United Kingdom
      2006   -   EUCTR2006-000391-32-DE   Germany;Netherlands;United Kingdom
   Britannia Pharmaceuticals Ltd.
      2006   Phase 2/Phase 3   NCT00346827   -
Apomorphine pump
   University Hospital, Rouen
      2020   -   NCT05331573   France
Aporon
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands
AQW051
   NOVARTIS FARMA
      2012   -   EUCTR2011-001092-39-IT   Germany;Italy;United States
   Novartis Pharma Services AG
      2011   -   EUCTR2011-001092-39-DE   France;Germany;Italy;United States
   Novartis Pharmaceuticals
      2011   Phase 2   NCT01474421   France;Germany;Italy;United States
Aricept
   Eisai Limited
      2002   Phase 3   NCT00165815   Germany;Ireland
   Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
      2023   Phase 2   EUCTR2022-001751-17-ES   Spain
   University of Virginia
      2024   Phase 2   NCT06903910   United States
Aricept 5 MG-filmtabletten
   Eisai Limited
      2004   -   EUCTR2004-003355-39-AT   Austria
Aricept 5MG-filmtabletten
   Eisai Limited
      2004   -   EUCTR2004-003355-39-AT   Austria
Aripiprazole
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2003   Phase 4   NCT00095810   United States
Armodafinil
   NYU Langone Health
      2011   -   NCT01256905   United States
AS2
   University College London
      2015   Phase 2   EUCTR2014-002697-37-GB   United Kingdom
Assessment during THE transition between OFF-levodopa (I.E. withdrawal OF levodopa phase) and ON-levodopa (I.E. effect OF levodopa phase)states
   University Hospital, Geneva
      2023   -   NCT06301282   Switzerland
Assessment OF cognition
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Assessment OF depression
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Assessment OF motor and NON-motors symptoms OF PD evaluation OF hyper- and hypodopaminergic behaviors
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Assessment OF quality OF life
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Assessment OF severity OF parkinson disease
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Assessments IN ON and OFF levodopa state
   University Hospital, Geneva
      2023   -   NCT06225869   Switzerland
Asyn MAB
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2020-004997-23-LU   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-PL   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States
ATH-1017
   Athira Pharma
      2022   Phase 2   NCT04831281   United States
ATM FOG IN PD
   Medical University of South Carolina
      2013   Phase 3   NCT03651856   United States
Atomoxetine
   Hubert Fernandez
      2016   Early Phase 1   NCT02879136   United States
   Johns Hopkins University
      2005   -   NCT00286949   United States
   Medical University of South Carolina
      2012   Phase 2   NCT01738191   United States
   University of Pennsylvania
      2004   Phase 4   NCT00304161   United States
Atypical antipsychotics
   Pontifical Catholic University of Argentina
      2015   -   NCT02409823   -
Autologous dopaminergic cell implantation
   Jeffrey S. Schweitzer, MD, PhD
      2025   Phase 1   NCT06687837   United States
Autologous induced neural stem CELL-derived DA precursor cells
   Xuanwu Hospital, Beijing
      2023   Phase 1   NCT05901818   China
Autologous mesenchymal stem cells
   Apeiron Research Center
      2025   Phase 1/Phase 2   NCT06858254   -
   Belarusian Medical Academy of Post-Graduate Education
      2017   Phase 2/Phase 3   NCT04146519   Belarus
Autologous midbrain dopamine neurons
   Penelope J. Hallett, Ph.D.
      2024   Phase 1   NCT06422208   United States
Autonomic testing ON and OFF levodopa
   University of Utah
      2022   Phase 2/Phase 3   NCT05487300   United States
AV-101
   VistaGen Therapeutics, Inc.
      2022   Phase 2   NCT04147949   -
AV1451 TAU
   Mayo Clinic
      2020   -   NCT04680130   United States
AVE8112
   Michael J. Fox Foundation for Parkinson's Research
      2013   Phase 1   NCT01803945   United States
AVP-923
   Avanir Pharmaceuticals
      2003   Phase 3   NCT00056524   United States
AVP-923-45
   Avanir Pharmaceuticals
      2013   Phase 2   NCT01767129   Canada;United States
Azathioprine
   Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
      2019   Phase 2   EUCTR2018-003089-14-GB   United Kingdom
AZD0328
   King's College London
      2022   Phase 2   NCT04810104   Norway
AZD3241 300 MG BID
   AstraZeneca
      2012   Phase 2   NCT01603069   United States
AZD3241 600 MG BID
   AstraZeneca
      2012   Phase 2   NCT01603069   United States
AZD3241 alternative titration scheme with formulation 1 or 2
   AstraZeneca
      2011   Phase 1   NCT01457807   United Kingdom
AZD3241 ER formulation 1
   AstraZeneca
      2011   Phase 1   NCT01457807   United Kingdom
AZD3241 extended release tablets 100 MG
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden
AZD3241 extended release tablets 25 MG
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden
Azilect
   Dresden University of Technology
      2011   -   EUCTR2010-023756-82-DE   Germany
   H. Lundbeck A/S
      2011   Phase 3   NCT01479530   China
      2011   Phase 3   NCT01268891   Korea, Republic of
   Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
      2007   -   EUCTR2007-004400-12-ES   Spain
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Technische Universität Dresden
      2009   -   EUCTR2008-005085-30-DE   Germany
   Teva Pharma GmbH
      2014   -   NCT02384512   Germany
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-011541-24-PT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-NL   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-IT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-HU   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-GB   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
      2009   Phase 4   EUCTR2009-011541-24-FR   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-DE   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
   Teva Pharmaceuticals Industries LtD
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
   University Hospital, Clermont-Ferrand
      2013   Phase 4   NCT01765257   France
   University of British Columbia
      2013   -   NCT02207387   Canada
Azilect 1 MG comprimidos
   Teva Pharmaceutical Industries Ltd
      2009   Phase 4   EUCTR2009-011541-24-ES   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Azilect 1MG
   Technische Universität Dresden
      2009   Phase 4   NCT00902941   Germany
B-STN DBS
   Vanderbilt University Medical Center
      2006   -   NCT00282152   United States
B6, B12, L-methylfolate
   North Shore Long Island Jewish Health System
      2006   -   NCT00853879   United States
Bacillus coagulans
   Jiujiang University Affiliated Hospital
      2023   Phase 2   ChiCTR2400087265   China
Bacillus licheniformis
   Beijing Friendship Hospital affiliated to Capital Medical University
      2018   -   ChiCTR1800014830   China
   Beijing Friendship Hospital, Capital Medical University
      2020   Phase 0   ChiCTR2200065638   China
      2017   Phase 0   ChiCTR2200066482   China
Bacillus subtilis
   University of Edinburgh
      2023   -   NCT06487975   Norway;United Kingdom
Balance & strengthening exercises
   Boston University Charles River Campus
      2011   -   NCT02302144   United States
Balance and strengthening exercises
   Istanbul University-Cerrahpasa
      2022   -   NCT05621642   -
Balance exercise
   Domen Kazuhisa
      2018   -   JPRN-jRCTs052180158   -
   Juntendo University
      2015   -   JPRN-UMIN000016591   Japan
   University of Pavia
      2014   -   NCT03314597   -
Balance training
   Alagumoorthi Gandhisubramanian
      2018   -   ChiCTR2200057135   India
   Gansu Provincial Hospital
      2020   Phase 0   ChiCTR2000035872   China
   Hyogo College of Medicine
      2018   -   JPRN-UMIN000033454   Japan
   National Taiwan University Hospital
      2007   Phase 1   NCT01301651   Taiwan
   Rehabilitation Institute of Chicago
      2010   -   NCT01228851   United States
   Shanghai University of Sport
      2020   -   ChiCTR2000038852   china
   University of Kiel
      2011   -   NCT02253563   -
   University of Sao Paulo General Hospital
      2015   -   NCT02488265   Brazil
Barium
   National Center of Neurology and Psychiatry
      2023   -   JPRN-UMIN000051942   Japan
      2023   -   JPRN-UMIN000051163   Japan
Bavisant dihydrochloride monohydrate
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
Bavisant hydrochloride monohydrate
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
Beam test TO predict falls
   University Medical Center Groningen
      2018   -   NCT03532984   Brazil;Germany;Hungary;Japan;Netherlands
BEE venom
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01341431   France
Befiradol
   Neurolixis SAS
      2021   Phase 2   EUCTR2020-006053-22-SE   Sweden
Bemdaneprocel
   BlueRock Therapeutics
      2025   Phase 3   NCT06944522   United States
BEN-2001
   BenevolentAI Bio
      2017   Phase 2   NCT03194217   United States
Benserazide
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal
      2011   Phase 3   NCT01227655   Portugal
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
   Universitätsklinik für Neurologie Innsbruck
      2010   -   EUCTR2010-019354-40-AT   Austria
Benserazide hydrochloride
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
Benzodiazepine
   The First Affiliated Hospital, Sun Yat-sen University
      2025   -   ChiCTR2400094616   China
Berachin
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
Berg balance scale
   Gazi University
      2018   -   NCT03587168   Turkey
Best medical treatment
   German Parkinson Study Group (GPS)
      2006   Phase 4   NCT00354133   France;Germany
   InSightec
      2024   -   NCT06584383   Germany;Spain
   Rennes University Hospital
      2017   Phase 3   NCT02864004   France
Best medical treatment (BMT): adjustment OF THE dopaminergic medication and NON-dopaminergic therapy customized FOR each patient according TO THE latest published consensus group recommendations
   University of Kiel
      2024   -   NCT06498349   Germany;Netherlands;Switzerland
Best medical treatment FOR management OF impulse control IN parkinson´S disease according TO widely accepted expert consensus paper
   Steffen Paschen
      2024   -   NCT06561919   Germany;Netherlands;Switzerland
Best Médical treatment
   Poitiers University Hospital
      2011   Phase 2   NCT01291537   France
Betaquik MCT supplement
   Université de Sherbrooke
      2022   -   NCT04322461   Canada
BF 2.649
   Bioprojet
      2007   Phase 2   EUCTR2007-003512-57-FR   France
BF 2.649 10 MG
   Bioprojet
      2007   Phase 2   NCT00642928   France
BF 2.649 20 MG
   Bioprojet
      2007   Phase 2   NCT00642928   France
BF 2.649 40 MG
   Bioprojet
      2007   Phase 2   NCT00642928   France
BF 2.649 5 MG
   Bioprojet
      2007   Phase 2   NCT00642928   France
BF2.649
   BIOPROJET
      2010   -   EUCTR2009-013886-24-SE   Czech Republic;Germany;Sweden
      2010   -   EUCTR2009-013886-24-DE   Czech Republic;Germany;Sweden
      2009   -   EUCTR2009-013886-24-CZ   Czech Republic;Germany;Sweden
      2009   Phase 3   EUCTR2009-013885-14-FR   France;Spain
      2009   Phase 3   EUCTR2009-013885-14-ES   France;Spain
   Bioprojet
      2010   Phase 3   NCT01066442   Germany
      2009   Phase 3   NCT01036139   France
BHV-8000
   Biohaven Therapeutics Ltd.
      2025   Phase 2/Phase 3   NCT06976268   -
BIA
   Bial - Portela & Ca, S.A.
      2020   Phase 4   EUCTR2020-001175-32-GB   Germany;Italy;Portugal;Spain;United Kingdom
BIA 28-6156 10 MG
   Bial R&D Investments, S.A.
      2023   Phase 2   NCT05819359   Canada;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
BIA 28-6156 60 MG
   Bial R&D Investments, S.A.
      2023   Phase 2   NCT05819359   Canada;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States
BIA 3-202
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal
   Bial - Portela C S.A.
      2006   Phase 1   NCT02772614   Switzerland
      2005   Phase 2   NCT02834507   -
      2005   Phase 1   NCT02778594   Portugal
      2005   Phase 1   NCT02774564   Portugal
      2001   Phase 1   NCT02763852   Portugal
      2001   Phase 1   NCT02763839   Portugal
      2000   Phase 1   NCT02763800   United Kingdom
      2000   Phase 1   NCT02763787   United Kingdom
BIA 6-512
   Bial - Portela C S.A.
      2006   Phase 1   NCT03097211   Portugal
      2006   Phase 1   NCT03094156   Portugal
      2005   Phase 1   NCT03093389   Portugal
BIA 6-512 100 MG
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091868   Portugal
BIA 6-512 100 MG dose
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal
BIA 6-512 200 MG dose
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal
BIA 6-512 25 MG
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091868   Portugal
BIA 6-512 25 MG dose
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal
BIA 6-512 400 MG
   Bial - Portela C S.A.
      2005   Phase 1   NCT03095092   Portugal
BIA 6-512 50 MG dose
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal
BIA 9-1067
   BIAL - PORTELA & Cª, S.A.
      2011   -   EUCTR2010-021860-13-IT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain
   BIAL - Portela & Ca, S.A.
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2010   -   EUCTR2010-021860-13-LT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
   BIAL Portela & Cª, S.A.
      2011   Phase 3   EUCTR2010-022366-27-GB   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom
      2011   -   EUCTR2010-022366-27-CZ   Argentina;Australia;Belgium;Chile;Czech Republic;Estonia;India;Israel;Korea, Republic of;Russian Federation;South Africa;United Kingdom
      2011   Phase 3   EUCTR2010-022366-27-BE   Belgium;Czech Republic;Estonia;United Kingdom
      2010   -   EUCTR2010-022366-27-EE   Belgium;Czech Republic;Estonia;United Kingdom
   BIAL – Portela & Cª, S.A.
      2021   Phase 3   EUCTR2020-005011-52-PT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-FR   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-CZ   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BG   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BE   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
   BIAL-Portela & Ca, S.A.
      2021   Phase 3   EUCTR2020-005011-52-IT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
      2020   Phase 4   EUCTR2020-001175-32-IT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
   Bial - Portela & Ca, S.A.
      2023   Phase 3   EUCTR2020-001175-32-PL   Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-001175-32-CZ   Czech Republic;Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-001176-15-PT   Germany;Portugal
      2021   Phase 4   EUCTR2020-001176-15-DE   Germany;Portugal
      2021   Phase 4   EUCTR2020-001175-32-PT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal
   Bial - Portela C S.A.
      2019   Phase 1   NCT03820037   United Kingdom
      2017   Phase 1   NCT03119194   United Kingdom
      2016   Phase 4   NCT02847442   Germany
      2014   Phase 1   NCT02305030   -
      2014   Phase 1   NCT02305017   -
      2011   Phase 1   NCT02170376   France
      2011   Phase 3   NCT01568073   Austria;Portugal
      2011   Phase 1   NCT01520987   United States
      2011   Phase 3   NCT01227655   Portugal
      2010   Phase 1   NCT02101190   France;Russian Federation
      2010   Phase 2   NCT01568047   Romania;Ukraine
      2010   Phase 1   NCT01532115   France
      2009   Phase 1   NCT02169466   Portugal
      2009   Phase 1   NCT02169440   Portugal
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine
      2009   Phase 1   NCT01536366   Portugal
      2009   Phase 1   NCT01533116   Canada
      2009   Phase 1   NCT01533077   Canada
      2009   Phase 1   NCT01532141   France
      2009   Phase 1   NCT01532128   France
      2009   Phase 1   NCT01515891   Switzerland
      2008   Phase 1   NCT02169895   Canada
      2008   Phase 1   NCT02169479   Canada
      2008   Phase 1   NCT02169453   Canada
      2008   Phase 1   NCT02092168   France
      2008   Phase 1   NCT02071810   France
      2007   Phase 1   NCT01520727   France
BIA 9-1067 15 MG
   Bial - Portela C S.A.
      2009   Phase 1   NCT01519284   Portugal
BIA 9-1067 25 MG
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France
BIA 9-1067 30 MG
   Bial - Portela C S.A.
      2009   Phase 1   NCT01519284   Portugal
BIA 9-1067 5 MG
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France
      2009   Phase 1   NCT01519284   Portugal
BIA 9-1067 micronized
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305316   -
BIA 9-1067 NON-micronized
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305316   -
Bifidobacterium
   Weihai Municipal Hospital
      2018   -   ChiCTR1800016977   China
BIIB014
   BIOGEN IDEC LTD
      2006   Phase 2   EUCTR2006-003490-27-GB   United Kingdom
   Biogen
      2004   Phase 2   NCT00451815   -
   Biogen Idec
      2007   Phase 2   NCT00442780   Former Serbia and Montenegro;Israel;Poland;Serbia
      2007   Phase 2   NCT00438607   India;Israel;United Kingdom
BIIB054
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-004610-95-IT   Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
   Biogen
      2019   Phase 1   NCT03716570   Japan
      2018   Phase 2   NCT03318523   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2015   Phase 1   NCT02459886   United States
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-004610-95-GB   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-FR   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-ES   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-DE   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-AT   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
BIIB094
   Biogen
      2019   Phase 1   NCT03976349   Canada;Israel;Norway;Spain;United Kingdom;United States
BIIB122
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2022-000747-77-IT   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-IT   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Biogen
      2022   Phase 3   NCT05418673   France;Germany;Italy;Spain;United Kingdom;United States
      2022   Phase 2   NCT05348785   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Biogen Idec Research Limited
      2023   Phase 2   EUCTR2021-004849-20-DE   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000747-77-ES   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000747-77-DE   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000747-77-BE   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-PL   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-NL   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-FR   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-AT   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
BIIB122 225 MG
   Denali Therapeutics Inc.
      2024   Phase 2   NCT06602193   Germany;Spain;United States
Bilateral high frequency deep brain stimulation OF THE subthalamic neucleus combined with best medical treatment according TO widely accepted expert consensus paper
   Steffen Paschen
      2024   -   NCT06561919   Germany;Netherlands;Switzerland
Bilateral high frequency deep brainstimulation OF THE subthalamic nucleus combined with best medical treatment
   University of Kiel
      2024   -   NCT06498349   Germany;Netherlands;Switzerland
Bilateral surgical infusion OF AAV-GAD into THE subthalamic nucleus
   Neurologix, Inc.
      2008   Phase 2   NCT00643890   United States
Biodex balance system
   Kirsehir Ahi Evran Universitesi
      2024   -   NCT06272838   Turkey
Biofluid samplings
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States
Biological/vaccine: allogeneic HB-admscs
   Hope Biosciences Stem Cell Research Foundation
      2021   Phase 2   NCT04995081   United States
Biomarker identification IN parkinson disease
   Neuromed IRCCS
      2019   -   NCT03466723   Italy
Bisphosphonates
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   Phase 3   EUCTR2010-018904-94-IT   Italy
Blood analysis
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Blood draw
   North Shore Long Island Jewish Health System
      2008   -   NCT00855556   United States
Blood sampling and DNA collection
   Assistance Publique - Hôpitaux de Paris
      2011   -   NCT02319395   France
BMS-9894923
   Allyx Therapeutics
      2024   Phase 1   NCT06309147   United States
Bone marrow derived mesenchymal stem cells
   Guangzhou General Hospital of Guangzhou Military Command
      2011   Phase 1/Phase 2   NCT01446614   China
BONT-A
   Western University, Canada
      2011   Phase 2   NCT02427646   -
Botox
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2011   -   EUCTR2009-017412-32-IT   Italy
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China
Botulinum toxin
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2011   -   EUCTR2009-017412-32-IT   Italy
   Rabin Medical Center
      2009   Phase 1   NCT00767546   -
   University Health Network, Toronto
      2014   Phase 4   NCT02472210   -
Botulinum toxin type A
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
   University of Calgary
      2021   Phase 2/Phase 3   NCT04277247   Canada
   University of Cincinnati
      2007   Phase 4   NCT00477802   United States
   Western University, Canada
      2016   Phase 2   NCT02668497   Canada
Botulinum toxin type A injection
   Centro Hospitalar de Lisboa Central
      2024   -   NCT06094309   Portugal
Botulinum toxin type B
   Solstice Neurosciences
      2007   Phase 2   NCT00515437   United States
Botulinum toxin: xeomin
   University Hospital, Clermont-Ferrand
      2009   Phase 3   NCT00909883   France
Brain mpet
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT02869945   France
Brain MRI with resting state scan
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT02869945   France
Breathing exercises
   Istanbul University-Cerrahpasa
      2022   -   NCT05621642   -
Brintellix - 20 MG/ML - gocce orali, soluzione - USO orale - flacone (vetro) 15 ML - 1 flacone
   IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
      -   Phase 4   EUCTR2018-004112-21-IT   Italy
Brisk walking and balance training
   The Hong Kong Polytechnic University
      2018   -   NCT04048291   Hong Kong
Bromocriptine
   Boehringer Ingelheim
      2003   Phase 3   NCT00240409   China
      1999   Phase 3   NCT02172573   -
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Sandoz
      2012   Phase 4   NCT01673724   Korea, Republic of
Bromocriptine and other dopamine agonists
   Boehringer Ingelheim
      1998   Phase 4   NCT02233023   -
BTRX-246040
   BlackThorn Therapeutics, Inc.
      2018   Phase 2   NCT03608371   United States
BTX-A
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China
Bumetanide white, oblong, scored tablet
   B&A Therapeutics
      2019   Phase 2   NCT03899324   France
Buntanetap
   Annovis Bio, Inc.
      2023   Phase 3   EUCTR2022-001542-38-PL   France;Germany;Hungary;Italy;Poland;Spain;United States
      2023   Phase 3   EUCTR2022-001542-38-IT   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-HU   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-ES   France;Germany;Hungary;Italy;Poland;Spain;United States
Buntanetap/posiphen
   Annovis Bio Inc.
      2022   Phase 3   NCT05357989   Germany;Hungary;Italy;Poland;Spain;United States
Bupleurum+ginkgo
   Xuanwu Hospital, Beijing
      2008   Phase 2   NCT01416818   China
Buspirone
   Oregon Health and Science University
      2016   Phase 1   NCT02589340   United States
   University of Rochester
      2016   Phase 2   NCT02803749   United States
Buspirone cloridrato
   Contera Pharma
      2023   Phase 2   EUCTR2022-002818-16-IT   France;Germany;Italy;Korea, Republic of;Spain
Buspirone hydrochloride
   Contera Pharma
      2023   Phase 2   EUCTR2022-002818-16-IT   France;Germany;Italy;Korea, Republic of;Spain
      2020   Phase 2   EUCTR2017-003415-19-IT   France;Germany;Italy;Spain
      2018   Phase 2   EUCTR2017-003415-19-ES   France;Germany;Spain
   Contera Pharma A/S
      2023   Phase 2   EUCTR2017-003415-19-SK   France;Germany;Italy;Korea, Republic of;Slovakia;Spain
      2022   Phase 2   EUCTR2022-002818-16-FR   France;Germany;Italy;Korea, Republic of;Spain
   Imperial College London-Imperial College Healthcare NHS Trust
      2015   Phase 4   EUCTR2014-005422-35-GB   United Kingdom
Butylphthalide
   The Second Affiliated Hospital of Soochow University
      2016   -   ChiCTR-IPR-16009395   China
   Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
      2018   Phase 4   ChiCTR1800017084   China
   Zhujiang Hospital of Southern Medical University
      2019   Phase 0   ChiCTR1900023725   China
Bydureon
   University College London
      2014   Phase 2   EUCTR2013-003363-64-GB   United Kingdom
   University College London Comprehensive Clinical Trial Unit
      2019   Phase 3   EUCTR2018-003028-35-GB   United Kingdom
   University College, London
      2020   Phase 3   NCT04232969   United Kingdom
Bydureon 2 MG powder and solvent FOR prolonged-release suspension
   Stockholm Health Care Services
      2019   Phase 2   EUCTR2019-000732-26-SE   Sweden
Byetta 5 micrograms
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom
C-11 ER176
   Mayo Clinic
      2020   -   NCT04680130   United States
C-11 PIB
   Mayo Clinic
      2020   -   NCT04680130   United States
C11-SY08
   Massachusetts General Hospital
      2024   Early Phase 1   NCT06098612   United States
Cabaser
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
Cabaseril
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
Cabaseril, 1,0 MG tablette
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Cabaseril, 2,0 MG tablette
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Cabergolina
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
Cabergoline
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
   Pfizer
      2004   Phase 4   NCT00174239   Australia;Italy;Spain;United Kingdom
   Technische Universität Dresden
      2005   Phase 4   NCT00153972   Germany
CADD-legacy ambulatory infusion pump
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
CADD-legacy® 1400 ambulatory infusion pump
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan
      2009   Phase 3   NCT00660673   Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States
      2009   Phase 3   NCT00357994   Germany;United States
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2006   Phase 4   NCT00141518   Norway;Sweden
Caffeine
   Department of Neurology, Juntendo University
      2016   -   JPRN-UMIN000022187   Japan
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan
   McGill University Health Center
      2014   Phase 3   NCT01738178   Brazil;Canada
Caffeine 100-200 MG BID
   Ron Postuma
      2007   Phase 2/Phase 3   NCT00459420   Canada
Caffeine alkaloid
   Ron Postuma
      2010   Phase 2   NCT01190735   Canada
Calcium
   VA Office of Research and Development
      2011   Phase 2   NCT01119131   United States
Cannabidiol
   King's College London
      2020   Phase 2   EUCTR2019-003623-37-GB   United Kingdom
   University of Colorado, Denver
      2018   Phase 2   NCT03582137   United States
      2016   Phase 2   NCT02818777   United States
Cannabidiol 100 MG/ML
   Laboratorio Elea Phoenix S.A.
      2024   Phase 2   NCT06629389   Argentina
Cannabidiol 300 MG/ML
   Laboratorio Elea Phoenix S.A.
      2024   Phase 2   NCT06629389   Argentina
Cannabidiol 400 MG/ML
   Laboratorio Elea Phoenix S.A.
      2024   Phase 2   NCT06629389   Argentina
Cannabis OIL
   University Health Network, Toronto
      2018   Phase 2   NCT03639064   -
Cannabis, medical
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States
Capsaicin
   University of Florida
      2017   -   NCT03321019   United States
      2014   Phase 1/Phase 2   NCT02183519   United States
Capsaicin vapor
   University of Florida
      2015   Phase 1   NCT02390089   United States
Carbamazepine
   Cerevel Therapeutics, LLC
      2022   Phase 1   NCT05581823   United States
Carbidopa
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal
      2011   Phase 3   NCT01227655   Portugal
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan
   Kyoto University
      2017   Phase 1,2   JPRN-UMIN000030084   Japan
   Kyoto University Hospital
      2018   Phase 3   JPRN-UMIN000033565   Japan
      2018   Phase 1,2   JPRN-UMIN000033564   Japan
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States
      2007   Phase 1   NCT00505843   United States
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States
      2011   Phase 1/Phase 2   NCT01229332   Israel
   Novartis
      2005   Phase 3   NCT00134966   Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States
   Oregon Health and Science University
      2009   Phase 2   NCT01399905   United States
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01296464   Finland;Sweden
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden
      2005   -   EUCTR2005-002654-21-SE   Sweden
   SynAgile Corporation
      2021   Phase 2   EUCTR2020-003372-41-IT   Italy;Luxembourg;Spain
      2021   Phase 1;Phase 2   EUCTR2020-003372-41-ES   Italy;Luxembourg;Spain
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy
   Vanderbilt University Medical Center
      2017   Phase 4   NCT03115827   United States
   XenoPort, Inc.
      2010   Phase 2   NCT01171313   United States
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   -
Carbidopa 20 MG
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
Carbidopa 200MG oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States
Carbidopa 25/levodopa 100MG TAB
   David Escobar
      2023   Phase 4   NCT06013956   United States
Carbidopa 27.5 MG
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
Carbidopa 65 MG capsule
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
Carbidopa and levodopa controlled release tablets
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04952194   China
Carbidopa and levodopa tablets, USP
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
Carbidopa anidra
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
Carbidopa INN
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
Carbidopa levodopa
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   Neurocrine Biosciences
      2018   Phase 1   NCT03496870   United States
Carbidopa monohydrate
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2016-001403-23-IT   European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-001403-23-HU   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-GR   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-FI   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2014-004865-26-GR   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-001403-23-SK   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2016   Phase 3   EUCTR2016-001403-23-ES   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2015   Phase 3   EUCTR2014-004865-26-SE   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2015   Phase 3   EUCTR2014-004865-26-IT   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-ES   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-DE   Australia;Canada;European Union;Germany;Italy;Spain;Sweden
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2009   Phase 3   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands
   Civitas Therapeutics, Inc.
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
Carbidopa pill
   XenoPort, Inc.
      2009   Phase 1/Phase 2   NCT00914602   United States
Carbidopa, levodopa, entacapone
   Novartis
      2005   Phase 4   NCT00143026   Australia;Philippines;Taiwan;Thailand
Carbidopa- levodopa
   Oregon Health and Science University
      2008   Phase 2   NCT00745277   United States
Carbidopa-4'-monophosphate
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
Carbidopa-levodopa
   Baylor College of Medicine
      2006   Phase 4   NCT00590122   United States
   Mostafa Bahaa
      2023   Phase 2   NCT05962957   Egypt
   Northwestern University
      2011   -   NCT01528592   United States
   Oregon Health and Science University
      2008   Phase 2   NCT00745277   United States
Carbidopa-levodopa 25 MG-100 MG oral tablet
   Western University, Canada
      2021   -   NCT04590612   -
Carbidopa/L-dopa/entacapone
   Molecular NeuroImaging
      2004   Phase 2   NCT00200447   -
Carbidopa/levodopa
   Acorda Therapeutics
      2012   Phase 2   NCT01617135   Israel;Serbia;United Kingdom
   Bristol-Myers Squibb
      2007   -   NCT00460954   Canada
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
Carbidopa/levodopa, AS prescribed BY treating physician
   University of Michigan
      2020   -   NCT04821830   United States
Carbidopa/levodopa, immediate release
   Intec Pharma Ltd.
      2009   Phase 2   NCT00918177   Israel
Carbidopa/levodopa/entacapone
   Novartis
      2008   Phase 4   NCT00642356   United States
   Novartis Pharmaceuticals
      2008   Phase 4   NCT00601978   United States
      2005   Phase 4   NCT00219284   Puerto Rico;United States
      2004   Phase 3   NCT00099268   Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Carbidopamonohydraat
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands
Carbodopa levadopa
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
Carbodopa/levadopa
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
Carbon
   Hospices Civils de Lyon
      2019   -   NCT03970239   France
   University of Texas Southwestern Medical Center
      2016   -   NCT03192046   United States
Carbon-14 BIA 28-6156
   Bial R&D Investments, S.A.
      2021   Phase 1   NCT05220072   United Kingdom
Cardiac monitoring
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
Carnosine supplementation
   Slovak Academy of Sciences
      2017   -   NCT03330470   Slovakia;Taiwan
Carvedilol
   Cedars-Sinai Medical Center
      2019   Phase 2   NCT04218968   United States
   Michele Tagliati, MD
      2019   Phase 2   NCT03775096   United States
Catapres ampoules
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom
CBD
   King's College London
      2020   Phase 2   EUCTR2019-003623-37-GB   United Kingdom
CBT and sleep hygiene
   McGill University Health Center
      2011   Phase 0   NCT01489982   Canada
CD-LD CR
   Impax Laboratories, LLC
      2006   Phase 2   NCT00279825   United States
CD-LD IR
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States
      2006   Phase 2   NCT00279825   United States
      2005   Phase 2   NCT00253084   United States
Cdnf
   Herantis Pharma Plc
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-SE   Finland;Sweden
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-FI   Finland;Sweden
      2017   Phase 1;Phase 2   EUCTR2015-004175-73-FI   Finland
   Renishaw Neuro Solutions Ltd.
      2019   Phase 1;Phase 2   EUCTR2017-005170-19-FI   Finland;Sweden
      2018   Phase 1;Phase 2   EUCTR2017-005170-19-SE   Finland;Sweden
Ceftriaxone
   BrainX Corporation
      2019   Phase 2   NCT03413384   Taiwan
Celecoxib 200MG
   Mostafa Bahaa
      2023   Phase 2   NCT05962957   Egypt
CEP-1347 10MG
   Cephalon
      2002   Phase 2/Phase 3   NCT00040404   Canada;Puerto Rico;United States
CEP-1347 50MG
   Cephalon
      2002   Phase 2/Phase 3   NCT00040404   Canada;Puerto Rico;United States
CEP1347 25MG
   Cephalon
      2002   Phase 2/Phase 3   NCT00040404   Canada;Puerto Rico;United States
CERE-120
   Ceregene Inc.
      2008   -   EUCTR2007-006721-27-GB   United Kingdom
      2008   -   EUCTR2007-006721-27-AT   Austria;United Kingdom
   Sangamo Therapeutics
      2006   Phase 2   NCT00400634   United States
CERE-120: AAV2-NTN
   Sangamo Therapeutics
      2005   Phase 1   NCT00252850   United States
CERE-120: adeno-associated virus delivery OF neurturin
   Sangamo Therapeutics
      2009   Phase 1/Phase 2   NCT00985517   United States
Cerebral dopamine neurotrophic factor
   Herantis Pharma Plc.
      2018   Phase 1/Phase 2   NCT03775538   Finland;Sweden
      2017   Phase 1/Phase 2   NCT03295786   Finland;Sweden
Ceretec (TM) estabilizado
   IDIBAPS
      2016   Phase 2   EUCTR2015-004238-85-ES   Spain
Champix
   VU University Medical Center
      2012   Phase 3   EUCTR2012-001530-34-NL   Netherlands
Chinese herbal medicine treatment
   Hong Kong Baptist University
      2022   Phase 2/Phase 3   NCT05001217   Hong Kong
Chocolate
   Technische Universität Dresden
      2013   -   NCT02275884   Germany
      2009   -   NCT00906763   Germany
Cilostazol
   Ain Shams University
      2024   Phase 2   NCT06612593   Egypt
Cipralex
   LUNDBECK ITALIA
      2008   -   EUCTR2007-004009-93-IT   Italy
Citalopram
   Western University, Canada
      2021   -   NCT04590612   -
Citalopram 20MG
   University of Michigan
      2021   Phase 2   NCT04497168   United States
Citicolin*1G/4ML IM IV 5 F
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy
Citicolina 1000 MG/DIE
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy
Citicolina sodica
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy
Clarithromycin
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT04070495   Japan
   Nicolaas Bohnen, MD, PhD
      2018   Phase 1/Phase 2   NCT03440112   United States
Clarium 50 MG retardtabletten
   Desitin Arzneimittel GmbH
      2009   -   EUCTR2009-012419-16-DE   Germany
Clartihromycin, amoxicillin, and omeprazole
   University of California, Los Angeles
      2008   Phase 3   NCT00664209   United States
CLE
   Impax Laboratories, LLC
      2010   Phase 3   NCT01130493   France;Germany;Italy;United States
Clenbuterol HCL
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
Clenbuterol hydrochloride
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom
Clinical and neuropsychological assessments
   Northwell Health
      2020   -   NCT04228172   United States
Clinical assessment
   Douglas Scharre
      2018   -   NCT03019757   United States
Clinical DBS setting
   Emory University
      2021   Phase 4   NCT06234995   United States
Clonazepam
   Seoul National University Hospital
      2016   Phase 2   NCT02789592   Korea, Republic of
Clonidine
   Hospices Civils de Lyon
      2019   Phase 2   NCT03552068   France
Clonidine hydrochloride
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom
Clozapine
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Memorial Hospital of Rhode Island
      1993   -   NCT00004826   -
Coarse wheat bran
   University of Florida
      2021   -   NCT04829760   United States
Cocoa
   Oxford Brookes University
      2017   -   NCT03288155   Italy
   Technische Universität Dresden
      2013   -   NCT02275884   Germany
Coenzyme Q10
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 2   NCT00004731   United States
   National University Hospital, Singapore
      2012   Phase 2/Phase 3   NCT01892176   Singapore
   Technische Universität Dresden
      2003   Phase 3   NCT00180037   Germany
Coenzyme Q10 with vitamin E
   Weill Medical College of Cornell University
      2008   Phase 3   NCT00740714   Canada;United States
Cognitive battery
   University of Massachusetts, Worcester
      2020   -   NCT04273672   United States
Cohort1
   Jichi Medical University
      2015   Phase 1/Phase 2   NCT02418598   Japan
Cohort2
   Jichi Medical University
      2015   Phase 1/Phase 2   NCT02418598   Japan
Collection OF CSF, blood, urine, saliva
   University Hospital, Montpellier
      2013   -   NCT02263235   France
Combination injection OF EPO and G-CSF
   Yonsei University
      2013   Phase 1/Phase 2   NCT02018406   Korea, Republic of
Combined balance and brisk walking training
   The Hong Kong Polytechnic University
      2020   -   NCT04665869   Hong Kong
Complex task practice
   KU Leuven
      2022   -   NCT05511597   Belgium
Computer game based balance and walking rehabilitation FOR individuals with parkinson'S disease
   University of Manitoba
      2017   -   NCT03232996   Canada
Comtan
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
   BIAL - PORTELA & Cª, S.A.
      2011   -   EUCTR2010-021860-13-IT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Russian Federation;Slovakia;Spain
   BIAL - Portela & Ca, S.A.
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2010   -   EUCTR2010-021860-13-LT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
      2006   Phase 1   NCT03094156   Portugal
      2005   Phase 2   NCT02834507   -
      2004   Phase 1   NCT03091868   Portugal
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   Kyowa Hakko U.K. Limited
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain
Comtan 200* 60 CPR 200 MG
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain
Comtess
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   Eisai Limited
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain
   Orion Corporation, Orion Pharma
      2002   Phase 4   NCT00247247   Germany
Conscious sedation
   Beijing Tiantan Hospital
      2022   -   NCT05550714   China
   Shanghai Jing'an District Central Hospital
      2016   Phase 0   ChiCTR2000037957   China
Conservative measures FOR orthostatic hypotension
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
Continuous apomorphine infusion
   Rennes University Hospital
      2009   Phase 3   NCT01039090   France
Continuous intrajejunal infusion OF levodopa-carbidopa
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2014   Phase 4   NCT02480803   Netherlands
Continuous release dopamine agonists
   University of Toledo Health Science Campus
      2007   Phase 3   NCT00465452   United States
Continuous subcutaneous lisuride infusion
   Axxonis Pharma AG
      2006   Phase 3   NCT00408915   Germany
Control surgery
   AskBio Inc
      2024   Phase 2   NCT06285643   Germany;Poland;United Kingdom;United States
Controlled-release levodopa / carbidopa
   Pfizer
      2004   Phase 4   NCT00174239   Australia;Italy;Spain;United Kingdom
Convection enhanced delivery/AAV2-gdnf
   National Institute of Neurological Disorders and Stroke (NINDS)
      2013   Phase 1   NCT01621581   United States
Conventional balance exercise
   Ziauddin University
      2022   -   NCT05325541   Pakistan
Conventional medication
   Hong Kong Baptist University
      2022   Phase 2/Phase 3   NCT05001217   Hong Kong
Conventional physiotherapy
   University of Valencia
      2021   -   NCT04963894   Spain
Conventional therapy
   Jinnah Postgraduate Medical Centre
      2022   -   NCT05696665   Pakistan
COQ10
   Department of Neurology, Juntendo University School of Medicine
      2009   -   JPRN-UMIN000007521   Japan
   Juntendo University Koshigaya Hospital
      2015   -   JPRN-UMIN000019090   Japan
   University of Rochester
      2004   Phase 2   NCT00076492   United States
Core stabilization exercises
   Istanbul University-Cerrahpasa
      2022   -   NCT05621642   -
CPL500036
   Celon Pharma S.A.
      2021   Phase 2   EUCTR2020-006004-16-PL   Poland;Ukraine
CPL500036 - high dose
   Celon Pharma SA
      2021   Phase 2   NCT05297201   Poland;Ukraine
CPL500036 - LOW dose
   Celon Pharma SA
      2021   Phase 2   NCT05297201   Poland;Ukraine
Creatine
   University of Rochester
      2007   Phase 3   NCT00449865   Canada;United States
      2003   Phase 2   NCT00063193   United States
Crexont ER
   Impax Laboratories, LLC
      2025   Phase 4   NCT06765668   United States
Crocin and apigenin
   Jinnah Postgraduate Medical Centre
      2022   -   NCT05696665   Pakistan
CST-103
   CuraSen Therapeutics, Inc.
      2024   Phase 2   NCT04935762   Australia
      2021   Phase 2   NCT04739423   Australia;New Zealand;United Kingdom
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom
CST-107
   CuraSen Therapeutics, Inc.
      2024   Phase 2   NCT04935762   Australia
      2021   Phase 1   NCT05033912   -
      2021   Phase 2   NCT04739423   Australia;New Zealand;United Kingdom
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom
CST-139
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
CT1
   University of California, San Diego
      2024   Phase 1   NCT06482268   United States
CU(II)atsm
   Collaborative Medicinal Development Pty Limited
      2017   Phase 1   NCT03204929   Australia
Custom device
   Aspen Neuroscience
      2024   Phase 1   NCT06344026   United States
CVD00118-E
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom
CVL-751
   Cerevel Therapeutics LLC
      2021   Phase 3   EUCTR2019-002952-17-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-IT   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002952-17-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002952-17-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002951-40-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002949-38-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 1   NCT04295642   United States
      2020   Phase 3   EUCTR2019-002952-17-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002952-17-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-PL   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
CVN424
   Cerevance Beta, Inc.
      2022   Phase 1   NCT05635461   United States
CVN424 150 MG
   Cerevance
      2024   Phase 3   NCT06553027   Philippines;United States
   Cerevance Beta, Inc.
      2023   Phase 2   NCT06006247   United States
CVN424 75 MG
   Cerevance
      2024   Phase 3   NCT06553027   Philippines;United States
CVT-301
   Acorda Therapeutics
      2019   Phase 1   NCT03887884   United States
      2016   Phase 1   NCT02812394   United States
      2015   Phase 3   NCT02352363   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   NCT02242487   Canada;Czech Republic;Czechia;Poland;Spain;United States
      2013   Phase 2   NCT01777555   Italy;Serbia;United Kingdom;United States
      2012   Phase 2   NCT01617135   Israel;Serbia;United Kingdom
   Civitas Therapeutics, Inc.
      2015   Phase 3   EUCTR2014-003799-22-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom
      2015   Phase 3   EUCTR2014-003799-22-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom
      2015   Phase 3   EUCTR2014-003799-22-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2013   -   EUCTR2012-005822-31-IT   Italy;Serbia;United Kingdom;United States
      2013   -   EUCTR2012-005822-31-GB   Italy;Serbia;United Kingdom;United States
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom
CVT-301 35MG
   Civitas Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005626-19-CZ   Canada;Czech Republic;Poland;Spain;United States
      2016   Phase 3   EUCTR2015-005067-17-CZ   Canada;Czech Republic;Poland;Spain;United States
   Civitas Therapeutics, a wholly owned subsidiary of Acorda
      2016   Phase 3   EUCTR2015-005626-19-ES   Canada;Czech Republic;Poland;Spain;United States
   Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005067-17-ES   Canada;Czech Republic;Poland;Spain;United States
CVT-301 50MG
   Civitas Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005626-19-CZ   Canada;Czech Republic;Poland;Spain;United States
      2016   Phase 3   EUCTR2015-005067-17-CZ   Canada;Czech Republic;Poland;Spain;United States
   Civitas Therapeutics, a wholly owned subsidiary of Acorda
      2016   Phase 3   EUCTR2015-005626-19-ES   Canada;Czech Republic;Poland;Spain;United States
   Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005067-17-ES   Canada;Czech Republic;Poland;Spain;United States
CVT-301 high dose
   Acorda Therapeutics
      2014   Phase 3   NCT02240030   Canada;Czech Republic;Czechia;Poland;Spain;United States
CVT-301 LOW dose
   Acorda Therapeutics
      2014   Phase 3   NCT02240030   Canada;Czech Republic;Czechia;Poland;Spain;United States
CVT-301, LIP
   Acorda Therapeutics
      2016   Phase 1   NCT02807675   United States
CVXL-0107
   CleveXel Pharma
      2016   Phase 2   NCT02641054   France
CX-8998
   Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
      2023   Phase 2   EUCTR2022-001063-27-PL   Germany;Poland;Spain;United States
      2023   Phase 2   EUCTR2022-001063-27-DE   Germany;Poland;Spain;United States
   Jazz Pharmaceuticals
      2019   Phase 2   NCT03436953   United States
Cyberknife
   Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
      2015   Phase 2   NCT02406105   Poland
Cycling intervention
   University of Michigan
      2023   -   NCT05948956   United States
Cymbalta
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
CYR-064
   University of Nebraska
      2025   Phase 1   NCT06498687   United States
Cystoscopic injection OF botox into THE urinary bladder
   Stanford University
      2009   Phase 4   NCT01421719   United States
D-serine
   Herzog Hospital
      2003   Phase 4   NCT00215904   Israel
DA-9701
   Seoul National University Hospital
      2016   Phase 4   NCT02775591   Korea, Republic of
      2013   Phase 4   NCT03022201   Korea, Republic of
DA-9805 45MG
   Dong-A ST Co., Ltd.
      2018   Phase 2   NCT03189563   United States
DA-9805 90MG
   Dong-A ST Co., Ltd.
      2018   Phase 2   NCT03189563   United States
Daaoi-P
   China Medical University Hospital
      2016   Phase 2   NCT04470037   Taiwan
Dacepton 5 MG/ML infuusioneste, liuos
   Eero Pekkonen
      2016   Phase 4   EUCTR2016-001690-33-FI   Finland
Daily ingestion OF lactobacillus plantarum PS128
   Professor Lu Neurological Clinic
      2019   -   NCT04389762   Taiwan
Dapagliflozin
   Mayo Clinic
      2024   Phase 4   NCT06263673   United States
Data capture
   Westfälische Wilhelms-Universität Münster
      2019   -   NCT03638479   Germany
Datscan
   CHU Toulouse
      2009   -   EUCTR2008-004906-15-FR   France
   Douglas Scharre
      2018   -   NCT03019757   United States
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
   Ken Marek, MD
      2010   Phase 2   NCT01141023   Australia;Austria;France;Germany;Greece;Israel;Italy;Norway;Spain;United Kingdom;United States
   MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
      2012   Phase 4   EUCTR2010-019894-13-IT   Italy;United States
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States
   UCB Biopharma SRL
      2021   Phase 2   EUCTR2020-003265-19-IT   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden
   University Hospital, Toulouse
      2009   Phase 2   NCT00940914   France
Datscan 74 MBQ/ML solution FOR injection
   ZIONEXA
      2021   Phase 3   EUCTR2019-000247-27-FR   France
Datscan and spect imaging
   Institute for Neurodegenerative Disorders
      2005   -   NCT00129181   Austria;Germany;Italy;Spain;United Kingdom
DBS setting maximizing prefrontal activation
   Emory University
      2021   Phase 4   NCT06234995   United States
DBS setting minimizing prefrontal activation
   Emory University
      2021   Phase 4   NCT06234995   United States
DC158AM
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France
DCI
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   -
   Osaka Redcross Hospital Wakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   -
Deanol pyroglutamate
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France
Debrumyl
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France
Deep brain stimulation
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2014   Phase 4   NCT02480803   Netherlands
   Beth Israel Deaconess Medical Center
      2016   -   NCT02994719   United States
   First Affiliated Hospital of Sun Yat-sen University
      2021   -   ChiCTR2200059544   China
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2014   -   NCT04928079   -
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China
Deferiprone
   ApoPharma
      2016   Phase 2   NCT02728843   Canada;France;Germany;United Kingdom
   Imperial College London
      2011   Phase 2   EUCTR2011-001148-31-GB   United Kingdom
   University Hospital, Lille
      2016   Phase 2   NCT02655315   Austria;Czech Republic;Czechia;France;Germany;Netherlands;Portugal;Spain;United Kingdom
      2011   -   NCT02880033   France
      2009   Phase 2/Phase 3   NCT00943748   France
Deferiprone 20MG
   Imperial College London
      2012   Phase 2   NCT01539837   United Kingdom
Deferiprone 30MG
   Imperial College London
      2012   Phase 2   NCT01539837   United Kingdom
Deferiprone 600 MG delayed release tablet
   ApoPharma
      2017   Phase 2   EUCTR2015-004344-19-DE   Canada;France;Germany;United Kingdom
      2016   Phase 2   EUCTR2015-004344-19-GB   Canada;France;Germany;United Kingdom
   ApoPharma Inc.
      2016   Phase 2   EUCTR2015-004344-19-FR   Canada;France;Germany;Italy;United Kingdom;United States
Deferiprone DR
   Centre Hospitalier Régional et Universitaire de Lille
      2016   Phase 2   EUCTR2015-003679-31-PT   Austria;Czech Republic;Netherlands;Portugal;Spain
      2016   Phase 2   EUCTR2015-003679-31-NL   Austria;Czech Republic;Netherlands;Portugal;Spain
      2016   Phase 2   EUCTR2015-003679-31-FR   Austria;Czech Republic;France;Netherlands;Portugal;Spain
      2016   Phase 3   EUCTR2015-003679-31-ES   Spain
      2016   Phase 2   EUCTR2015-003679-31-CZ   Austria;Czech Republic;Netherlands;Portugal;Spain
      2016   Phase 2   EUCTR2015-003679-31-AT   Austria;Czech Republic;France;Germany;Netherlands;Portugal;Spain;United Kingdom
Desmopressin acetat
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany
Desmotabs
   Johannes Gutenberg University Mainz
      2009   Phase 4   NCT00806468   Germany
Desmotabs® 0,2 MG tabletten
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany
Desmotabs® 0,2MG tabletten
   Universität Mainz, Klinik und Poliklinik für Neurologie
      2008   -   EUCTR2008-003966-25-DE   Germany
Determination OF drug effects through amantadine cessation
   Seoul National University Hospital
      2020   -   NCT04260581   Korea, Republic of
Dexdor
   Clínica Universidad de Navarra/Universidad de Navarra
      2016   Phase 4   EUCTR2016-002680-34-ES   Spain
      2014   -   EUCTR2014-000868-17-ES   Spain
Dexmedetomidina
   Clínica Universidad de Navarra/Universidad de Navarra
      2016   Phase 4   EUCTR2016-002680-34-ES   Spain
      2014   -   EUCTR2014-000868-17-ES   Spain
Dexmedetomidine
   Beijing Tiantan Hospital
      2023   -   NCT05197439   China
      2022   Phase 4   NCT05376761   China
   Clinica Universidad de Navarra, Universidad de Navarra
      2017   Phase 4   NCT02982512   Spain
      2014   Phase 4   NCT02256319   Spain
   Clínica Universidad de Navarra/Universidad de Navarra
      2016   Phase 4   EUCTR2016-002680-34-ES   Spain
      2014   -   EUCTR2014-000868-17-ES   Spain
   Diskapi Teaching and Research Hospital
      2013   Phase 4   NCT01789385   Turkey
   Shanghai Jing'an District Central Hospital
      2016   Phase 0   ChiCTR2000037957   China
   The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
      2022   Phase 0   ChiCTR2100048680   China
   University of Wisconsin, Madison
      2012   Phase 4   NCT01721460   United States
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China
Dexmedetomidine hydrochloride infusion
   Vanderbilt University
      2008   Phase 2/Phase 3   NCT00608231   United States
Dexterity
   Sage Bionetworks
      2015   -   NCT02696603   United States
Dextromethorphan
   National Institute of Neurological Disorders and Stroke (NINDS)
      1993   Phase 2   NCT00001365   United States
DHA
   VA Office of Research and Development
      2012   Phase 1   NCT01563913   United States
Diary completion
   Institut de Myologie, France
      2016   -   NCT02785978   France
Different diets
   Sheba Medical Center
      2014   -   NCT02274324   -
Digipark monitor
   DIAMPARK
      2024   -   NCT06401395   France
Dihydroergot mesylate
   Nanjing First Hospital, Nanjing Medical University
      2023   -   NCT06035913   China
Dihydroergotine mesylate sustained-release tablets
   Second Affiliated Hospital of Soochow University
      2023   -   NCT06319118   China
Dihydroergotoxine mesylate
   Nanjing First Hospital Affiliated to Nanjing Medical University
      2017   -   ChiCTR-IPR-17011155   China
Dipivefrin
   katsuno Masahisa
      2017   Phase 2   JPRN-jRCTs041180018   -
Dipivefrine
   Nagoya University
      2017   -   JPRN-UMIN000026128   Japan
Dipraglurant
   Addex Pharma S.A.
      2021   Phase 2/Phase 3   NCT05116813   United States
      2021   Phase 2/Phase 3   NCT04857359   United States
   Addex Pharma SA
      2011   Phase 2   EUCTR2010-022517-25-DE   Austria;France;Germany;United States
      2011   -   EUCTR2010-022517-25-AT   Austria;France;Germany;United States
Ditropan elixir
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom
DM-1992
   Depomed
      2012   Phase 2   NCT01515410   United States
DNA analysis
   University of Massachusetts, Worcester
      2020   -   NCT04273672   United States
DNA/genetictesting
   Northwell Health
      2020   -   NCT04228172   United States
DNL151
   Biogen
      2019   Phase 1   NCT04056689   Belgium;Netherlands;United Kingdom;United States
   Biogen Idec Research Limited
      2022   Phase 3   EUCTR2022-000747-77-DE   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
DNL151, DN0001575, DN1575
   BIOGEN IDEC RESEARCH LIMITED
      2022   Phase 3   EUCTR2022-000747-77-IT   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-IT   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   Biogen Idec Research Limited
      2023   Phase 2   EUCTR2021-004849-20-DE   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000747-77-ES   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 3   EUCTR2022-000747-77-BE   Argentina;Belgium;Brazil;Canada;Egypt;France;Germany;Israel;Italy;Norway;Portugal;Spain;Tunisia;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-PL   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-NL   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-FR   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2022   Phase 2   EUCTR2021-004849-20-AT   Austria;Canada;China;France;Germany;Israel;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
DNL201
   Denali Therapeutics Inc.
      2018   Phase 1   NCT03710707   United States
Docosahexaenoic acid
   VA Office of Research and Development
      2012   Phase 1   NCT01563913   United States
Domperidone
   Canadian Network for Observational Drug Effect Studies, CNODES
      2013   -   NCT02500108   Canada
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
   Seoul National University Hospital
      2013   Phase 4   NCT03022201   Korea, Republic of
   University Health Network, Toronto
      2006   Phase 2   NCT00305331   Canada
Dompéridone
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
Donepezil
   Inje University
      2015   Phase 2   NCT02415062   Korea, Republic of
   Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
      2023   Phase 2   EUCTR2022-001751-17-ES   Spain
   Kansai Medical University
      2013   -   JPRN-UMIN000010752   Japan
   Kyung Hee University Hospital
      2017   Phase 4   NCT03011476   Korea, Republic of
   National Hospital of Utano
      2013   -   JPRN-UMIN000010778   Japan
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 4   NCT00030979   United States
   Newcastle-upon-Tyne Hospitals NHS Trust
      2013   Phase 3   NCT01014858   United Kingdom
   Oregon Health and Science University
      2018   Early Phase 1   NCT03599726   United States
      2014   Phase 2   NCT02206620   United States
      2011   Phase 4   NCT01521117   United States
      2005   -   NCT00912808   -
   Per Borghammer
      2013   -   NCT02012595   Denmark
      2013   -   NCT01877538   Denmark
   University of Chicago
      2016   Phase 2   NCT02857244   United States
   University of Virginia
      2024   Phase 2   NCT06903910   United States
   Yonsei University
      2015   Phase 2   NCT02450786   Korea, Republic of
   Zealand University Hospital
      2020   Phase 4   NCT04117178   Denmark
Donepezil hydrochloride
   Clinical Research Center, Utano National Hospital, National Hospital Organization
      2010   -   JPRN-UMIN000003080   Japan
   Designated Research, National Hospital Organization
      2011   Phase 3   JPRN-UMIN000005403   Japan
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2023   Phase 2   NCT05709301   -
   National Hospital Organization, Sendai-Nishitaga Hospital
      2013   -   JPRN-UMIN000009958   Japan
Donepezil sandoz
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark
Dopafuse delivery system
   SynAgile Corporation
      2021   Phase 2   EUCTR2020-003372-41-IT   Italy;Luxembourg;Spain
      2021   Phase 1;Phase 2   EUCTR2020-003372-41-ES   Italy;Luxembourg;Spain
Dopamine
   Medical Corporation Abe Neurology Clinic
      2016   -   JPRN-UMIN000024859   Japan
   Nihon Kohden Corporation
      2015   Phase 3   JPRN-jRCT2092220299   Japan
   University of Toronto
      2015   Phase 2   NCT02347059   Canada
Dopamine agent
   I.R.C.C.S. Fondazione Santa Lucia
      2014   Phase 4   NCT03151460   Italy
Dopaminergic agonist + apomorphine
   Rennes University Hospital
      2019   -   NCT03693872   France
Dopaminergic agonists
   Sandoz
      2012   Phase 4   NCT01683253   Korea, Republic of
Dopaminergic medication
   Universidad Francisco de Vitoria
      2023   -   NCT06214377   Spain
Doxepin and zopiclone
   McGill University Health Center
      2011   Phase 0   NCT01489982   Canada
DPA
   Nantes University Hospital
      2018   Phase 2   NCT03230526   France
DPA-714 metabolite analysis
   University of Alabama at Birmingham
      2018   Phase 1/Phase 2   NCT03457493   United States
Droxidopa
   Alberto Espay, MD, MSc
      2019   Phase 4   NCT04510922   United States
   Chelsea Therapeutics
      2013   Phase 3   NCT01927055   United States
      2012   Phase 1/Phase 2   NCT01331122   Canada;United States
      2010   Phase 3   NCT01176240   United States
   Colorado Springs Neurological Associates
      2016   -   NCT03173781   United States
   Henry Ford Health System
      2015   Phase 2   NCT02066571   United States
   Loma Linda University
      2021   Phase 2   NCT03446807   United States
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
   St. Joseph's Hospital and Medical Center, Phoenix
      2018   Phase 2   NCT03567447   United States
   Vanderbilt University Medical Center
      2017   Phase 4   NCT03115827   United States
      2016   Phase 1   NCT02897063   United States
   William Ondo, MD
      2018   Phase 4   NCT03229174   United States
DSP-9632P 27.5 MG
   Sumitomo Pharma Co., Ltd.
      2022   Phase 1   NCT05435729   Japan
DSP-9632P 55.0 MG
   Sumitomo Pharma Co., Ltd.
      2022   Phase 1   NCT05435729   Japan
DSP-9632P 82.5 MG
   Sumitomo Pharma Co., Ltd.
      2022   Phase 1   NCT05435729   Japan
Duloxetine
   Ando Rina
      2015   Phase 2   JPRN-jRCTs061180028   -
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
   Department of Neurology, Juntendo University School of Medicine
      2015   -   JPRN-UMIN000016734   Japan
   Ehime University Hospital Dept. of Clinical pharmacology and Neurology
      2014   Phase 2   JPRN-UMIN000016893   Japan
   Osaka Redcross Hospital
      2014   -   JPRN-UMIN000015559   Japan
   University Hospital, Toulouse
      2011   Phase 3   NCT01504178   France
   University of Chicago
      2016   Phase 2   NCT02857244   United States
Duloxetine hydrochloride
   Eli Lilly and Company
      2007   Phase 4   NCT00437125   Italy
Duodopa
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2016-001403-23-IT   European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-001403-23-HU   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-GR   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-FI   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2014-004865-26-GR   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-001403-23-SK   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2016   Phase 3   EUCTR2016-001403-23-ES   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2015   Phase 3   EUCTR2014-004865-26-SE   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2015   Phase 3   EUCTR2014-004865-26-IT   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-ES   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-DE   Australia;Canada;European Union;Germany;Italy;Spain;Sweden
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2015   Phase 4   EUCTR2015-002631-17-ES   Spain
   LobSor Pharmaceuticals AB
      2015   Phase 1   NCT02448914   Sweden
   Organisation name was not entered
      2008   -   EUCTR2008-003225-16-FI   Finland
   Poitiers University Hospital
      2011   Phase 2   NCT01291537   France
   University Hospital of Ferrara
      2022   -   NCT06432309   Italy
   Vastra Gotaland Region
      2018   Phase 1   NCT03419806   Sweden
Duodopa GEL intestinale
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
Duodopa intestinal GEL
   Solvay Pharmaceuticals GmbH
      2005   -   EUCTR2005-002654-21-SE   Sweden
Duodopa intestinalgel
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden
Duodopa LD/CD 20/5 MG/ML
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States
Duodopa, 20 MG/ML + 5 MG/ML, intestinal GEL
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2009   Phase 3   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States
Duodopa, levodopa 20 MG/ML + carbidopa 5 MG/ML, intestinal GEL
   Academic Medical Center
      2014   Phase 4   EUCTR2014-004501-32-NL   Netherlands
Duodopa®intestinal GEL
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
DYT 1 dystonia
   University of Florida
      2014   -   NCT02046447   United States
E2007
   EISAI LTD UK
      2007   Phase 3   EUCTR2007-000801-30-IT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2006-005714-12-IT   Italy
      2006   Phase 3   EUCTR2006-002339-26-IT   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-IT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000361-35-IT   Czech Republic;Italy
   Eisai Inc.
      2007   Phase 2   NCT00451633   Germany;Italy
      2007   Phase 2   NCT00427011   United States
      2006   Phase 3   NCT00360412   Germany
      2005   Phase 2   NCT00165789   United States
   Eisai Limited
      2007   Phase 3   EUCTR2007-000801-30-PL   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   Phase 3   EUCTR2007-000801-30-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   Phase 3   EUCTR2007-000801-30-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002339-26-PT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-HU   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-ES   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-DE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   NCT00360308   France
      2006   Phase 3   NCT00286897   Austria;Belgium;Czech Republic;Estonia;Former Serbia and Montenegro;France;Germany;Hungary;Israel;Italy;Lithuania;Poland;Portugal;Serbia;South Africa;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002339-26-SE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-LT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-GB   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-EE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-CZ   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-BE   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-AT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-SE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-PT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-LT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-HU   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004314-33-GB   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004314-33-ES   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-EE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-DE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-BE   Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-004314-33-AT   Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2004   Phase 2   NCT01172379   Czech Republic;France;Germany;Italy;Serbia;Spain
      2004   -   EUCTR2004-000361-35-CZ   Czech Republic;Italy
E2027
   Eisai Inc.
      2021   Phase 2   NCT04764669   Canada;United States
Ebixa
   Chru de Lille
      2009   Phase 3   EUCTR2008-008210-38-FR   France
   H. Lundbeck A/S
      2007   Phase 3   EUCTR2005-002038-36-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   Phase 4   EUCTR2005-002038-36-GB   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2005-002038-36-FR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-002038-36-DE   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-002038-36-AT   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
   Neurologisk afdeling F
      2005   Phase 2   EUCTR2004-004139-74-DK   Denmark
   Neuropsychiatric clinic
      2006   -   EUCTR2005-004109-27-SE   Sweden
Edaravone
   nanjing brain hospital
      2022   Phase 4   ChiCTR2200056774   China
Egcg
   Xuanwu Hospital, Beijing
      2006   Phase 2   NCT00461942   China
ELC200
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal
Elecsys (roche) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
Electroacupuncture
   Nantes University Hospital
      2014   -   NCT02236260   France
Electroencephalogram
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
Electrolyte beverage
   University of Michigan
      2023   -   NCT05948956   United States
Electromyography
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
Eliprodil
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001929   United States
Elobixibat
   Hatano Taku
      2020   -   JPRN-jRCTs031200172   -
Eltoprazine HCL
   PsychoGenics Inc
      2010   -   EUCTR2009-015928-28-SE   Sweden
Eltoprazine hydrochloride
   Amarantus BioScience Holdings, Inc.
      2015   -   EUCTR2015-000373-13-DE   France;Germany;Sweden;United States
Embryonic dopamine cell implant surgery
   University of Colorado, Denver
      1995   Phase 3   NCT00038116   United States
EMD 128130
   MERCK KGaA
      2004   Phase 3   EUCTR2004-001594-25-ES   Austria;Finland;Spain
   MERCK S.P.A.
      2004   -   EUCTR2004-001593-10-IT   Italy;United Kingdom
   National Institute of Neurological Disorders and Stroke (NINDS)
      2001   Phase 2   NCT00009048   United States
EMD128130
   MERCK KGaA
      2004   Phase 3   EUCTR2004-001594-25-ES   Austria;Finland;Spain
   Merck KGaA
      2005   Phase 3   EUCTR2005-000444-84-GB   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000444-84-FI   Finland;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000444-84-ES   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000444-84-AT   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001594-25-AT   Austria;Finland;Spain
      2005   Phase 3   EUCTR2004-001593-10-GB   Italy;United Kingdom
      2004   -   EUCTR2004-001594-25-FI   Finland;Spain
ENA713
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom
ENA713B
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain
Endurance
   University of Vigo
      2018   -   NCT03882398   Spain
ENT-01
   Enterin Inc.
      2017   Phase 1/Phase 2   NCT03047629   United States
Entacapon
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
Entacapona
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain
Entacapone
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
   Assistance Publique - Hôpitaux de Paris
      2006   Phase 4   NCT00373087   France
   BIAL - Portela & Ca, S.A.
      2010   -   EUCTR2010-021860-13-LT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal
   Bial - Portela C S.A.
      2011   Phase 1   NCT02170376   France
      2011   Phase 3   NCT01568073   Austria;Portugal
      2009   Phase 1   NCT01519284   Portugal
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
      2019   -   JPRN-UMIN000037390   Japan
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   Eisai Limited
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
   Geriatric Hospital of Hainan
      2019   -   ChiCTR1900022534   China
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain
   Kansai Medical University
      2010   -   JPRN-UMIN000003601   Japan
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain
   National Institute of Neurological Disorders and Stroke (NINDS)
      2007   Phase 1/Phase 2   NCT00547911   United States
   NeuroDerm Ltd.
      2014   Phase 1   NCT02096601   Israel;United States
   Novartis
      2005   Phase 3   NCT00134966   Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States
      2003   Phase 2   NCT00237263   United States
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom
   Orion Corporation, Orion Pharma
      2009   Phase 1   NCT01070628   Finland
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   -
Entacapone 400MG oral dose
   Daniel Claassen
      2020   Phase 1   NCT04246437   United States
Entacapone and carbidopa
   Orion Corporation, Orion Pharma
      2008   Phase 2   NCT00562198   Finland
Entacapone INN
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
Entecapone
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom
EPI-589
   BioElectron Technology Corporation (formerly Edison Pharmaceuticals Inc.)
      2016   Phase 2   EUCTR2015-001786-10-GB   Germany;United Kingdom;United States
      2016   Phase 2   EUCTR2015-001786-10-DE   Germany;United Kingdom;United States
   PTC Therapeutics
      2016   Phase 2   NCT02462603   Germany;United Kingdom;United States
EPI-743 200MG
   University of South Florida
      2013   Phase 2   NCT01923584   United States
EPI-743 400MG
   University of South Florida
      2013   Phase 2   NCT01923584   United States
Equfina
   Eisai Co., Ltd.
      2020   -   NCT04724109   Japan
Equfina 50 MG
   Eisai Korea Inc.
      2021   -   NCT05225324   Korea, Republic of
ER CD-LD
   Impax Laboratories, LLC
      2016   Phase 2   NCT03007888   United States
ER tablet 100 MG AZD3241
   AstraZeneca
      2012   Phase 2   NCT01527695   Sweden
ER tablet 25 MG AZD3241
   AstraZeneca
      2012   Phase 2   NCT01527695   Sweden
Eradication OF helcobacter pylori
   National University of Malaysia
      2012   -   NCT02112812   Malaysia
Eradication therapy FOR H.pylori infection
   National University of Malaysia
      2012   -   NCT02112812   Malaysia
Eradication therapy FOR helicobacter pylori
   National University of Malaysia
      2012   -   NCT02112812   Malaysia
Erythromycin
   Virginia Commonwealth University
      2013   -   NCT02005029   United States
Erythropoietin
   International Center for Neurological Restoration, Cuba
      2008   Phase 1   NCT01010802   Cuba
Escitalopram
   LUNDBECK ITALIA
      2008   -   EUCTR2007-004009-93-IT   Italy
   Osaka Redcross Hospital
      2014   -   JPRN-UMIN000015559   Japan
   University College, London
      2021   Phase 3   NCT03652870   United Kingdom
Escitalopram oxalate
   University College London Comprehensive Clinical Trials Unit
      2019   Phase 3   EUCTR2018-002942-35-GB   United Kingdom
Esketamine
   Beijing Tiantan Hospital
      2024   -   NCT06543563   China
   RenJi Hospital
      2024   -   NCT06658132   China
Esomeprazole
   Utano National Hospital, National Hospital Organaization
      2015   Phase 1   JPRN-UMIN000016659   Japan
Eszopiclone
   University of Medicine and Dentistry of New Jersey
      2006   Phase 3   NCT00324896   United States
Ethnodyne visio
   University Hospital, Strasbourg, France
      2016   -   NCT02815800   France
Etomidate
   Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
      2022   -   ChiCTR2200055817   China
      2020   Phase 4   ChiCTR2000039697   China
   First Affiliated Hospital of Sun Yat-sen University
      2023   -   ChiCTR2400087001   China
      2021   -   ChiCTR2400092724   China
Evaluation BY investigator
   University of Michigan
      2015   Phase 2   NCT02933372   -
Evaluation OF mathematical models
   Stardots AB
      2025   -   NCT06586320   United States
Exablate mrgfus subthalamotomy
   InSightec
      2024   -   NCT06584383   Germany;Spain
Exelon
   Oregon Health and Science University
      2011   Phase 4   NCT01340885   United States
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom
   University of Pennsylvania
      2011   Phase 4   NCT01519271   United States
Exelon 4.6 MG/24 H transdermal patch
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain
Exelon 9.5 MG/24 H transdermal patch
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain
Exelon path transdermal
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain
Exenatide
   Center for Neurology, Stockholm
      2020   Phase 2   NCT04305002   Sweden
   Stockholm Health Care Services
      2019   Phase 2   EUCTR2019-000732-26-SE   Sweden
   University College London
      2014   Phase 2   EUCTR2013-003363-64-GB   United Kingdom
   University College London Comprehensive Clinical Trial Unit
      2019   Phase 3   EUCTR2018-003028-35-GB   United Kingdom
   University College, London
      2020   Phase 3   NCT04232969   United Kingdom
      2014   Phase 2   NCT01971242   United Kingdom
      2010   Phase 2   NCT01174810   United Kingdom
   University of Florida
      2018   Phase 1   NCT03456687   United States
Exenatide 10 micrograms
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom
Exenatide 5 micrograms
   University College London
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom
Exercise
   Affiliated Lianyungang Hospital of Xuzhou Medical University
      2017   -   ChiCTR-IPR-17011875   China
   Chengdu Sport University
      2024   -   ChiCTR2400088282   China
   Department of Neurology, Fukuoka university
      2022   -   JPRN-UMIN000047341   Japan
   Nagasaki Kita Hospital
      2022   -   JPRN-UMIN000049425   Japan
   Shanghai Shangti orthopedic hospital; Shanghai University of Sport
      2024   Phase 1   ChiCTR2400087568   China
   Slovak Academy of Sciences
      2017   -   NCT03330470   Slovakia;Taiwan
   University of British Columbia
      2013   -   NCT02207387   Canada
Exercise IN water
   Pardis Specialized Wellness Institute
      2022   -   NCT05737992   Iran, Islamic Republic of
Exergame
   University of Arizona
      2014   -   NCT02777060   United States
Exidavnemab
   BioArctic AB
      2024   Phase 2   NCT06671938   Poland;Spain
EXN-32
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy
EXN-44
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy
Extended release melatonin
   Mayo Clinic
      2022   -   NCT05307770   United States
F-18 fpcit
   Asan Medical Center
      2006   Phase 3   NCT00468078   Korea, Republic of
F18-AV-45
   Douglas Scharre
      2018   -   NCT03019757   United States
Famotidine
   University Health Network, Toronto
      2011   Phase 2   NCT01937078   Canada
   Utano National Hospital, National Hospital Organaization
      2015   Phase 1   JPRN-UMIN000016659   Japan
Fasting blood test
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
Fasudil hydrochloride
   Klinikum rechts der Isar der Technischen Universität München
      2023   Phase 2   EUCTR2021-003879-34-DE   Germany
   Technical University of Munich
      2023   Phase 2   NCT05931575   Germany
FB-101
   1ST Biotherapeutics, Inc.
      2019   Phase 1   NCT04165837   United States
FB418
   1ST Biotherapeutics, Inc.
      2023   Phase 1   NCT05995782   Korea, Republic of
FDG PET scan
   Northwell Health
      2020   -   NCT04228172   United States
FDG-PET
   Douglas Scharre
      2018   -   NCT03019757   United States
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
Febuxostat
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   -
   StaGen Co. Ltd.
      2018   -   JPRN-UMIN000030930   Japan
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan
Fecal microbiota transfer provided BY human biome institute
   Medical University of Warsaw
      2022   Phase 2   NCT05204641   Poland
Fecal microbiota transplant
   ProgenaBiome
      2024   Phase 1   NCT06647277   United States
Fecal microbiota transplantation
   Guangzhou First People's Hospital
      2021   -   NCT04837313   China
   Huashan Hospital, Fudan University
      2019   Phase 0   ChiCTR1900027055   China
   Tenth People's Hospital, Medical School of Tongji University
      2020   Phase 0   ChiCTR2000037776   -
      2020   Phase 0   ChiCTR2000036143   China
   The No.1 People's Hospital of Xiangyang, Affiliated to Hubei University of Medicine
      2024   -   ChiCTR2400085736   China
Ferriprox 500 MG
   Centre Hospitalier Régional et Universitaire de Lille
      2016   Phase 3   EUCTR2015-003679-31-ES   Spain
Fesoterodine
   Sir Mortimer B. Davis - Jewish General Hospital
      2016   Phase 4   NCT02385500   Canada
Fetal porcine cells, neurocell-PD
   Genzyme, a Sanofi Company
      1997   Phase 2   NCT00226460   United States
Fexofenadine
   Tanta University
      2024   Phase 2/Phase 3   NCT06785298   Egypt
Filgrastim
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of
Finamine tablets
   Yiling Pharmaceutical Inc.
      2017   Phase 1   NCT04162275   China
Finasteride
   AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
      2011   -   EUCTR2011-000612-26-IT   Italy
Fipamezole
   Juvantia Pharma Ltd
      2008   Phase 2   NCT00758849   France;Portugal
      2007   Phase 2   NCT00559871   India;United States
Fipamezole hydrochloride 30 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fipamezole hydrochloride 60 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fipamezole hydrochloride 90 MG oral disintegrating tablets
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Fipamezole ODT
   Valeant Pharmaceuticals International, Inc.
      2010   -   NCT01140841   United States
Fipamezole ODT cohort 2
   Valeant Pharmaceuticals International, Inc.
      2010   -   NCT01149811   United States
Flecainide acetate
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States
Flecainidum
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States
Flexibility and strengthening exercise
   The Hong Kong Polytechnic University
      2020   -   NCT04665869   Hong Kong
Florbetapir F 18
   Avid Radiopharmaceuticals
      2009   Phase 2   NCT00857532   United States
Fludrocortisone
   Christian Baumann
      2012   Phase 2   NCT01993680   Switzerland
   Royal Brisbane and Women's Hospital
      2005   Phase 1   NCT00103597   Australia
Fluid biopsy capsule
   Nimble Science Ltd.
      2024   -   NCT06003608   Canada
Flumazenil
   Nicolaas Bohnen, MD, PhD
      2018   Phase 1/Phase 2   NCT03440112   United States
   Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
      2013   -   JPRN-UMIN000011111   Japan
   University of Michigan
      2018   Phase 1/Phase 2   NCT03462641   United States
Fluoro[18F]promethazine
   Xuanwu Hospital, Beijing
      2024   -   NCT06456684   China
Fluoroscopic swallow evaluation
   University of Florida
      2017   -   NCT03321019   United States
Fluoroscopy
   National Institute of Neurological Disorders and Stroke (NINDS)
      2017   Phase 1   NCT03104725   United States
Flutemetamol
   Itoh Yoshiaki
      2019   -   JPRN-jRCTs051180214   -
Flutemetamol F18 injection
   Skane University Hospital
      2017   -   NCT03174938   Sweden
FOG
   University of Florida
      2015   Phase 1   NCT02390089   United States
Folic acid 1 MG
   Oregon Health and Science University
      2024   -   NCT06772220   United States
Folic acid tablet
   Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
      2023   Phase 2   NCT05959044   Bangladesh
Folic acid, vitamin B6, vitamin B12
   North Shore Long Island Jewish Health System
      2006   -   NCT00853879   United States
Foliglurax
   H. Lundbeck A/S
      2020   Phase 1   NCT04322227   France
      2019   Phase 1   NCT04175132   Sweden
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom
Fortiral
   Ospedale Generale Di Zona Moriggia-Pelascini
      2022   -   NCT05523791   Italy
Foscarbidopa
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
Foscarbidopa and foslevodopa
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
Foslevodopa
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
Four square step test
   Gazi University
      2018   -   NCT03587168   Turkey
FPFS-1169
   Fujimoto Pharmaceutical Corporation
      2006   Phase 2   EUCTR2006-000361-11-GB   United Kingdom
Functional magnetic resonance imaging
   University of Florida
      2016   Phase 2   NCT02789020   United States
Functional mobility
   Ankara Yildirim Beyazit University
      2019   -   NCT04420910   Turkey
Functional reach test
   Gazi University
      2018   -   NCT03587168   Turkey
Furosemide injection
   University of Alberta
      2021   Phase 3   NCT04706910   Canada
Fursultiamine
   Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
      2017   -   JPRN-UMIN000025703   Japan
G-CSF
   Buddhist Tzu Chi General Hospital
      2010   Phase 2   NCT01227681   Taiwan
G2019S LRRK2
   Escape Bio, Inc.
      2021   -   NCT04919356   United States
Gabapentin
   ASOCIACIÓN INSTITUTO BIODONOSTIA
      2012   Phase 2   EUCTR2011-005839-91-ES   Spain
Gabapentina kern pharma
   ASOCIACIÓN INSTITUTO BIODONOSTIA
      2012   Phase 2   EUCTR2011-005839-91-ES   Spain
Gait and balance
   Sage Bionetworks
      2015   -   NCT02696603   United States
Gait and balance group training
   Karolinska Institutet
      2010   -   NCT01417598   Sweden
Gait and balance training
   Forschungszentrum Juelich
      2023   -   NCT06617884   Germany
   Prof. Massimo Filippi
      2023   -   NCT05799690   Italy
Gait and balance training program
   University of California, San Francisco
      2010   Phase 2   NCT01162226   United States
Galantamine
   Memorial Hospital of Rhode Island
      2004   -   NCT00211588   United States
Galantamine hydrobromide
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   Phase 2   EUCTR2009-011093-15-DE   Germany
Ganoderma
   Xuanwu Hospital, Beijing
      2018   Phase 3   NCT03594656   China
      2005   Phase 2   NCT00224263   China
GE180 PET scan
   Aaron Ritter, MD
      2018   Phase 2   NCT03702816   United States
Gemfibrozil
   Forest Hills Lab
      2027   Phase 2   NCT05931484   -
General anesthesia
   Beijing Tiantan Hospital
      2022   -   NCT05550714   China
   First Affiliated Hospital of Sun Yat-sen University
      2021   -   ChiCTR2200059544   China
   Kyoto University Hospital
      2018   Phase 3   JPRN-UMIN000033565   Japan
      2018   Phase 1,2   JPRN-UMIN000033564   Japan
GENZ-682452-AU
   Genzyme Corporation
      2019   Phase 2   EUCTR2016-000657-12-GR   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2016-000657-12-AT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-PT   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-DE   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000657-12-SE   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000657-12-ES   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Ghrelin
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000017036   Japan
Glial cell LINE-derived neurotrophic factor
   North Bristol NHS Trust
      2012   Phase 2   NCT03652363   -
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom
Glucose
   National Institute of Mental Health (NIMH)
      1998   -   NCT00004451   United States
Glutathione
   University of South Florida
      2003   Phase 2   NCT01177319   United States
Glycerol phenylbutyrate
   University of Colorado, Denver
      2014   Phase 1   NCT02046434   United States
Glycopyrrolate
   Ottawa Hospital Research Institute
      2016   Phase 2   NCT02382198   Canada
GM1 ganglioside
   Thomas Jefferson University
      1999   Phase 2   NCT00037830   United States
GM608
   Genervon Biopharmaceuticals, LLC
      2013   Phase 2   NCT01850381   United States
Gocovri
   Oregon Health and Science University
      2020   Phase 4   NCT04387773   United States
Gold nanocrystals
   Clene Nanomedicine
      2019   Phase 2   NCT03815916   United States
GPI 1485
   Eisai Inc.
      2002   Phase 2   NCT00209508   -
   University of Rochester
      2004   Phase 2   NCT00076492   United States
Grapefruit
   Osaka University Graduate School of Medicine Department of Neurosurgery
      2016   Phase 1   JPRN-UMIN000021236   Japan
Green TEA
   Xuanwu Hospital, Beijing
      2006   Phase 2   NCT00461942   China
GRF6021
   Alkahest, Inc.
      2018   Phase 2   NCT03713957   Australia;France;United States
Group AD ANTI-PD + antidepressant
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States
Group R rasagiline
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States
Group R+AD rasagiline + antidepressant
   Teva Pharmaceutical Industries
      2009   -   NCT00955604   United States
GSK962040
   GlaxoSmithKline
      2012   Phase 2   NCT01602549   Australia;Germany;Sweden;United Kingdom
   GlaxoSmithKline Research and Development Limited
      2013   -   EUCTR2011-004438-32-SE   Australia;Germany;Sweden;United Kingdom
      2013   -   EUCTR2011-004438-32-DE   Australia;Germany;Sweden;United Kingdom
      2012   Phase 2   EUCTR2011-004438-32-GB   Germany;Sweden;United Kingdom
GT-02287
   Gain Therapeutics, Inc.
      2025   Phase 1   NCT06732180   Australia
H215O PET
   University Hospital, Toulouse
      2002   -   NCT01044992   France
HA 1A anticorpo monoclonale umano classe IGM
   BIOGEN IDEC RESEARCH LIMITED
      2018   Phase 2   EUCTR2016-004610-95-IT   Australia;Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
Haescs
   Shanghai East Hospital
      2023   Phase 1   NCT05691114   China
Haescs treatment
   Shanghai East Hospital
      2022   Early Phase 1   NCT05435755   China
HB-admscs
   Hope Biosciences Stem Cell Research Foundation
      2023   -   NCT04772378   United States
      2021   Phase 2   NCT04928287   United States
Healthy AGE-matched controls
   Giovanni Mirabella
      2020   -   NCT03665493   Italy
Healthy donor-derived FMT capsule
   Shanghai Zhongshan Hospital
      2025   -   NCT06388863   China
HEC122505msoh
   Sunshine Lake Pharma Co., Ltd.
      2021   Phase 1   NCT04625361   China
Helicobacter pylori eradication therapy
   University of Malaya
      2013   -   NCT02108704   Malaysia
Hemicellulose crystalline
   Rottapharm Spain
      2006   Phase 1   NCT00507715   Spain
Hemoglobin
   Karolinska Institutet
      2004   -   NCT06224725   Sweden
Heptaminol hydrochloride
   PIERRE FABRE MEDICAMENT
      2008   Phase 3   EUCTR2007-002195-34-FR   France
HER-096
   Herantis Pharma Plc.
      2024   Phase 1   NCT06659562   Finland
      2023   Phase 1   NCT05915247   Finland
Hericium erinaceus mycelium
   National Cheng-Kung University Hospital
      2020   -   NCT04428983   Taiwan
Heshouwu
   Fudan University
      2008   Phase 2/Phase 3   NCT00656253   China
HF0220
   Hunter-Fleming Ltd
      2007   -   EUCTR2005-005791-32-SE   Sweden;United Kingdom
      2006   Phase 2   EUCTR2005-005791-32-GB   Sweden;United Kingdom
High dose affitope® PD03A + adjuvant
   Affiris AG
      2014   Phase 1   NCT02267434   Austria
High dose anavex2-73
   Anavex Life Sciences Corp.
      2018   Phase 2   NCT03774459   Australia;Spain
High dose levodopa
   Rush University Medical Center
      2018   -   NCT04956939   United States
High fiber supplement
   Rutgers, The State University of New Jersey
      2021   Phase 1   NCT04976959   United States
High intensity exercise and balance training
   University of Nevada, Las Vegas
      2014   Phase 2   NCT02230267   United States
High protein. T-diet plus range
   Vegenat, S.A.
      2010   -   NCT01192529   Spain
HIGH-frequency-only stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
HIGH-intensity training IN shallow and deep water
   Federal University of Health Science of Porto Alegre
      2021   -   NCT04863118   Brazil
HNC364
   Guangzhou Henovcom Bioscience Co. Ltd.
      2022   Phase 1   NCT05523570   United States
HNC364 injectable suspension
   Guangzhou Henovcom Bioscience Co. Ltd.
      2025   Phase 1   NCT06798519   -
Hoehn and yahr scale
   Gazi University
      2018   -   NCT03587168   Turkey
Home based balance training
   University of Arizona
      2014   -   NCT02777060   United States
Home functional balance physiotherapy
   University of Valencia
      2021   -   NCT04963894   Spain
HOV-12020
   National Neuroscience Institute
      2021   Phase 2   NCT04491383   Singapore
HRG2010
   Jiangsu HengRui Medicine Co., Ltd.
      2024   Phase 3   NCT06596876   China
      2023   Phase 2   NCT06614153   China
      2021   Phase 1   NCT06976346   China
HUC-MSC-SEV-001 nasal drops
   Xuanwu Hospital, Beijing
      2024   Phase 1   NCT06607900   China
Human amniotic epithelial stem cells
   Shanghai East Hospital
      2020   Early Phase 1   NCT04414813   China
Human dopaminergic progenitor cells
   iRegene Therapeutics Co., Ltd.
      2024   Phase 1   NCT06608355   China
      2024   Phase 1/Phase 2   NCT06167681   China
Human neural stem cell
   Second Affiliated Hospital of Soochow University
      2017   Phase 2/Phase 3   NCT03128450   China
Human stem cells
   Celavie Bioscences, LLC
      2014   Phase 1   NCT02780895   Mexico
Hydrocortisone cream
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands
Hydrocortisone cream 10MG/G FNA fagron
   University Medical Center Groningen
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands
Hydrogen
   Department of Neurology, Juntendo University School of Medicine
      2010   -   JPRN-UMIN000007497   Japan
   Juntendo University Koshigaya Hospital
      2019   -   JPRN-UMIN000035602   Japan
      2015   -   JPRN-UMIN000019090   Japan
   Juntendo University School of Medicine, Neurology
      2013   -   JPRN-UMIN000010014   Japan
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000019082   Japan
   Nagoya graduate school of medicine university
      2015   -   JPRN-UMIN000019654   Japan
   Novartis
      2002   Phase 1/Phase 2   NCT00407212   Brazil;Canada;France;Germany;Italy;Netherlands;Portugal;United Kingdom;United States
   Stony Brook University
      2019   Phase 2/Phase 3   NCT03971617   United States
Hydrolyzed guar GUM
   IRCCS San Raffaele Roma
      2016   Phase 2   NCT04569656   Italy
Hydroxychloroquine
   Ottawa Hospital Research Institute
      2025   Phase 2   NCT06816810   Canada
Hypoestoxide
   University of Ibadan
      2022   Phase 1/Phase 2   NCT04858074   Nigeria
Hypoxic GAS mixture
   Radboud University Medical Center
      2022   Phase 1/Phase 2   NCT05214287   Netherlands
I-123-5-IA85380
   National Institute of Neurological Disorders and Stroke (NINDS)
      2003   -   NCT00058721   United States
Iberogast
   Nantes University Hospital
      2016   Phase 2   NCT02719496   France
ICA07 therapy
   iCamuno Biotherapeutics Ltd.
      2025   Phase 1   NCT06821529   China
Idebenone
   Second Affiliated Hospital of Soochow University
      2019   Phase 4   NCT03727295   -
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2020   Phase 2/Phase 3   NCT04152655   China
Identification OF comt HH, comt HL or comt LL genes
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT02869945   France
IKT-148009
   ABLi Therapeutics, Inc.
      2023   Phase 2   NCT05424276   United States
      2021   Phase 1   NCT04350177   United States
Iloperidone
   Vanda Pharmaceuticals
      2022   Phase 2   NCT05344365   United States
Immediate release carbidopa/levodopa
   Novartis
      2008   Phase 4   NCT00642356   United States
   Novartis Pharmaceuticals
      2004   Phase 3   NCT00099268   Austria;Belgium;Canada;Finland;France;Germany;Greece;Italy;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
Immediate release carbidopa/levodopa 10/100 MG
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Immediate release carbidopa/levodopa 25/100 MG
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Immediate release melatonin
   Mayo Clinic
      2022   -   NCT05307770   United States
Incobotulinum toxin A
   Beth Israel Deaconess Medical Center
      2012   Phase 2   NCT01653132   United States
      2012   Phase 2   NCT01565395   United States
Incobotulinumtoxina
   Merz Pharmaceuticals GmbH
      2014   Phase 3   NCT02091739   Germany;Poland;United States
   Yale University
      2012   Phase 2   NCT02419313   United States
Inertial measurement unite
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
Infusion pump: CADD-legacy® 1400 pump
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan
Infusions OF young plasma
   Stanford University
      2016   Phase 1   NCT02968433   United States
Inhaled VR040
   South Glasgow University Hospitals NHS Trust
      2006   Phase 2   NCT01683292   United Kingdom
Injection
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2011   -   EUCTR2009-017412-32-IT   Italy
   AstraZeneca AB
      2012   -   EUCTR2011-004803-19-SE   Finland;Sweden
      2012   -   EUCTR2011-004803-19-FI   Finland;Sweden
   Biogen Idec Research Limited
      2018   Phase 2   EUCTR2016-004610-95-GB   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-FR   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-ES   Austria;Canada;France;Germany;Israel;Italy;Spain;Sweden;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-DE   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2016-004610-95-AT   Austria;Canada;France;Germany;Israel;Italy;Spain;United Kingdom;United States
   CHU Toulouse
      2009   -   EUCTR2008-004906-15-FR   France
      2007   -   EUCTR2006-005318-11-FR   France
   CHU de Rennes
      2009   Phase 3   EUCTR2008-006045-10-FR   France
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
   Ceregene Inc.
      2008   -   EUCTR2007-006721-27-GB   United Kingdom
      2008   -   EUCTR2007-006721-27-AT   Austria;United Kingdom
   Copka Sonpashan
      2024   -   NCT06319625   -
   Criceto IKM B.V.
      2020   Phase 1;Phase 2   EUCTR2019-003315-60-NL   Netherlands
   Dept. of Clinical pharmacology and Neurology, Ehime University
      2012   -   JPRN-UMIN000007617   Japan
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2020-004997-23-LU   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-PL   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   Phase 3   EUCTR2010-018904-94-IT   Italy
   Fujimoto Pharmaceutical Corporation
      2006   Phase 2   EUCTR2006-000361-11-GB   United Kingdom
   Fundació Clínic per la Recerca Biomèdica
      2016   Phase 4   EUCTR2014-001014-25-ES   Spain
   IDIBAPS
      2016   Phase 2   EUCTR2015-004238-85-ES   Spain
   InBrain Pharma SAS
      2020   Phase 1;Phase 2   EUCTR2020-000155-12-FR   France
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain
      2007   Phase 1   NCT00427674   United States
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
   Institute of Biomedical Research and Innovation
      2015   -   JPRN-UMIN000016485   Japan
   Juha Rinne / PET Centre
      2018   Phase 2   EUCTR2018-000405-23-FI   Finland
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Kyoto University Hospital
      2018   Phase 3   JPRN-UMIN000033565   Japan
      2018   Phase 1,2   JPRN-UMIN000033564   Japan
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04384666   United States
   MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
      2012   Phase 4   EUCTR2010-019894-13-IT   Italy;United States
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
   Muhammad
      2024   -   NCT06301724   Myanmar
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-002033-30-IT   Belgium;France;Hungary;Italy;Netherlands;Spain;United Kingdom
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-IT   Austria;Germany;Israel;Italy;United States
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-002033-30-NL   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-HU   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-GB   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2016   Phase 3   EUCTR2016-002033-30-FR   Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002033-30-ES   Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-002033-30-BE   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005814-31-FR   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005814-31-AT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-DE   Austria;Germany;Israel;Italy;United States
      2016   Phase 2   EUCTR2015-005078-39-AT   Austria;Germany;Israel;Italy;United States
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
   Oxford BioMedica (UK) Ltd
      2010   -   EUCTR2009-017253-35-GB   United Kingdom
      2010   Phase 1;Phase 2   EUCTR2007-001109-26-GB   United Kingdom
   PIAM FARMACEUTICI S.P.A.
      2016   Phase 4   EUCTR2014-005562-30-IT   Italy
   Parkinson's disease and Movement Disorder Center
      2012   -   JPRN-UMIN000009099   Japan
   Region Skåne – Skåne University Hospital
      2022   Phase 1;Phase 2   EUCTR2021-001366-38-SE   Sweden;United Kingdom
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Shanghai Tongji Hospital, Tongji University
      2017   -   ChiCTR-INR-17012013   China
   Stockholm Health Care Services
      2019   Phase 2   EUCTR2019-000732-26-SE   Sweden
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
   UCB Biopharma SRL
      2021   Phase 2   EUCTR2020-003265-19-IT   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden
   University College London
      2014   Phase 2   EUCTR2013-003363-64-GB   United Kingdom
      2010   Phase 2   EUCTR2009-018137-37-GB   United Kingdom
   University College London Comprehensive Clinical Trial Unit
      2019   Phase 3   EUCTR2018-003028-35-GB   United Kingdom
   University Medical Center Groningen
      2022   Phase 2   EUCTR2021-005024-37-NL   Netherlands
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands
   Voyager Therapeutics, Inc.
      2019   Phase 2   EUCTR2017-004685-10-PL   Poland;United States
Injection OF apomorphine
   University Hospital, Toulouse
      2011   Phase 3   NCT01504178   France
Injection OF normal saline
   Yonsei University
      2013   Phase 1/Phase 2   NCT02018406   Korea, Republic of
Injection OF umbilical cord derived mscs
   University of Jordan
      2018   Phase 1/Phase 2   NCT03684122   Jordan
INN NOT available AT this time
   Region Skåne – Skåne University Hospital
      2022   Phase 1;Phase 2   EUCTR2021-001366-38-SE   Sweden;United Kingdom
Inosine
   Dept. of Clinical pharmacology and Neurology
      2016   Phase 1   JPRN-UMIN000009062   Japan
   Ehime University Graduate School of Medicine
      2016   Phase 2   JPRN-UMIN000020527   Japan
   Kamatani Naoyuki
      2019   Phase 1   JPRN-jRCTs031190115   -
   Michael Alan Schwarzschild
      2016   Phase 3   NCT02642393   Puerto Rico;United States
   Nagai Masahiro
      2016   Phase 2   JPRN-jRCTs061180060   -
   StaGen Co. Ltd.
      2018   -   JPRN-UMIN000030930   Japan
   The Parkinson Study Group
      2009   Phase 2   NCT00833690   United States
   Tsukuba International Clinical Pharmacology Clinic
      2016   -   JPRN-UMIN000024312   Japan
INS-GSH
   Gateway Institute for Brain Research
      2022   Phase 2   NCT05266417   United States
Insulin
   dr.dargahi
      2020   Phase 2   NCT04687878   Iran, Islamic Republic of
Intervention FOR madopar + entacapone group
   Yousheng Xiao
      2025   Phase 4   NCT06928519   China
Intracerebral microinjections
   NeuroGeneration
      2022   Phase 1/Phase 2   NCT03309514   -
Intranasal glutathione - (IN)GSH
   Bastyr University
      2012   Phase 1   NCT01398748   United States
Intranasal insulin
   Peter Novak
      2014   Phase 2   NCT02064166   United States
Intravenous infusion
   VA Office of Research and Development
      2019   -   NCT04064294   United States
Intravenous levodopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00089622   United States
      2004   Phase 2   NCT00086294   United States
      2004   Phase 2   NCT00076674   United States
Intravesical injection OF botulinum A toxin
   University Of Perugia
      2008   Phase 4   NCT00822913   -
Inulin
   Hirooka Yoshiki
      2022   Phase 1-2   JPRN-jRCTs041220054   -
Inulin, B-vitamins and vitamin D
   University of Ulster
      2024   -   NCT06697626   United Kingdom
Iodio ioflupano-123I
   UCB Biopharma SRL
      2021   Phase 2   EUCTR2020-003265-19-IT   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Ioflupane
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
   MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
      2012   Phase 4   EUCTR2010-019894-13-IT   Italy;United States
   Umeå University Hospital
      2015   Phase 2   EUCTR2015-003045-26-SE   Sweden
   University Hospital, Toulouse
      2009   Phase 2   NCT00940914   France
   Weill Medical College of Cornell University
      2018   Phase 1/Phase 2   NCT03675282   United States
Ioflupane I 123
   Julie Gurwell
      2018   -   NCT03531086   United States
Ipratropium
   University Health Network, Toronto
      2004   Phase 2   NCT00296946   Canada
Iproniazid
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
IPS-NSC cells
   Allife Medical Science and Technology Co., Ltd.
      2019   Early Phase 1   NCT03815071   -
IPT803
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
IPX054 100 MG
   Impax Laboratories, LLC
      2005   Phase 1/Phase 2   NCT00239564   United States
IPX054 150 MG
   Impax Laboratories, LLC
      2005   Phase 1/Phase 2   NCT00239564   United States
IPX054 200 MG
   Impax Laboratories, LLC
      2006   Phase 2   NCT00279825   United States
      2005   Phase 2   NCT00253084   United States
      2005   Phase 1/Phase 2   NCT00239564   United States
IPX054 250 MG
   Impax Laboratories, LLC
      2006   Phase 2   NCT00279825   United States
      2005   Phase 1/Phase 2   NCT00239564   United States
IPX054 300 MG
   Impax Laboratories, LLC
      2005   Phase 1/Phase 2   NCT00239564   United States
IPX066
   Impax Laboratories, LLC
      2011   Phase 3   NCT01411137   United States
      2010   Phase 3   NCT01130493   France;Germany;Italy;United States
      2009   Phase 3   NCT00974974   Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States
      2008   Phase 2   NCT00869791   United States
IPX066 145 MG
   Impax Laboratories, LLC
      2010   Phase 3   NCT01096186   Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States
IPX066 145 MG LD
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States
IPX066 195 MG
   Impax Laboratories, LLC
      2010   Phase 3   NCT01096186   Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States
IPX066 195 MG LD
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States
IPX066 245 MG
   Impax Laboratories, LLC
      2010   Phase 3   NCT01096186   Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States
IPX066 245 MG LD
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States
IPX066 95 MG
   Impax Laboratories, LLC
      2010   Phase 3   NCT01096186   Canada;Estonia;Germany;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United States
IPX066 95 MG LD
   Impax Laboratories, LLC
      2009   Phase 3   NCT00880620   Canada;Estonia;Latvia;Lithuania;Romania;Ukraine;United States
IPX066-145
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
IPX066-195
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
IPX066-245
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
IPX066-95
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
IPX203
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002234-21-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-IT   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-ES   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-DE   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-CZ   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
   Oslo University Hospital
      2021   Phase 3   EUCTR2021-000541-41-DE   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
IPX203 140 MG
   Impax Laboratories, LLC
      2019   Phase 3   NCT03877510   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IPX203 180 MG
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States
IPX203 210 MG
   Impax Laboratories, LLC
      2019   Phase 3   NCT03877510   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IPX203 270 MG
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States
IPX203 280 MG
   Impax Laboratories, LLC
      2019   Phase 3   NCT03877510   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IPX203 350 MG
   Impax Laboratories, LLC
      2019   Phase 3   NCT03877510   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IPX203 ER CD-LD
   Impax Laboratories, LLC
      2018   Phase 3   NCT03670953   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IR CD-LD
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, LLC
      2018   Phase 3   NCT03670953   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2016   Phase 2   NCT03007888   United States
      2009   Phase 3   NCT00974974   Canada;France;Germany;Poland;Romania;Spain;Ukraine;United States
      2008   Phase 2   NCT00869791   United States
IR CD-LD (carbidopa-levodopa) tablets
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002233-37-PL   Canada;Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-IT   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-GB   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-DE   Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002233-37-CZ   Czech Republic;France;Germany;Italy;Poland;Spain;United Kingdom;United States
IR LD / CD
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
IR LD/CD
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
Irbd
   Beijing Friendship Hospital
      2022   Phase 4   NCT06710574   China
IRL752
   Integrative Research Laboratories AB
      2017   Phase 2   EUCTR2017-001673-17-FI   Finland;Sweden
   Integrative Research Laboratories Sweden AB (IRLAB)
      2023   Phase 2   EUCTR2019-002627-16-NL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-PL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-FR   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-ES   France;Germany;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-DE   France;Germany;Netherlands;Poland;Spain;Sweden
IRL790
   Integrative Research Laboratories AB
      2018   Phase 2   NCT03368170   Sweden;United Kingdom
      2016   Phase 1/Phase 2   NCT03531060   -
   Integrative Research Laboratories AB (IRLAB)
      2019   Phase 2   EUCTR2017-003458-18-SE   Sweden
      2017   Phase 2   EUCTR2017-003458-18-GB   Sweden;United Kingdom
   Integrative Research Laboratories Sweden AB
      2021   Phase 2   EUCTR2020-002010-41-IT   France;Israel;Italy;Poland;Serbia;United States
   Integrative Research Laboratories Sweden AB (IRLAB)
      2020   Phase 2   EUCTR2020-002010-41-FR   France;Israel;Italy;Poland;Serbia;United States
IRX4204
   Io Therapeutics
      2014   Phase 1   NCT02438215   United States
ISC-hpnsc
   Cyto Therapeutics Pty Limited
      2016   Phase 1   NCT02452723   Australia
Isicom
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
Isoflurane
   Columbia University
      2003   -   NCT00615472   United States
Isradipine
   Northwestern University
      2008   Phase 2   NCT00753636   United States
   University of Rochester
      2014   Phase 3   NCT02168842   Canada;United States
Isradipine CR 10MG
   Northwestern University
      2009   Phase 2   NCT00909545   Canada;United States
Isradipine CR 20MG
   Northwestern University
      2009   Phase 2   NCT00909545   Canada;United States
Isradipine CR 5MG
   Northwestern University
      2009   Phase 2   NCT00909545   Canada;United States
Istradefylline
   Fukuoka University
      2016   -   JPRN-UMIN000024536   Japan
   Hatano Taku
      2019   -   JPRN-jRCTs031180248   -
   Juntendo University Shizuoka Hospital
      2016   -   JPRN-UMIN000020288   Japan
   KYOWA HAKKO KIRIN PHARMA, INC.
      2016   Phase 3   EUCTR2015-003887-34-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-002844-93-IT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain
   Kyowa Hakko Kirin Company, Limited
      2009   Phase 3   NCT00957203   Japan
      2009   Phase 3   NCT00955526   Japan
      2007   Phase 2   NCT00455507   Japan
      2005   Phase 2   NCT00250393   Japan
      2005   Phase 2   NCT00199355   Japan
   Kyowa Hakko Kirin Pharma, Inc.
      2014   Phase 3   EUCTR2013-002254-70-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-002844-93-LV   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-LT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-GB   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-ES   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-EE   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-AT   Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain
   Kyowa Kirin Co., Ltd.
      2004   Phase 3   NCT00199394   United Kingdom
   Kyowa Kirin Pharmaceutical Development, Inc.
      2016   Phase 3   EUCTR2015-003887-34-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2016   Phase 3   EUCTR2015-003887-34-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2016   Phase 3   EUCTR2015-003887-34-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2005   Phase 3   NCT00199381   United States
   Kyowa Kirin, Inc.
      2005   Phase 2   NCT00199433   United States
      2004   Phase 3   NCT00199420   United States
      2004   Phase 3   NCT00199407   United States
      2004   Phase 3   NCT00199368   United States
      2002   Phase 2/Phase 3   NCT00955045   United States
      2002   Phase 2   NCT00456794   United States
      2002   Phase 2   NCT00456586   United States
   Osaka Red Cross Hospital
      2017   -   JPRN-UMIN000026492   Japan
   Takahashi Makio
      2017   -   JPRN-jRCTs051180185   -
   Tsuboi Yoshio
      2017   -   JPRN-jRCTs071180014   Japan;N A
   University of Chicago
      2005   Phase 3   NCT00203957   United States
Istradefylline 20 MG
   Ichinomiya Nishi Hospital
      2019   -   JPRN-UMIN000037422   Japan
      2019   -   JPRN-UMIN000037421   Japan
   Kyowa Kirin Co., Ltd.
      2013   Phase 3   NCT01968031   Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States
Istradefylline 20 MG or 40 MG
   Kyowa Kirin Co., Ltd.
      2015   Phase 3   NCT02610231   Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States
Istradefylline 40 MG
   Kyowa Kirin Co., Ltd.
      2014   Phase 1   NCT02174250   United States
      2013   Phase 3   NCT01968031   Canada;Czech Republic;Czechia;Germany;Israel;Italy;Poland;Serbia;United States
   Medical University of South Carolina
      2022   -   NCT05182151   United States
Istradefylline medication
   Virginia Commonwealth University
      2022   Phase 2   NCT05333549   United States
Istradefylline pill
   Georgetown University
      2023   Phase 4   NCT05885360   United States
ITI-214
   Intra-Cellular Therapies, Inc.
      2017   Phase 1/Phase 2   NCT03257046   United States
IV apomorphine
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 2   NCT00040209   United States
IV levodopa
   National Institute of Neurological Disorders and Stroke (NINDS)
      2005   Phase 2   NCT00108667   United States
      2002   Phase 2   NCT00040209   United States
      2001   Phase 2   NCT00013624   United States
      2001   Phase 2   NCT00009048   United States
      2000   Phase 2   NCT00006337   United States
IZD174
   Inflazome UK Ltd
      2020   Phase 1   NCT04338997   -
J-tube
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States
      2009   Phase 3   NCT00357994   Germany;United States
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2006   Phase 4   NCT00141518   Norway;Sweden
Jejunal extension tube
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie (prior sponsor, Abbott)
      2006   Phase 4   NCT00141518   Norway;Sweden
JM-010
   Bukwang Pharmaceutical
      2015   Phase 2   NCT02439203   South Africa
   Contera Pharma
      2023   Phase 2   EUCTR2022-002818-16-IT   France;Germany;Italy;Korea, Republic of;Spain
      2020   Phase 2   EUCTR2017-003415-19-IT   France;Germany;Italy;Spain
      2018   Phase 2   EUCTR2017-003415-19-ES   France;Germany;Spain
   Contera Pharma A/S
      2024   Phase 2   NCT05516875   Italy;Spain
      2023   Phase 2   EUCTR2017-003415-19-SK   France;Germany;Italy;Korea, Republic of;Slovakia;Spain
      2022   Phase 2   EUCTR2022-002818-16-FR   France;Germany;Italy;Korea, Republic of;Spain
JM-010 group A
   Contera Pharma
      2019   Phase 2   NCT03956979   France;Germany;Italy;Korea, Republic of;Spain
JM-010 group B
   Contera Pharma
      2019   Phase 2   NCT03956979   France;Germany;Italy;Korea, Republic of;Spain
JNJ-31001074
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States
   BenevolentAI Bio
      2017   Phase 2   EUCTR2017-000877-35-GB   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-ES   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-DE   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000877-35-CZ   Czech Republic;Germany;Italy;Poland;Spain;United Kingdom;United States
JNJ31-31001074
   BENEVOLENTAI BIO
      2017   Phase 2   EUCTR2017-000877-35-IT   Czech Republic;Czechia;Germany;Italy;Poland;Spain;United Kingdom;United States
JP 1730
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   Phase 2   NCT00040209   United States
JP-1730/F01
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
JP-1730/F02
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
JP-1730/F03
   Juvantia Pharma Ltd
      2008   -   EUCTR2007-004890-24-PT   France;Portugal
      2008   -   EUCTR2007-004890-24-FR   France;Portugal
Juvit D3
   Medical University of Gdansk
      2019   -   NCT04768023   Poland
JX2105
   Zhejiang Jingxin Pharmaceutical Co., Ltd.
      2024   Phase 1   NCT06537050   China
JZP-110
   Jazz Pharmaceuticals
      2017   Phase 2   NCT03037203   United States
JZP385
   Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
      2023   Phase 2   EUCTR2022-001063-27-PL   Germany;Poland;Spain;United States
      2023   Phase 2   EUCTR2022-001063-27-DE   Germany;Poland;Spain;United States
K0706
   Sun Pharma Advanced Research Company (SPARC) Limited
      2019   Phase 2   EUCTR2018-003337-15-SK   Hungary;India;Poland;Slovakia;Spain;United States
      2019   Phase 2   EUCTR2018-003337-15-HU   Hungary;India;Poland;Slovakia;Spain;United States
      2019   Phase 2   EUCTR2018-003337-15-ES   Czech Republic;Hungary;India;Poland;Slovakia;Spain;United States
   Sun Pharma Advanced Research Company Limited
      2019   Phase 2   NCT03655236   Hungary;India;Poland;Slovakia;Spain;United States
      2017   Phase 1   NCT02970019   United States
KDT-3594
   Kissei Pharmaceutical Co., Ltd.
      2024   Phase 2   NCT06722729   Japan
      2021   Phase 2   NCT04867551   Japan
      2019   Phase 2   NCT03845387   Japan
      2017   Phase 1   NCT03068481   Japan
   Shimizu Yoshitaka
      2021   Phase 2   JPRN-jRCT2031210089   -
Ketamine
   Maastricht University
      2022   Phase 2   EUCTR2021-000041-40-NL   Netherlands
   PharmaTher Inc.
      2021   Phase 2   NCT04912115   United States
   University of Arizona
      2019   Phase 1   NCT06021756   United States
   VA Office of Research and Development
      2025   Phase 2   NCT06231563   United States
   Yancheng Third People's Hospital
      2024   -   ChiCTR2500098063   China
Ketamine hydrochloride
   Yale University
      2024   Phase 2   NCT06402955   United States
Ketamine infusion
   Yale University
      2021   Phase 2   NCT04944017   United States
Ketone ester (R)-3-hydroxybutyl (R)-3-hydroxybutyrate
   University of Michigan
      2023   -   NCT05778695   United States
Ketone ester beverage
   University of Michigan
      2023   -   NCT05948956   United States
Ketone ester drink
   University of Oxford
      2011   -   NCT01364545   United Kingdom
Ketone ester elite endurance nutrition drink
   University of Florida
      2019   -   NCT04477161   United States
KL002 injection solution
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2023   Early Phase 1   NCT05882487   China
KM-819
   FAScinate Therapeutics Inc.
      2022   Phase 2   NCT05670782   United States
   Kainos Medicine Inc.
      2016   Phase 1   NCT03022799   Korea, Republic of
KP405
   Kariya Pharmaceuticals
      2024   Early Phase 1   NCT06189170   United Kingdom
KW-6002
   KYOWA HAKKO KIRIN PHARMA, INC.
      2016   Phase 3   EUCTR2015-003887-34-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States
   KYOWA HAKKO UK LTD
      2005   -   EUCTR2004-002844-93-IT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-000817-20-IT   Italy;Latvia;Lithuania;Spain
   Kyowa Hakko Kirin Company, Limited
      2005   Phase 2   NCT00250393   Japan
      2005   Phase 2   NCT00199355   Japan
   Kyowa Hakko Kirin Pharma, Inc.
      2014   Phase 3   EUCTR2013-002254-70-IT   Canada;Czech Republic;Germany;Israel;Italy;Poland;Serbia;United States
   Kyowa Hakko U.K. Limited
      2005   -   EUCTR2004-002844-93-LV   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-LT   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-GB   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-ES   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-EE   Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-002844-93-AT   Austria;Estonia;Italy;Latvia;Lithuania;Spain;United Kingdom
      2005   -   EUCTR2004-000817-20-AT   Austria;Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LV   Italy;Latvia;Lithuania;Spain
      2004   -   EUCTR2004-000817-20-LT   Italy;Latvia;Lithuania;Spain
      2004   Phase 3   EUCTR2004-000817-20-GB   Austria;Italy;Latvia;Lithuania;Spain;United Kingdom
      2004   -   EUCTR2004-000817-20-ES   Italy;Latvia;Lithuania;Spain
   Kyowa Kirin Co., Ltd.
      2004   Phase 3   NCT00199394   United Kingdom
   Kyowa Kirin Pharmaceutical Development, Inc.
      2016   Phase 3   EUCTR2015-003887-34-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2016   Phase 3   EUCTR2015-003887-34-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2016   Phase 3   EUCTR2015-003887-34-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-PL   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-DE   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
      2014   Phase 3   EUCTR2013-002254-70-CZ   Canada;Czech Republic;Germany;Israel;Poland;Serbia;United States
   Kyowa Kirin, Inc.
      2005   Phase 2   NCT00199433   United States
      2004   Phase 3   NCT00199420   United States
      2004   Phase 3   NCT00199407   United States
      2004   Phase 3   NCT00199368   United States
      2002   Phase 2   NCT00456794   United States
      2002   Phase 2   NCT00456586   United States
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006337   United States
KW-6356
   Kyowa Hakko Kirin Co., Ltd.
      2016   Phase 2   JPRN-jRCT2080223340   -
   Kyowa Kirin Co., Ltd.
      2020   Phase 1   NCT04342273   Japan
      2019   Phase 1   NCT04070495   Japan
      2019   Phase 1   NCT03970798   Japan
      2018   Phase 2   NCT03703570   Japan
      2018   Phase 2   JPRN-jRCT2080224050   Japan
      2016   Phase 2   NCT02939391   Japan
KW-6356 high dose
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan
KW-6356 LOW dose
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan
KW-6356 middle dose
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan
KW-6356 X dose
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan
KW-6356 Y dose
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03830528   Japan
KW-6500
   Kyowa Hakko Kirin Co., Ltd
      2010   Phase 3   NCT01063621   Japan
      2010   Phase 3   NCT01058291   Japan
      2009   Phase 3   NCT00955318   Japan
L-123 ioflupane
   Wisconsin Institute for Neurologic and Sleep Disorders S.C.
      2014   -   NCT02138682   United States
L-3-(3,4-dihydroxyphenyl)alanine
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
L-dopa
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   -
   MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
      2012   Phase 4   NCT01770145   United States
   Merck Sharp & Dohme Corp.
      2007   Phase 2   NCT00537017   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States
      2006   Phase 2   NCT00406029   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States
   Nihon Kohden Corporation
      2015   Phase 3   JPRN-jRCT2092220299   Japan
   Osaka Redcross Hospital Wakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   Phase 2   EUCTR2009-011093-15-DE   Germany
   UCB Pharma
      2012   Phase 3   NCT01646255   China
   University Hospital, Toulouse
      2011   Phase 3   NCT01504178   France
   University of Toronto
      2015   Phase 2   NCT02347059   Canada
   Utano National Hospital, National Hospital Organization
      2016   Phase 3   JPRN-UMIN000022529   Japan
L-dopa 140 MG
   Impel NeuroPharma Inc.
      2018   Phase 2   NCT03541356   Australia
L-dopa 35 MG
   Impel NeuroPharma Inc.
      2018   Phase 2   NCT03541356   Australia
L-dopa 70MG/carbidopa 7MG
   Impel NeuroPharma Inc.
      2018   Phase 2   NCT03541356   Australia
L-dopa/ modopar
   Chru de Lille
      2009   Phase 3   EUCTR2008-008210-38-FR   France
L-dopa/ddci
   Bial - Portela C S.A.
      2021   Phase 4   NCT04990284   Germany;Italy;Portugal;Spain;United Kingdom
L-dops
   St. Joseph's Hospital and Medical Center, Phoenix
      2016   Phase 2   NCT02812147   United States
L-tyrosine
   New York Institute of Technology
      2014   Phase 0   NCT02259049   United States
Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
   Tanta University
      2022   Phase 3   NCT05576818   Egypt
Lactobacillus casei
   University of Salerno
      2019   -   NCT04293159   Italy
Lactobacillus plantarum
   Yancheng Tinghu District People's Hospital
      2022   -   ChiCTR2300077412   China
Lactobacillus plantarum PS128
   Professor Lu Neurological Clinic
      2018   -   NCT03566589   Taiwan
Lactose
   Ehime University Graduate School of Medicine
      2016   Phase 2   JPRN-UMIN000020527   Japan
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan
   Utano National Hospital, National Hospital Organization
      2016   Phase 3   JPRN-UMIN000022529   Japan
Lactulose
   Shaoxing Hospital of Traditional Chinese Medicine,Shaoxing TCM Hospital Affiliated to Zhejiang Chinese Medical University
      2024   -   ChiCTR2400087750   China
LBT-3627
   Longevity Biotech Australia Pty Ltd (subsidiary)
      2024   Phase 1   NCT06466525   Australia
Lcig
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States
      2009   Phase 3   NCT00357994   Germany;United States
      2006   Phase 4   NCT00141518   Norway;Sweden
   Fujita Health University School of Medicine Department of Gastroenterology
      2020   Phase 4   JPRN-UMIN000040889   Japan
   NeuroDerm Ltd.
      2015   Phase 1   NCT02604914   United Kingdom
   Vastra Gotaland Region
      2018   Phase 1   NCT03419806   Sweden
LD / BE
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
LD+ddci
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia
LD-ddci
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia
LD/CD
   AbbVie
      2020   Phase 3   NCT04380142   Australia;United States
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
LD/CD SC solution
   NeuroDerm Ltd.
      2014   Phase 1   NCT02096601   Israel;United States
Lenrispodun
   Intra-Cellular Therapies, Inc.
      2023   Phase 2   NCT05766813   United States
Leptin
   Nagoya University Graduate School of Medicine
      2015   -   JPRN-UMIN000017036   Japan
Leucine
   University Hospital, Montpellier
      2013   -   NCT02263235   France
Levetiracetam
   1st Hospital of Social Security Services
      2006   Phase 2   NCT00291733   Greece
   Technische Universität Dresden
      2006   Phase 4   NCT00307450   Germany
   The University of Queensland
      2021   Phase 2   NCT04643327   Australia
   UCB Pharma
      2003   Phase 2   NCT00160576   -
   University of South Florida
      2007   Phase 4   NCT00584025   United States
Levodopa
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2016   Phase 3   EUCTR2016-001403-23-IT   European Union;Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie Deutschland GmbH & Co. KG
      2018   Phase 3   EUCTR2016-001403-23-HU   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-GR   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2016-001403-23-FI   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2017   Phase 3   EUCTR2014-004865-26-GR   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-001403-23-SK   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2016   Phase 3   EUCTR2016-001403-23-ES   European Union;Finland;Greece;Hungary;Slovakia;Spain;United States
      2015   Phase 3   EUCTR2014-004865-26-SE   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden;United States
      2015   Phase 3   EUCTR2014-004865-26-IT   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-ES   Australia;Canada;European Union;Germany;Greece;Italy;Spain;Sweden
      2015   Phase 3   EUCTR2014-004865-26-DE   Australia;Canada;European Union;Germany;Italy;Spain;Sweden
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2009   Phase 3   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
   Abbott Japan Co., Ltd.
      2011   Phase 2   JPRN-jRCT2080221657   -
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
   Ankara Ataturk Sanatorium Training and Research Hospital
      2023   Phase 4   NCT06115538   Turkey
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
   Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
      2022   Phase 0   ChiCTR2400084951   China
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal
   Bial - Portela C S.A.
      2011   Phase 3   NCT01568073   Austria;Portugal
      2011   Phase 3   NCT01227655   Portugal
   Biogen
      2016   Phase 2   NCT03000569   United States
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands
   Chinese Academy of Sciences
      2017   Phase 1/Phase 2   NCT03119636   China
   Civitas Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005626-19-CZ   Canada;Czech Republic;Poland;Spain;United States
      2016   Phase 3   EUCTR2015-005067-17-CZ   Canada;Czech Republic;Poland;Spain;United States
      2015   Phase 3   EUCTR2014-003799-22-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom
      2015   Phase 3   EUCTR2014-003799-22-GB   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom
      2015   Phase 3   EUCTR2014-003799-22-DE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2015   Phase 3   EUCTR2014-003799-22-AT   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Serbia;Spain;United Kingdom;United States
      2013   -   EUCTR2012-005822-31-IT   Italy;Serbia;United Kingdom;United States
      2013   -   EUCTR2012-005822-31-GB   Italy;Serbia;United Kingdom;United States
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom
   Civitas Therapeutics, a wholly owned subsidiary of Acorda
      2016   Phase 3   EUCTR2015-005626-19-ES   Canada;Czech Republic;Poland;Spain;United States
   Civitas Therapeutics, a wholly owned subsidiary of Acorda Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-005067-17-ES   Canada;Czech Republic;Poland;Spain;United States
   CleveXel Pharma
      2016   Phase 2   NCT02641054   France
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy
   Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital
      2014   -   ChiCTR-DDD-17010794   China
   Department of Neuroscience, neurology
      2007   -   EUCTR2007-004985-41-SE   Sweden
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   Emory University
      2021   Phase 4   NCT06234995   United States
   First Affiliated Hospital of Anhui Medical University
      2023   Phase 0   ChiCTR2300070333   China
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China
   Gezhouba Central Hospital of Sinopharm
      2024   -   ChiCTR2400082309   China
   GlaxoSmithKline
      2011   -   NCT01545856   -
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan
   Hatano Taku
      2019   -   JPRN-jRCTs031180248   -
   IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LV   Estonia;Latvia;Lithuania
      2009   -   EUCTR2009-010193-38-EE   Estonia;Latvia;Lithuania
   IMPAX Pharmaceuticals a Division of IMPAX Laboratories, Inc.
      2009   -   EUCTR2009-010193-38-LT   Estonia;Latvia;Lithuania
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-017182-38-PL   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceutical Division (Impax)
      2010   -   EUCTR2009-017182-38-LV   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-LT   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-EE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc. acting through its Impax Pharmaceuticals Division
      2010   Phase 3   EUCTR2009-017182-38-ES   Estonia;Germany;Latvia;Lithuania;Poland;Spain
      2010   -   EUCTR2009-017182-38-DE   Estonia;Germany;Latvia;Lithuania;Poland;Spain
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-FR   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-DE   Belgium;France;Germany;Italy
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
   Impax Laboratories, LLC
      2020   Phase 3   EUCTR2018-002234-21-GB   Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-IT   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-ES   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-DE   Czech Republic;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002234-21-CZ   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
   Institute for Neurodegenerative Disorders
      2004   Phase 2   NCT00096720   United States
   Institute of Clinical Pharmacology, Central South University
      2012   -   ChiCTR-OCS-12002720   -
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China
   Kanazashi Shuichi
      2024   Phase 2   JPRN-jRCT2061230065   -
   Kansai Medical University
      2012   -   JPRN-UMIN000007896   Japan
   Kevin J. Black, MD
      2017   Phase 1   NCT03205956   United States
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States
      2007   Phase 1   NCT00505843   United States
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States
   NOVARTIS FARMA
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom
   National Institute of Neurological Disorders and Stroke (NINDS)
      1998   Phase 3   NCT00004733   United States
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States
   Novartis
      2005   Phase 3   NCT00134966   Canada;Czech Republic;Czechia;Israel;Italy;Poland;Portugal;Turkey;United States
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany
   Oregon Health and Science University
      2010   -   NCT01003002   United States
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom
   Oslo University Hospital
      2021   Phase 3   EUCTR2021-000541-41-DE   Czech Republic;Czechia;Estonia;France;Germany;Italy;Latvia;Lithuania;Poland;Romania;Spain;Ukraine;United Kingdom;United States
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   Phase 2   EUCTR2009-011093-15-DE   Germany
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   -
   Qilu Hospital of Shandong University
      2019   -   NCT05901350   China
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
   Solvay Pharmaceuticals BV.
      2008   -   EUCTR2006-005186-18-IT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
   Solvay Pharmaceuticals GmbH
      2006   -   EUCTR2005-002654-21-NO   Norway;Sweden
      2005   -   EUCTR2005-002654-21-SE   Sweden
   SynAgile Corporation
      2021   Phase 2   EUCTR2020-003372-41-IT   Italy;Luxembourg;Spain
      2021   Phase 1;Phase 2   EUCTR2020-003372-41-ES   Italy;Luxembourg;Spain
   Takeda Pharmaceutical Company Limited
      2015   Phase 3   JPRN-jRCT2080222710   Japan
   Technische Universität Dresden
      2005   Phase 4   NCT00153972   Germany
   Tianjin Huanhu Hospital
      2023   -   ChiCTR2300075996   China
      2019   Phase 0   ChiCTR1900025372   China
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
   University Hospital Bispebjerg and Frederiksberg
      2019   -   NCT06275633   Denmark
   University Hospital, Toulouse
      2016   Phase 2/Phase 3   NCT02601586   France
      2002   -   NCT01044992   France
   Universitätsklinik für Neurologie Innsbruck
      2010   -   EUCTR2010-019354-40-AT   Austria
   VA Office of Research and Development
      2006   -   NCT00467597   United States
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy
   Yagi Michio
      2021   Phase 1   JPRN-jRCT2051200104   -
Levodopa (drug), intraduodenal administration
   University Hospital, Akershus
      2006   Phase 4   NCT00272688   Norway
Levodopa (L-dopa) + standard care
   Bial - Portela C S.A.
      2020   -   NCT03959540   United Kingdom
Levodopa / benserazid
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
Levodopa / benserazide 200 + 50 MG
      2013   -   EUCTR2012-001245-40-IT   Italy
Levodopa / carbidopa solution
   NEURODERM LTD.
      2018   Phase 3   EUCTR2016-002033-30-IT   Belgium;France;Hungary;Italy;Netherlands;Spain;United Kingdom
Levodopa 100 MG / benserazide 25 MG
   Bial - Portela C S.A.
      2005   Phase 1   NCT02778594   Portugal
Levodopa 100 MG A CAP
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
Levodopa 125 MG A CAP
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
Levodopa 150 MG A CAP
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
Levodopa 75 MG A CAP
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
Levodopa acute challenge
   Institut de Myologie, France
      2016   -   NCT02785978   France
Levodopa and carbidopa
   NeuroDerm Ltd.
      2014   Phase 2   NCT01883505   Israel
Levodopa and decarboxylase inhibitor
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
Levodopa and domperidone
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006077   United States
Levodopa benserazide madopar
   IRCCS San Raffaele Roma
      2014   Phase 4   NCT02741947   Italy
Levodopa benserazide teva italia
   IRCCS San Raffaele Roma
      2014   Phase 4   NCT02741947   Italy
Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00357994   Germany;United States
Levodopa cyclops
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands
   PureIMS B.V.
      2023   Phase 1   NCT06037590   Bulgaria
Levodopa dispersible
   Seoul National University Hospital
      2015   Phase 4   NCT02769793   Korea, Republic of
Levodopa formulation
   Sumitomo Pharma Co., Ltd.
      2022   Phase 1   NCT05435729   Japan
Levodopa infusion
   Helsinki University
      2009   Phase 4   NCT00914134   Finland
Levodopa INN
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
Levodopa MR
   Orion Corporation, Orion Pharma
      2016   Phase 2   NCT02764125   Finland;Germany;Hungary;Latvia
Levodopa or acupuncture
   Oregon Health and Science University
      2005   -   NCT00692328   United States
Levodopa powder FOR inhalation
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands
Levodopa tablet
   Western University, Canada
      2019   -   NCT04054960   Canada
Levodopa, carbidopa, entacapone
   Orion Corporation, Orion Pharma
      2015   Phase 1   NCT02554734   Finland
Levodopa, carbidopa, ODM-104
   Orion Corporation, Orion Pharma
      2017   Phase 1   NCT03140956   Finland
      2015   Phase 1   NCT02554734   Finland
      2014   Phase 1   NCT02312232   Finland
Levodopa, decarboxylase inhibitor and comt inhibitor
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
Levodopa-4'-monophosphate
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2020   Phase 3   EUCTR2019-004235-23-IT   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-IT   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
   AbbVie Deutschland
      2020   Phase 3   EUCTR2018-002144-85-DE   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-NL   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-GB   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-ES   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-DK   Australia;Belgium;Canada;Denmark;Germany;Italy;Japan;Netherlands;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-002144-85-BE   Australia;Belgium;Canada;Denmark;Germany;Japan;Netherlands;Spain;United Kingdom;United States
   Abbvie Deutschland GmbH & Co. KG
      2021   Phase 3   EUCTR2019-004235-23-SE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004235-23-DE   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-NL   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-GB   Australia;Canada;Japan;Russian Federation;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004235-23-DK   Australia;Canada;Denmark;Germany;Italy;Japan;Netherlands;Russian Federation;Sweden;United Kingdom;United States
Levodopa-carbidopa
   AbbVie
      2010   Phase 1   NCT01484990   Germany;Sweden
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy
   Fujita Health University School of Medicine Department of Gastroenterology
      2020   Phase 4   JPRN-UMIN000040889   Japan
   Mostafa Bahaa
      2023   Phase 2/Phase 3   NCT06113640   Egypt
   Osmotica Pharmaceutical Corp.
      2007   Phase 2   NCT00558337   Argentina
   Tanta University
      2023   Phase 2   NCT05781711   Egypt
Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States
Levodopa-carbidopa immediate release
   Nimble Science Ltd.
      2024   -   NCT06003608   Canada
Levodopa-carbidopa immediate release (LC-IR) tablets
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States
Levodopa-carbidopa intestinal GEL
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
      2015   Phase 3   NCT02549092   Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan
      2009   Phase 3   NCT00660673   Australia;Canada;Czech Republic;Czechia;Israel;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom;United States
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2006   Phase 4   NCT00141518   Norway;Sweden
Levodopa-carbidopa multilayer extended release tablet
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany
Levodopa-carbidopa-entacapone
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain
Levodopa/benserazide
   Bial - Portela C S.A.
      2009   Phase 1   NCT01533116   Canada
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039201   China
   Yousheng Xiao
      2025   Phase 4   NCT06928519   China
Levodopa/benserazide 100/25 MG
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France
Levodopa/benzeraside
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
Levodopa/benzerazide
   Bial - Portela C S.A.
      2010   Phase 2   NCT01568047   Romania;Ukraine
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine
Levodopa/carbidopa
   AbbVie
      2020   Phase 3   NCT04380142   Australia;United States
   Bial - Portela C S.A.
      2011   Phase 1   NCT02170376   France
      2010   Phase 2   NCT01568047   Romania;Ukraine
      2009   Phase 2   NCT01568034   Portugal;Romania;Ukraine
      2009   Phase 1   NCT01533116   Canada
      2009   Phase 1   NCT01519284   Portugal
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain
   Juntendo University School of Medicine
      2017   -   JPRN-UMIN000025645   Japan
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain
   NeuroDerm Ltd.
      2015   Phase 1   NCT02486432   -
   ONO PHARMACEUTICAL CO.,LTD.
      2014   Phase 1   JPRN-jRCT2080222651   -
      2013   Phase 1   JPRN-jRCT2080222143   -
   Orion Corporation, Orion Pharma
      2009   Phase 1   NCT01070628   Finland
   Sandoz
      2012   Phase 4   NCT01683253   Korea, Republic of
   Taguchi Fumi
      2023   Phase 2   JPRN-jRCT2021230019   -
   Tanta University
      2024   Phase 2/Phase 3   NCT06785298   Egypt
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039201   China
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden
      2008   Phase 4   NCT00888186   Sweden
Levodopa/carbidopa 100/25
   Bial - Portela C S.A.
      2010   Phase 1   NCT02169414   France
Levodopa/carbidopa oral formulation A
   University of Minnesota
      2025   Early Phase 1   NCT05471609   United States
Levodopa/carbidopa oral formulation B
   University of Minnesota
      2025   Early Phase 1   NCT05471609   United States
Levodopa/carbidopa oral formulation C
   University of Minnesota
      2025   Early Phase 1   NCT05471609   United States
Levodopa/carbidopa solution
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2016-002033-30-NL   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-HU   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-GB   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2016   Phase 3   EUCTR2016-002033-30-FR   Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002033-30-ES   Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-002033-30-BE   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005814-31-FR   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005814-31-AT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-DE   Austria;Germany;Israel;Italy;United States
      2016   Phase 2   EUCTR2015-005078-39-AT   Austria;Germany;Israel;Italy;United States
Levodopa/carbidopa solution FOR SC administration
   NeuroDerm Ltd.
      2012   Phase 1   NCT01725802   Israel
Levodopa/carbidopa/entacapone
   Department of Neurology, Dongyang People’s Hospital, Affiliated to Wenzhou Medical University.
      2021   Phase 0   ChiCTR2400091631   China
   Novartis
      2006   Phase 4   NCT00391898   Spain
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal
   Orion Corporation, Orion Pharma
      2005   Phase 4   NCT00125567   Denmark;Finland;Germany;Ireland;Sweden;United Kingdom
   Second Affiliated Hospital of Soochow University
      2023   Phase 4   NCT06236230   China
Levodopa/ddci
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
Levodopa/dopa decarboxylase inhibitor
   Bial - Portela C S.A.
      2016   Phase 4   NCT02847442   Germany
Liatermin
   Amgen
      2003   Phase 1   NCT00115427   United States
      2003   Phase 1/Phase 2   NCT00111982   United States
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom
Lidocaine
   Dept. of Clinical pharmacology and Neurology, Ehime University
      2012   -   JPRN-UMIN000007617   Japan
   Parkinson's disease and Movement Disorder Center
      2012   -   JPRN-UMIN000009099   Japan
Lidocaine hydrochloride
   Copka Sonpashan
      2024   -   NCT06319625   -
   Muhammad
      2024   -   NCT06301724   Myanmar
   Nantes University Hospital
      2014   -   NCT02236260   France
Linaclotide
   The 988th Hospitail of Joint Logistic Support Force
      2021   Phase 4   ChiCTR2100043303   China
Lipopolysaccharide
   University of Exeter
      2022   -   NCT05205291   United Kingdom
Liquigen MCT OIL
   National Institute of Neurological Disorders and Stroke (NINDS)
      2021   Phase 1   NCT04584346   United States
Liraglutide
   Cedars-Sinai Medical Center
      2017   Phase 2   NCT02953665   United States
Lisparin
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Lisuride
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
Lisuride hydrogenmaleate
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Lisuride transdermal system
   National Institute of Neurological Disorders and Stroke (NINDS)
      2004   Phase 2   NCT00089622   United States
Lisuride TTS
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
Lithium
   State University of New York at Buffalo
      2024   Phase 1/Phase 2   NCT06339034   United States
      2019   Phase 1   NCT04273932   United States
Lithium aspartate
   State University of New York at Buffalo
      2024   Phase 1/Phase 2   NCT06592014   United States
      2023   Phase 1   NCT06099886   United States
Live combined bifidobacterium,lactobacillus and enterococcus capsules
   Beijing Friendship Hospital
      2021   Phase 4   NCT04871464   China
Lixisenatide
   University Hospital, Toulouse
      2018   Phase 2   NCT03439943   France
Local trade name, 2MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Local trade name, 4MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Local trade name, 8MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Lovastatin
   National Taiwan University Hospital
      2017   Phase 2   NCT03242499   Taiwan
LOW dose affitope® PD03A + adjuvant
   Affiris AG
      2014   Phase 1   NCT02267434   Austria
LOW dose levodopa
   Rush University Medical Center
      2018   -   NCT04956939   United States
LOW-frequency-only stimulation
   James Liao
      2021   Phase 1   NCT05022147   United States
Lower limb strength
   Ankara Yildirim Beyazit University
      2019   -   NCT04420910   Turkey
LU 00-800
   H. Lundbeck A/S
      2006   Phase 4   EUCTR2005-002038-36-GB   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
LU AF28996
   H. Lundbeck A/S
      2023   Phase 1   NCT06004180   Japan
      2020   Phase 1   NCT04291859   France;Germany;Netherlands;Spain;United States
LU AF82422
   H. Lundbeck A/S
      2018   Phase 1   NCT03611569   United States
Lubiprostone
   Baylor College of Medicine
      2009   Phase 4   NCT00908076   United States
   Dokkyo Medical University
      2016   -   JPRN-UMIN000022023   Japan
      2016   -   JPRN-UMIN000022022   Japan
   University of Arkansas
      2009   -   NCT00669461   United States
Lumbar puncture
   National Institute of Neurological Disorders and Stroke (NINDS)
      2017   Phase 1   NCT03104725   United States
Lumipulse (fujirebio) abeta42, ttau and ptau
   Skane University Hospital
      2017   -   NCT03174938   Sweden
LY03003
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04630860   China
      2020   Phase 3   NCT04571164   China
      2020   Phase 1   NCT04384666   United States
      2018   Phase 1   NCT04629404   China
      2018   Phase 1   NCT03733561   United States
      2018   Phase 1   NCT03589066   United States
      2017   Phase 1   NCT04045678   China
      2013   Phase 1   NCT04627155   -
      2013   Phase 1   NCT02055274   United States
   Peking University Third Hospital
      2018   Phase 3   NCT04455555   China
   Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.
      2019   Phase 1   JPRN-jRCT2080224689   Japan
LY03009 F1
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia
LY03009 F2
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia
LY03009 F3
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia
LY03009 F4
   Luye Pharma Group Ltd.
      2021   Phase 1   NCT04593511   Australia
LY03017
   Luye Pharma Group Ltd.
      2025   Phase 1   NCT06980207   China
      2025   Phase 1   NCT06793995   China
      2024   Phase 1   NCT06388551   China
LY300164
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00004576   United States
LY3154207
   Eli Lilly and Company
      2017   Phase 2   NCT03305809   Canada;China;Puerto Rico;United States
      2015   Phase 1   NCT02562768   United States
LY3884961
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;Netherlands;United States
LY3962681
   Prevail Therapeutics
      2024   Phase 1   NCT06565195   Japan;United States
LY4006896
   Eli Lilly and Company
      2025   Phase 1   NCT06809400   United States
Madopar
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China
   Henan University of Traditional Chinese Medicine
      2009   -   ChiCTR-TRC-12002150   China
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT06976346   China
   Universitätsklinik für Neurologie Innsbruck
      2010   -   EUCTR2010-019354-40-AT   Austria
Madopar 125 MG T, tablets
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
Madopar 125 MG, orodispersible tablet
   Pharmaceutical Technology and Biopharmacy, University of Groningen
      2018   Phase 2   EUCTR2017-004006-18-NL   Netherlands
Madopar 200+50 MG
      2013   -   EUCTR2012-001245-40-IT   Italy
Madopar LT
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
Madopar monotherapy
   Peking University Third Hospital
      2018   Phase 4   NCT04968613   China
Madopar TAB. 125 or perkin TAB. 25-100MG
   SK Chemicals Co., Ltd.
      2021   Phase 4   NCT04821687   Korea, Republic of
Madopar® 125
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela C S.A.
      2001   Phase 1   NCT02763852   Portugal
Madopar® 250
   Bial - Portela C S.A.
      2006   Phase 1   NCT03097211   Portugal
      2006   Phase 1   NCT03094156   Portugal
Madopar® HBS
   Bial - Portela C S.A.
      2009   Phase 1   NCT02169466   Portugal
Madopar® HBS 125
   Bial - Portela C S.A.
      2004   Phase 1   NCT03091543   Portugal
Magnesium oxide
   Dokkyo Medical University
      2016   -   JPRN-UMIN000022023   Japan
      2016   -   JPRN-UMIN000022022   Japan
Maltodextrin
   Affiliated Hospital of Guangdong Medical University
      2023   Phase 3   ChiCTR2300076923   China
   University of Florida
      2021   -   NCT04829760   United States
Mannitol
   Hadassah Medical Organization
      2018   Phase 2   NCT03823638   Israel
Mantadix
   CHU Toulouse
      2007   -   EUCTR2006-006684-22-FR   France
   CHU de Toulouse
      2012   Phase 2   EUCTR2011-005201-75-FR   France
   University Hospital, Toulouse
      2007   Phase 4   NCT00632762   France
Marketed pramipexole ER
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States
Mars
   Eisai Limited
      2007   Phase 3   EUCTR2007-000801-30-PL   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   Phase 3   EUCTR2007-000801-30-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   Phase 3   EUCTR2007-000801-30-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2007-000801-30-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Poland;Spain
      2007   -   EUCTR2006-002937-20-HU   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   Phase 3   EUCTR2006-002937-20-FR   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002937-20-ES   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2007   -   EUCTR2006-002339-26-PT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-HU   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-ES   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2007   -   EUCTR2006-002339-26-DE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002937-20-LV   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-LT   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-EE   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002937-20-CZ   Czech Republic;Estonia;France;Hungary;Italy;Latvia;Lithuania;Spain
      2006   -   EUCTR2006-002339-26-SE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-LT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-GB   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-EE   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-CZ   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-BE   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-002339-26-AT   Austria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-SE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-PT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-LT   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-HU   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004314-33-GB   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   Phase 3   EUCTR2005-004314-33-ES   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-EE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-DE   Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-CZ   Austria;Belgium;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004314-33-BE   Austria;Belgium;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2005   -   EUCTR2005-004314-33-AT   Austria;Estonia;Germany;Hungary;Italy;Lithuania;Portugal;Spain;Sweden;United Kingdom
      2004   -   EUCTR2004-000361-35-CZ   Czech Republic;Italy
Masitinib mesylate
   AB Science
      2015   Phase 2   EUCTR2010-024424-26-SK   Bulgaria;Czech Republic;France;Germany;Hungary;Romania;Slovakia;South Africa;Spain;United States
Massage with A spiky ball
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands
Mavoglurant
   NOVARTIS FARMA
      2012   -   EUCTR2011-004378-27-IT   Austria;Canada;Germany;Hungary;Italy;Spain;United States
   Novartis Pharma Services AG
      2012   -   EUCTR2011-004378-27-SK   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
      2012   -   EUCTR2011-004378-27-HU   Austria;Canada;France;Germany;Hungary;Italy;Spain;United States
      2012   -   EUCTR2011-004378-27-AT   Austria;Canada;France;Germany;Hungary;Italy;Slovakia;Spain;Switzerland;Turkey;United States
Measurement OF serum level OF ANTI-dementia drug
   Zealand University Hospital
      2020   Phase 4   NCT04117178   Denmark
MED ON plus
   IRCCS Istituto delle Scienze Neurologiche di Bologna
      2023   Phase 4   NCT06316232   Italy
MEDI1341
   AstraZeneca
      2020   Phase 1   NCT04449484   United States
      2017   Phase 1   NCT03272165   United Kingdom;United States
Medical cannabis
   Sheba Medical Center
      2021   -   NCT05106504   Israel
Mediterranean diet supplemented with medium-chain triglyceride OIL
   University of British Columbia
      2023   -   NCT05469997   Canada
Mediterranean-ketogenic diet
   University of British Columbia
      2023   -   NCT05469997   Canada
Melatonin
   Instituto Mexicano del Seguro Social
      2021   Phase 2/Phase 3   NCT04287543   Mexico
   KIMJisun
      2016   Phase 4   NCT03258294   -
   Kuhnil Pharmaceutical Co., Ltd.
      2016   Phase 4   NCT02768077   -
   University College London
      2015   Phase 2   EUCTR2014-002697-37-GB   United Kingdom
   University College, London
      2015   Phase 2   NCT02359448   United Kingdom
Melatonin PR
   Seoul National University Hospital
      2016   Phase 2   NCT02789592   Korea, Republic of
Melevodopa and decarboxylase inhibitor
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy
Melperon
   OVATION PHARMACEUTICALS INC
      2007   -   EUCTR2007-002874-75-IT   Italy
      2007   -   EUCTR2007-000307-15-IT   Italy
Melperone HCL
   Lundbeck LLC
      2005   Phase 2   NCT00125138   India;Italy;United States
Memantin orion
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark
Memantine
   Baylor College of Medicine
      2006   Phase 4   NCT00646204   United States
   Department of Neurology, Juntendo University School of Medicine
      2013   -   JPRN-UMIN000010596   Japan
   H. Lundbeck A/S
      2007   Phase 4   NCT00855686   Germany
   Helse Stavanger HF
      2006   Phase 2   NCT00630500   Norway;Sweden;United Kingdom
   Johns Hopkins University
      2006   -   NCT00294554   United States
   Nagoya City University
      2013   -   JPRN-UMIN000046104   Japan
   Neurologisk afdeling F
      2005   Phase 2   EUCTR2004-004139-74-DK   Denmark
   Regional Dementia Research Centre, Dept of Neurology
      2018   Phase 4   EUCTR2017-002707-10-DK   Denmark
   University Hospital, Lille
      2009   Phase 4   NCT01108029   France
   University of Aarhus
      2005   -   NCT00375778   Denmark
   Wayne State University
      2019   Phase 3   NCT03858270   United States
   Zealand University Hospital
      2020   Phase 4   NCT04117178   Denmark
Memantine hydrochloride
   H. Lundbeck A/S
      2007   Phase 3   EUCTR2005-002038-36-GR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   Phase 4   EUCTR2005-002038-36-GB   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2005-002038-36-FR   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-002038-36-DE   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-002038-36-AT   Austria;France;Germany;Greece;Italy;Spain;United Kingdom
Memory
   Sage Bionetworks
      2015   -   NCT02696603   United States
Mesdopetam
   Integrative Research Laboratories AB
      2020   Phase 2   NCT04435431   France;Israel;Italy;Poland;Serbia;United States
      2018   Phase 2   NCT03368170   Sweden;United Kingdom
   Integrative Research Laboratories Sweden AB
      2021   Phase 2   EUCTR2020-002010-41-IT   France;Israel;Italy;Poland;Serbia;United States
   Integrative Research Laboratories Sweden AB (IRLAB)
      2020   Phase 2   EUCTR2020-002010-41-FR   France;Israel;Italy;Poland;Serbia;United States
Mesencephalic neuronal precursor cells
   Bundang CHA Hospital
      2013   Phase 1/Phase 2   NCT01860794   Korea, Republic of
Mesenchymal stem cells
   Hebei Newtherapy BIo-Pharma technology Co., Ltd.
      2018   Phase 1   NCT03550183   China
   Hope Biosciences Stem Cell Research Foundation
      2024   -   NCT06056427   -
   The University of Texas Health Science Center, Houston
      2020   Phase 2   NCT04506073   United States
Mestinon
   Department of Neurology, Roskilde Hospital
      2012   Phase 2   EUCTR2012-000122-21-DK   Denmark
Metformin
   Institute of Clinical Pharmacology, Central South University
      2012   Phase 1 study   ChiCTR-TTRCC-12002751   China
   Peking Union Medical College Hospital
      2020   Phase 4   ChiCTR2000029465   China
   Tanta University
      2023   Phase 2   NCT05781711   Egypt
Methylphenidate
   Department of Veterans Affairs
      2006   -   NCT00393562   United States
   Hubert Fernandez
      2016   Early Phase 1   NCT02879136   United States
   Laval University
      2010   Phase 4   NCT01244269   Canada
   Oregon Health and Science University
      2004   Phase 2   NCT00359723   United States
   Ralph H. Johnson VA Medical Center
      2024   Phase 2   NCT05669170   -
   University Hospital, Lille
      2009   Phase 4   NCT00914095   France
   University of Cincinnati
      2007   Phase 4   NCT00526630   United States
Methylphenidate hydrochloride
   University Medical Center Groningen
      2010   -   EUCTR2009-012643-42-NL   Netherlands
Methylprednisolone
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;Netherlands;United States
Mibg label with I123 or I124
   Tel-Aviv Sourasky Medical Center
      2013   Phase 2   NCT01931488   Israel
MID dose anavex2-73
   Anavex Life Sciences Corp.
      2018   Phase 2   NCT03774459   Australia;Spain
Midazolam
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan
   PharmaTher Inc.
      2021   Phase 2   NCT04912115   United States
Midodrine
   Philadelphia Veterans Affairs Medical Center
      2014   -   NCT02365012   United States
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
      2016   Phase 1   NCT02897063   United States
Minocycline
   University of Rochester
      2003   Phase 2   NCT00063193   United States
Minodronic acid
   Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
      2018   -   JPRN-UMIN000033285   Japan
Minzasolmin
   UCB Biopharma SRL
      2022   Phase 2   NCT05543252   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
Mirabegron
   Al Zahraa Hospital
      2017   -   JPRN-UMIN000043848   Asia(except Japan)
   Daniel Burdick, MD
      2014   Phase 4   NCT02092181   United States
   HealthPartners Institute
      2015   Phase 4   NCT02536976   United States
   Seoul National University Hospital
      2017   Phase 4   NCT03412513   Korea, Republic of
Mirapex
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal
   Boehringer Ingelheim
      2005   Phase 4   NCT00144300   United States
   Institute for Neurodegenerative Disorders
      2004   Phase 2   NCT00096720   United States
   Rajesh Pahwa, MD
      2006   Phase 3   NCT00275275   United States
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal
Mirapex ER
   Seoul National University Hospital
      2011   Phase 4   NCT01515774   Korea, Republic of
Mirapex LA
   Boehringer Ingelheim
      2012   -   NCT01525641   Japan
Mirapexin
   First Affiliated Hospital of Xinjiang Medical University
      2007   -   ChiCTR-TRC-07000027   China
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland
Mirapexin / sifrol
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
Mirapexin extended release various strengths
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom
Mirapexin*30CPR 0,7MG
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy
Mirapexin/sifrol
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
Mirtazapine 15 MG
   Leila Dargahi. PharmD PhD
      2022   Phase 2   NCT06530290   Iran, Islamic Republic of
Mitoq
   Antipodean Pharmaceuticals, Inc.
      2006   Phase 2   NCT00329056   Australia;New Zealand
MK0657
   Merck Sharp & Dohme Corp.
      2007   Phase 1   NCT00505843   United States
Mobile platform exercise
   University of Pavia
      2014   -   NCT03314597   -
Moclobemide
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
Modafinil
   Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
      2015   -   JPRN-UMIN000019676   Japan
   Department of Veterans Affairs
      2006   -   NCT00393562   United States
   University of Chicago
      2016   Phase 2   NCT02857244   United States
Modafinil 50MG
   University of Arkansas
      2017   Early Phase 1   NCT03083132   United States
Modiodal
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States
Modopar
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
Modopar 125
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Modopar 62,5
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Monitor
   Chengdu Sport University
      2024   -   ChiCTR2400088282   China
Monoamine oxidase B inhibitors
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain
Montelukast
   Mostafa Bahaa
      2023   Phase 2/Phase 3   NCT06113640   Egypt
Montelukast krka
   Stockholm Health Care Services
      2021   Phase 2   EUCTR2020-000148-76-SE   Sweden
Motilium
   CHU de Toulouse
      2010   Phase 3   EUCTR2010-018650-12-FR   France
Motion capture system
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
Motor assessment
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
Motor assessments before taking regular PD treatment
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
Motor assessments ON regular PD treatment
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
Moxifloxacin
   Bial - Portela C S.A.
      2010   Phase 1   NCT01532115   France
   Kyowa Kirin Co., Ltd.
      2020   Phase 1   NCT04342273   Japan
   Sunovion
      2017   Phase 2   NCT03187301   Italy;United States
Moxifloxacin infusion
   UCB Pharma
      2006   Phase 1   NCT00292227   South Africa
MP+ddci
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia
MP-equivalent
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia
MP-LOW
   ASST Gaetano Pini-CTO
      2016   Phase 2   NCT02680977   Bolivia
MRI scan
   Northwell Health
      2020   -   NCT04228172   United States
MRX0005
   4D pharma plc
      2022   Phase 1   NCT05832775   -
MRX0029
   4D pharma plc
      2022   Phase 1   NCT05832775   -
MSK-DA01 cell delivery device
   BlueRock Therapeutics
      2021   Phase 1   NCT04802733   Canada;United States
MT101-5
   Mthera Pharma Co., Ltd.
      2025   Phase 2   NCT06175767   -
      2022   Phase 1   NCT05844787   United States
Multi-strain probiotic
   King's College Hospital NHS Trust
      2019   -   NCT05146921   United Kingdom
Multidisciplinary intensive rehabilitation treatment
   Ospedale Generale Di Zona Moriggia-Pelascini
      2013   -   NCT02100176   Italy
Muscimol
   National Institute of Neurological Disorders and Stroke (NINDS)
      2009   Phase 1   NCT00921128   United States
Mushroom
   Xuanwu Hospital of Capital Medical University
      2021   Phase 0   ChiCTR2100050538   China
Music
   University of British Columbia
      2013   -   NCT02207387   Canada
Mémantine
   Chru de Lille
      2009   Phase 3   EUCTR2008-008210-38-FR   France
N acetyl cysteine
   Thomas Jefferson University
      2020   Phase 2   NCT04459052   United States
N-0923
   National Institute of Neurological Disorders and Stroke (NINDS)
      1999   Phase 2   NCT00001931   United States
N-acetylcysteine
   National Institute of Neurological Disorders and Stroke (NINDS)
      2017   Phase 1   NCT03104725   United States
   University of Minnesota
      2011   Phase 1   NCT01427517   United States
   Weill Medical College of Cornell University
      2012   Phase 1/Phase 2   NCT01470027   United States
N-acetylcysteine capsule
   University of Minnesota
      2014   Phase 2   NCT02212678   United States
N04bc07
   CHU Rennes
      2021   Phase 4   EUCTR2021-000826-89-FR   France
N04bd02
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
N04bd03
   IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
      -   Phase 4   EUCTR2016-000973-19-IT   Italy
Nabilone
   Medizinische Universität Innsbruck, Universitätsklinik für Neurologie
      2018   Phase 3   EUCTR2017-004253-16-AT   Austria
      2017   Phase 2   EUCTR2017-000192-86-AT   Austria
Nabilone 0.25 MG
   Medical University Innsbruck
      2018   Phase 3   NCT03773796   Austria
      2017   Phase 2   NCT03769896   Austria
Nacom
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   Phase 2   EUCTR2009-011093-15-DE   Germany
Nacom 100
   IMPAX LABORATORIES, INC.
      2010   -   EUCTR2009-017238-39-IT   France;Germany;Italy
   Impax Laboratories, Inc., acting through its Impax Pharmaceuticals Division (Impax)
      2010   Phase 3   EUCTR2009-017238-39-BE   Belgium;France;Germany;Italy
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany
Nacom levodopa+cardidopa
   MERCK SERONO SA
      2009   -   EUCTR2008-002769-30-IT   Italy
Nadolol
   CuraSen Therapeutics, Inc.
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom
NAL
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Nalmefene
   University Hospital, Clermont-Ferrand
      2016   Phase 2   NCT02934919   France
Naloxone hydrochloride dihydrate
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Naltrexone
   University of Pennsylvania
      2009   Phase 4   NCT01052831   United States
Nardil
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
Nasojejunal (NJ) tube
   AbbVie
      2015   Phase 3   NCT02549092   Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States
NBTX-001
   Nobilis Therapeutics Inc.
      2019   Phase 1   NCT04097080   Russian Federation
ND0611
   NeuroDerm Ltd.
      2010   Phase 1   NCT01103011   Israel
ND0612
   NEURODERM LTD.
      2020   Phase 3   EUCTR2018-004156-37-IT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2016-002033-30-IT   Belgium;France;Hungary;Italy;Netherlands;Spain;United Kingdom
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-IT   Austria;Germany;Israel;Italy;United States
   NeuroDerm Ltd.
      2020   Phase 3   EUCTR2018-004156-37-SK   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-SE   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-PT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-NL   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-GB   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-FR   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-ES   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-BE   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-004156-37-AT   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-HU   Austria;Belgium;Canada;Czech Republic;France;Hungary;Israel;Italy;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-004156-37-CZ   Austria;Belgium;Czech Republic;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;United Kingdom;United States
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2016-002033-30-NL   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-HU   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 3   EUCTR2016-002033-30-GB   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-PL   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-HU   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-ES   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2017   Phase 2   EUCTR2015-005814-31-DE   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Romania;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2017   Phase 2   EUCTR2015-005814-31-CZ   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2017   Phase 2   EUCTR2015-005814-31-BE   Austria;Belgium;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Spain;Ukraine;United States
      2016   Phase 3   NCT02782481   Israel
      2016   Phase 2   NCT02726386   Austria;Czechia;France;Germany;Israel;Italy;Poland;Spain;United States
      2016   Phase 3   EUCTR2016-002033-30-FR   Belgium;Canada;Denmark;France;Hungary;Israel;Netherlands;Spain;Sweden;United Kingdom;United States
      2016   Phase 3   EUCTR2016-002033-30-ES   Belgium;Canada;Denmark;France;Israel;Netherlands;Spain;Sweden;United States
      2016   Phase 3   EUCTR2016-002033-30-BE   Belgium;Chile;Czech Republic;Denmark;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 2   EUCTR2015-005814-31-FR   Austria;Belgium;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005814-31-AT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-DE   Austria;Germany;Israel;Italy;United States
      2016   Phase 2   EUCTR2015-005078-39-AT   Austria;Germany;Israel;Italy;United States
      2015   Phase 1   NCT02604914   United Kingdom
      2012   Phase 1   NCT01486628   Israel
ND0612 (levodopa/carbidopa solution) + morning oral IR-LD/CD
   NeuroDerm Ltd.
      2015   Phase 2   NCT02577523   Austria;Israel;Italy;United States
ND0612 solution FOR SC infusion
   NeuroDerm Ltd.
      2019   Phase 3   NCT04006210   Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
ND1421
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom
ND1587
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
ND1589
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
ND1590
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
ND1702
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
NE3107
   BioVie Inc.
      2025   Phase 2   NCT06757010   United States
      2022   Phase 1/Phase 2   NCT05083260   United States
Nebicapone
   BIAL - Portela & Cª, SA
      2006   -   EUCTR2006-001793-24-PT   Austria;Portugal
      2006   -   EUCTR2006-001793-24-AT   Austria;Portugal
   Bial - Portela C S.A.
      2006   Phase 2   NCT03103399   -
      2006   Phase 1   NCT03097211   Portugal
      2001   Phase 1   NCT02772627   Portugal
Nebulizer
   University of Florida
      2015   Phase 1   NCT02390089   United States
Nelotanserin
   Axovant Sciences Ltd.
      2016   Phase 2   NCT02871427   United States
      2016   Phase 2   NCT02708186   United States
Neridronic acid
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   Phase 3   EUCTR2010-018904-94-IT   Italy
Nerixia*IM EV 1F 25MG
   FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
      2010   Phase 3   EUCTR2010-018904-94-IT   Italy
NEU-120
   Neurim Pharmaceuticals Ltd.
      2008   Phase 1/Phase 2   NCT00607451   Israel
NEU-411
   Neuron23 Inc.
      2025   Phase 2   NCT06680830   United States
Neupro
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
   Luye Pharma Group Ltd.
      2013   Phase 1   NCT02055274   United States
   Peking University Third Hospital
      2021   -   NCT04957420   China
   SCHWARZ PHARMA
      2008   -   EUCTR2006-006752-35-IT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Sandoz
      2019   Phase 1   NCT04183634   Germany
   UCB BIOSCIENCES GMBH
      2013   -   EUCTR2012-002840-26-IT   Austria;Bulgaria;Hungary;Italy;Russian Federation;Slovenia;Spain;Turkey;Ukraine;United States
   UCB Biosciences GmbH
      2013   -   EUCTR2012-002840-26-SK   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-SI   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-RO   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-HU   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-ES   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-BG   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-AT   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002608-42-HU   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
      2013   Phase 4   EUCTR2012-002608-42-GB   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
      2013   -   EUCTR2012-002608-42-DE   Germany;Hungary;Poland;Slovakia;United Kingdom;United States
      2012   -   EUCTR2012-002608-42-SK   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
   UCB Pharma
      2011   -   NCT01330290   Germany
   UCB Pharma SA
      2011   -   EUCTR2010-021394-37-IT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain
Neupro 2 MG/24 H parche transdérmico
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
Neupro 2 MG/24 H transdermal patch
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany
Neupro 2MG/24 H transdermal patch
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
Neupro 2MG/24H transdermal patch
   Schwarz Biosciences GmbH
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
Neupro 4 MG / 24 HR. transdermal patch
   Luye Pharma Group Ltd.
      2020   Phase 1   NCT04384666   United States
Neupro 4 MG/24 H parche transdérmico
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
Neupro 4 MG/24 H transdermal patch
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany
Neupro 4MG/24 H transdermal patch
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
Neupro 4MG/24H transdermal patch
   Schwarz Biosciences GmbH
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
Neupro 4MG/24HR transdermal patch
   Luye Pharma Group Ltd.
      2018   Phase 1   NCT03733561   United States
Neupro 6 MG/24 H parche transdérmico
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
Neupro 6 MG/24 H transdermal patch
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany
Neupro 6MG/24 H transdermal patch
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
Neupro 6MG/24H transdermal patch
   Schwarz Biosciences GmbH
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
Neupro 8 MG/24 H parche transdérmico
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
Neupro 8 MG/24 H transdermal patch
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany
Neupro 8MG/24H transdermal patch
   Schwarz Biosciences GmbH
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
Neupro*28CER 2MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*28CER 4MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*28CER 6MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*28CER 8MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*7CER 4MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*7CER 6MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro*7CER 8MG/24H
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
Neupro® 8 MG/24 H
   Luye Pharma Switzerland AG
      2021   Phase 2   EUCTR2021-000867-65-DE   Germany
Neuraceq
   Fundació Clínic per la Recerca Biomèdica
      2016   Phase 4   EUCTR2014-001014-25-ES   Spain
   Institute for Neurodegenerative Disorders
      2016   Phase 2   EUCTR2015-004129-15-ES   Spain
Neurobloc
   AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
      2011   -   EUCTR2009-017412-32-IT   Italy
Neurocognitive assessment
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
Neuroepo
   International Center for Neurological Restoration, Cuba
      2015   Phase 1/Phase 2   NCT04110678   Cuba
Neurostimulation
   David Escobar
      2023   Phase 4   NCT06013956   United States
Neurpro
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy
Niacin
   VA Office of Research and Development
      2020   -   NCT03808961   United States
      2016   -   NCT03462680   United States
Niacinamide
   VA Office of Research and Development
      2020   -   NCT03808961   United States
Nicorette 10MG/ 16 H
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France
Nicorette 15 MG/ 16 H
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France
Nicorette 5 MG/ 16 H
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France
Nicotinamide
   Queen Elizabeth Hospital
      2005   -   EUCTR2004-005034-39-GB   United Kingdom
Nicotinamide riboside
   Haukeland University Hospital
      2023   Phase 2   NCT05589766   Norway
      2020   Phase 3   NCT03568968   Norway
      2019   -   NCT03816020   Norway
Nicotine
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2008   -   EUCTR2008-001336-13-FR   France
   El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
      2019   Phase 2   NCT03865121   Mexico
   Neuraltus Pharmaceuticals, Inc.
      2009   Phase 1/Phase 2   NCT00957918   United States
   Philipps-University Marburg
      2011   Phase 2   EUCTR2010-020299-42-DE   Germany;United States
Nicotine GUM
   New York Institute of Technology
      2015   -   NCT02452125   United States
Nicotine patch
   Department of Clinical Pharmacology and Neurology Ehime University graduated School of Medicine
      2015   -   JPRN-UMIN000016664   Japan
   University of Vermont
      2010   Phase 4   NCT01216904   United States
Nicotine transdermal patch
   James BOYD MD
      2012   Phase 2   NCT01560754   Germany;United States
Nicotinell 17,5 MG/24-stunden-pflaster
   Philipps-University Marburg
      2011   Phase 2   EUCTR2010-020299-42-DE   Germany;United States
Nicotinell 35 MG/24-stunden-pflaster
   Philipps-University Marburg
      2011   Phase 2   EUCTR2010-020299-42-DE   Germany;United States
Nilotinib
   Georgetown University
      2017   Phase 2   NCT02954978   United States
      2014   Phase 1   NCT02281474   United States
   Northwestern University
      2017   Phase 2   NCT03205488   United States
Nitisinone
   Synosia Therapeutics AG
      2009   Phase 2   EUCTR2009-013670-41-FR   Czech Republic;France
      2009   -   EUCTR2009-013670-41-CZ   Czech Republic;France
Nitrogen
   Juntendo University School of Medicine, Neurology
      2013   -   JPRN-UMIN000010014   Japan
NJ-tube: silicon ED tube
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan
NLX-112
   Neurolixis SAS
      2021   Phase 2   NCT05148884   Sweden
      2021   Phase 2   EUCTR2020-006053-22-SE   Sweden
NLY01
   Neuraly, Inc.
      2020   Phase 2   NCT04154072   Canada;United States
Nmda
   Pfizer
      2005   Phase 2   NCT00163085   United States
NO4bd03
   I.R.C.C.S. FONDAZIONE S.LUCIA
      2018   Phase 4   EUCTR2017-002239-41-IT   Italy
NON intervention-genetic testing
   Scripps Translational Science Institute
      2015   -   NCT02668835   -
NON intervention-monitoring device
   Scripps Translational Science Institute
      2015   -   NCT02668835   -
NON-motor symptoms
   Ankara Yildirim Beyazit University
      2019   -   NCT04420910   Turkey
Normal saline
   Asubio Pharmaceuticals, Inc.
      2007   Phase 2   NCT00623363   Guatemala;Romania;United States
   Beijing Tiantan Hospital
      2024   -   NCT06543563   China
   Parkinson's disease and Movement Disorder Center
      2012   -   JPRN-UMIN000009099   Japan
   Shanghai Jing'an District Central Hospital
      2016   Phase 0   ChiCTR2000037957   China
   Vanderbilt University
      2008   Phase 2/Phase 3   NCT00608231   United States
   dr.dargahi
      2020   Phase 2   NCT04687878   Iran, Islamic Republic of
Northera
   Alberto Espay, MD, MSc
      2019   Phase 4   NCT04510922   United States
   The Cooper Health System
      2017   Phase 4   NCT03034564   United States
Nortriptyline
   Rutgers, The State University of New Jersey
      2003   Phase 2   NCT00062738   United States
   University College, London
      2021   Phase 3   NCT03652870   United Kingdom
Nortriptyline hydrochloride
   University College London Comprehensive Clinical Trials Unit
      2019   Phase 3   EUCTR2018-002942-35-GB   United Kingdom
NPC transplantation
   Chinese Academy of Sciences
      2017   Phase 1/Phase 2   NCT03119636   China
NS 2330
   Boehringer Ingelheim
      2003   Phase 2   NCT00148512   Austria;El Salvador;France;Germany;Netherlands;Spain;United Kingdom
      2003   Phase 2   NCT00148486   Canada;United States
NS2330
   National Institute of Neurological Disorders and Stroke (NINDS)
      2000   Phase 2   NCT00006077   United States
NT 101
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
Ntcell implantation
   Living Cell Technologies
      2016   Phase 2   NCT02683629   New Zealand
Nuplazid
   Hôpitaux Universitaires de Strasbourg
      2019   Phase 2   EUCTR2016-001229-15-FR   France
Nuplazid 34 MG oral capsule
   Humanis Saglik Anonim Sirketi
      2024   Phase 1   NCT06450184   India
Nutritional assessment
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
NW-1015
   MERCK SERONO SA
      2010   Phase 2   EUCTR2010-020109-34-IT   Italy;Spain
      2009   Phase 3   EUCTR2008-005492-94-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
   Merck Serono International S.A.
      2008   Phase 3   EUCTR2007-002964-90-ES   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-002963-28-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2007   Phase 3   EUCTR2007-002964-90-NL   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2007-002964-90-FI   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Merck Serono S.A - Geneva
      2008   Phase 3   EUCTR2007-002964-90-GB   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
   Merck Serono S.A-Geneva
      2009   -   EUCTR2007-002963-28-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
   Merck Serono S.A. - Geneva
      2010   Phase 2   EUCTR2010-020109-34-ES   Italy;Spain
      2010   Phase 2   EUCTR2009-017174-20-FR   Austria;France;Germany
      2010   Phase 3   EUCTR2008-005492-94-NL   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2008-005492-94-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2007-002964-90-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-SK   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   -   EUCTR2008-005492-94-HU   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-GB   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2007-002964-90-FR   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2008   -   EUCTR2007-002964-90-DE   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
      2007   Phase 3   EUCTR2007-002964-90-SK   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2007   Phase 3   EUCTR2007-002963-28-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
   Merck Serono S.A.-Geneva
      2008   -   EUCTR2007-002964-90-HU   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Merck Serono SA - Geneva
      2009   Phase 3   EUCTR2008-004146-88-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2009   -   EUCTR2008-004146-88-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   -   EUCTR2008-004146-88-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   Phase 3   EUCTR2008-004146-88-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2009   Phase 3   EUCTR2008-001966-10-SK   Austria;Estonia;Hungary;Slovakia;United Kingdom
      2009   -   EUCTR2008-001966-10-HU   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-GB   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-EE   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-AT   Austria;Estonia;Hungary;United Kingdom
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy
      2006   -   EUCTR2006-005860-14-IT   Italy
      2004   -   EUCTR2004-000835-27-IT   Italy;Spain
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain
   Newron Pharmaceuticals
      2011   -   EUCTR2008-005492-94-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2010   -   EUCTR2008-004146-88-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   -   EUCTR2008-005492-94-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2008-005492-94-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2008-004146-88-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   -   EUCTR2008-004146-88-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   Phase 3   EUCTR2008-004146-88-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      -   -   EUCTR2008-005492-94-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
   Newron Pharmaceuticals S.P.A
      2005   Phase 3   EUCTR2004-000835-27-ES   Italy;Spain
   Newron Pharmaceuticals S.p.A.
      2004   Phase 3   EUCTR2004-000833-12-ES   Italy;Spain
   Newron Pharmaceuticals SpA
      2011   Phase 3   EUCTR2007-002964-90-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2010   -   EUCTR2007-002963-28-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2009   -   EUCTR2007-002964-90-AT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2007-002963-28-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   -   EUCTR2007-002963-28-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2009   -   EUCTR2007-002963-28-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2008   -   EUCTR2007-002964-90-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2007   -   EUCTR2007-002963-28-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States
NW-1015E, EMD 1195686, MSC2191632B
   Merck Serono S.A. - Geneva
      2011   -   EUCTR2009-017174-20-AT   Austria;Canada;France;Germany;South Africa
      2010   -   EUCTR2009-017174-20-DE   Austria;Canada;France;Germany;South Africa
NYX-458
   Aptinyx
      2019   Phase 2   NCT04148391   United States
O-15 water
   National Institute of Mental Health (NIMH)
      2002   -   NCT00024622   United States
Observational cohort
   Acorda Therapeutics
      2015   Phase 3   NCT02352363   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Netherlands;Poland;Romania;Serbia;Spain;United Kingdom;United States
OC oral solution treatment A
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States
OC oral solution treatment B
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States
OC oral solution treatment C
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States
OC oral solution treatment D
   Orient Pharma Co., Ltd.
      2011   Phase 2   NCT01370811   United States
ODM-101
   Orion Corporation
      2011   -   EUCTR2010-022200-46-LV   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-LT   Finland;Germany;Latvia;Lithuania
      2011   -   EUCTR2010-022200-46-FI   Finland;Germany;Latvia;Lithuania
      -   -   EUCTR2010-022200-46-DE   Finland;Germany;Latvia;Lithuania
ODM-101 105MG carbidopa
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01766258   -
ODM-101 65MG carbidopa
   Orion Corporation, Orion Pharma
      2011   Phase 2   NCT01766258   -
ODM-104
   Orion Corporation
      2017   Phase 2   EUCTR2015-004507-23-HU   Finland;Germany;Hungary;Latvia
      2017   Phase 2   EUCTR2015-004507-23-FI   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-LV   Finland;Germany;Hungary;Latvia
      2016   Phase 2   EUCTR2015-004507-23-DE   Finland;Germany;Hungary;Latvia
OFF dopaminergic medication
   James Liao
      2021   Phase 1   NCT05022147   United States
OM meditation
   Andrew Newberg
      2024   Phase 2   NCT05103618   United States
Omeprazole
   Beijing Friendship Hospital, Capital Medical University
      2024   Phase 0   ChiCTR2400084565   China
ON dopaminergic medication
   James Liao
      2021   Phase 1   NCT05022147   United States
Onabotulinumtoxin A injection
   University of North Carolina, Chapel Hill
      2018   Phase 2   NCT03301272   United States
Onabotulinumtoxina
   Johns Hopkins University
      2018   Phase 1   NCT03069911   United States
Ondansetron 8 MG FILM-coated tablets
   University College London
      2020   Phase 2   EUCTR2019-003962-41-GB   United Kingdom
Ondansetron hydrochloride dihydrate
   University College London
      2020   Phase 2   EUCTR2019-003962-41-GB   United Kingdom
Ongentys
   BIAL - Portela & Ca, S.A.
      2016   Phase 4   EUCTR2016-002391-27-GB   Germany;United Kingdom
      2016   Phase 4   EUCTR2016-002391-27-DE   Germany;United Kingdom
   BIAL – Portela & Cª, S.A.
      2021   Phase 3   EUCTR2020-005011-52-FR   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BG   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BE   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
   BIAL-Portela & Ca, S.A.
      2021   Phase 3   EUCTR2020-005011-52-IT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
   Bial - Portela & Ca, S.A.
      2023   Phase 3   EUCTR2020-001175-32-PL   Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-001175-32-CZ   Czech Republic;Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-001175-32-PT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2020   Phase 4   EUCTR2020-001175-32-GB   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela C S.A.
      2019   Phase 1   NCT03820037   United Kingdom
Ongentys 50 MG capsule rigide
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
      2020   Phase 4   EUCTR2020-001175-32-IT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
Ongentys 50 MG hard capsules
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-001176-15-PT   Germany;Portugal
      2021   Phase 4   EUCTR2020-001176-15-DE   Germany;Portugal
Ongentys 50MG
   SK Chemicals Co., Ltd.
      2021   Phase 4   NCT04821687   Korea, Republic of
ONO-2506PO
   Ono Pharmaceutical Co. Ltd
      2004   Phase 2   NCT00212693   -
OPC
   Bial - Portela C S.A.
      2017   Phase 1   NCT03116295   Germany
      2014   Phase 1   NCT03116308   -
      2011   Phase 1   NCT02169427   Netherlands
Opicapone
   BIAL - Portela & Ca, S.A.
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
   BIAL – Portela & Cª, S.A.
      2021   Phase 3   EUCTR2020-005011-52-PT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-FR   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-CZ   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BG   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 3   EUCTR2020-005011-52-BE   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
   BIAL-Portela & Ca, S.A.
      2021   Phase 3   EUCTR2020-005011-52-IT   Belgium;Bulgaria;Czech Republic;Czechia;France;Germany;Italy;Poland;Portugal;Serbia;Spain;Turkey;Ukraine;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
      2020   Phase 4   EUCTR2020-001175-32-IT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-001176-15-PT   Germany;Portugal
      2021   Phase 4   EUCTR2020-001176-15-DE   Germany;Portugal
      2020   Phase 4   EUCTR2020-001175-32-GB   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela C S.A.
      2021   Phase 4   NCT04990284   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   NCT04986995   Portugal
      2020   -   NCT03959540   United Kingdom
      2017   Phase 1   NCT03116295   Germany
      2014   Phase 1   NCT03116308   -
   Neurocrine Biosciences
      2021   -   NCT04787965   United States
      2018   Phase 1   NCT03496870   United States
   Rabin Medical Center
      2013   Phase 3   NCT01851850   Israel
Opicapone 50 MG
   Bial - Portela C S.A.
      2021   Phase 4   NCT04986982   United Kingdom
      2021   Phase 3   NCT04978597   Bulgaria
   Ruijin Hospital, Shanghai Jiaotong University School of Medicine
      2023   Phase 3   ChiCTR2300069899   China
   University Hospital of Ferrara
      2022   -   NCT06432309   Italy
Opicapone 50 MG hard capsules
   Bial - Portela & Ca, S.A.
      2023   Phase 3   EUCTR2020-001175-32-PL   Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-001175-32-CZ   Czech Republic;Czechia;Germany;Italy;Poland;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-001175-32-PT   Czech Republic;Germany;Italy;Poland;Portugal;Spain;United Kingdom
Optimal drug therapy
   Vanderbilt University Medical Center
      2006   -   NCT00282152   United States
Optimized antiparkinsonian treatment
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
Optimized medical treatment
   AbbVie
      2015   Phase 3   NCT02549092   Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States
Optimized oral treatment
   University Hospital, Lille
      2020   Phase 1/Phase 2   NCT04332276   France
Optional blood-oxygen-level dependent functionalmri
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
Optional pharmacogenetic assessment
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
Oral ANTI-parkinson drugs and injection OF botulinum toxin
   Zhujiang Hospital
      2023   Early Phase 1   NCT05997043   China
Oral ANTI-parkinson'S drugs
   Zhujiang Hospital
      2023   Early Phase 1   NCT05997043   China
Oral escitalopram
   New York University School of Medicine
      2003   Phase 2/Phase 3   NCT00070941   United States
Oral glucose tolerance test
   University Hospital Schleswig-Holstein
      2023   -   NCT05998772   Germany
Oral IR-LD/CD
   NeuroDerm Ltd.
      2019   Phase 3   NCT04006210   Austria;Belgium;Czechia;France;Hungary;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Serbia;Slovakia;Spain;Ukraine;United Kingdom;United States
Oral levodopa/carbidopa
   AbbVie (prior sponsor, Abbott)
      2011   Phase 2   NCT01479127   Japan
Orfadin
   Synosia Therapeutics AG
      2009   Phase 2   EUCTR2009-013670-41-FR   Czech Republic;France
      2009   -   EUCTR2009-013670-41-CZ   Czech Republic;France
OSU 6162 similar TO (-)-OSU 6162
   Björn Holmberg
      2010   Phase 1;Phase 2   EUCTR2009-016360-37-SE   Sweden
OSU6162 similar TO (-)-OSU 6162
   A. Carlsson Research AB
      2014   Phase 2   EUCTR2013-002545-10-SE   Sweden
Other nervous system drugs
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy
Other parkinson'S disease treatments
   Merck Sharp & Dohme Corp.
      2007   Phase 2   NCT00537017   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States
      2006   Phase 2   NCT00406029   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States
OVER-encapsulated entacapone tablets
   BIAL - Portela & Ca, S.A.
      2011   -   EUCTR2010-021860-13-SK   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   Phase 3   EUCTR2010-021860-13-RO   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-ES   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2011   -   EUCTR2010-021860-13-DE   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-CZ   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-BG   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2011   -   EUCTR2010-021860-13-AT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-PT   Austria;Bosnia and Herzegovina;Bulgaria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Montenegro;Netherlands;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;Spain;Ukraine
      2010   -   EUCTR2010-021860-13-LV   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
      2010   -   EUCTR2010-021860-13-HU   Austria;Bulgaria;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Romania;Slovakia;Spain
OVER-encapsulated modafinil
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States
Oxaloacetate
   University of Kansas Medical Center
      2012   Phase 2/Phase 3   NCT01741701   United States
OXB-102
   Sio Gene Therapies
      2018   Phase 1/Phase 2   NCT03720418   France;United Kingdom
OXN 10 MG / 5 MG PR
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
OXN 20 MG / 10 MG PR
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
OXN 5 MG/2.5 MG PR
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Oxybuprocaine
   Utano National Hospital, National Hospital Organization
      2013   -   JPRN-UMIN000017695   Japan
Oxybutynin and darifenacin
   Department of Veterans Affairs
      2009   -   NCT00892450   United States
Oxybutynin hydrochloride
   Summit (Cambridge) Ltd.
      2007   -   EUCTR2007-004654-81-GB   United Kingdom
Oxycodo
   Mundipharma Research GmbH & Co. KG
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
Oxycodone hydrochloride
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Oxycodone/naloxone prolonged release tablets
   Mundipharma Research GmbH & Co KG
      2011   Phase 3   NCT01439100   Czech Republic;Germany;Hungary;Poland;Romania;Spain;United Kingdom
Oxycodone/naloxone prolonged release tablets 10 MG /5 MG
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Oxycodone/naloxone prolonged release tablets 20 MG /10 MG
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Oxycodone/naloxone prolonged release tablets 5 MG /2.5 MG
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Oxycontin LP 10MG
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Oxycontin LP 20MG
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Oxycontin LP 5MG
   UHToulouse
      2016   Phase 2;Phase 3   EUCTR2015-001523-24-FR   France
Oxygen-15 water
   National Institute of Mental Health (NIMH)
      1993   -   NCT00001258   United States
Oxytocin synthetic
   Abteilung für Neurologie der Medizinischen Universität Innsbruck
      2019   Phase 2   EUCTR2018-002877-23-AT   Austria
P2b001
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States
   Pharma Two B Ltd.
      2013   Phase 2/Phase 3   NCT01968460   Israel;United States
P2b001 0.6/0.75 MG
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States
Paracetamol
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305017   -
Parapres
   INSTITUT DE RECERCA HSCSP
      2016   Phase 2   EUCTR2016-000679-25-ES   Spain
Parcopa
   Baylor College of Medicine
      2006   Phase 4   NCT00590122   United States
   UCB Pharma
      2005   Phase 3   NCT00139880   United States
      2004   Phase 3   NCT00139867   United States
Pardaprunox
   Solvay Pharmaceuticals
      2006   Phase 3   NCT00335166   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
Pardoprunox
   Abbott Products
      2009   Phase 2   NCT00903838   Germany;Italy;Portugal
   Solvay Pharmaceuticals
      2007   Phase 3   NCT00407095   Albania;Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States
      2007   Phase 3   NCT00406588   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Latvia;Lithuania;Peru;Russian Federation;Ukraine;United States
      2007   Phase 3   NCT00335374   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
      2007   Phase 3   NCT00332917   Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States
      2006   Phase 3   NCT00269516   Argentina;Belgium;Bulgaria;Canada;Chile;Colombia;Croatia;Finland;Former Serbia and Montenegro;India;Israel;Mexico;New Zealand;Peru;Romania;Russian Federation;Serbia;Slovakia;South Africa;Sweden;Ukraine;United States
Pardoprunox hydrochloride
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal
   Solvay Pharmaceuticals
      2009   Phase 3   EUCTR2007-001095-36-SK   Hungary;Slovakia
      2008   Phase 3   EUCTR2007-001096-10-SK   Hungary;Slovakia
      2008   -   EUCTR2007-001096-10-HU   Hungary
      2008   -   EUCTR2007-001095-36-HU   Hungary
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal
Parkinson mpower mobile application
   Sage Bionetworks
      2015   -   NCT02696603   United States
Paroxetine
   Osaka Redcross Hospital
      2014   -   JPRN-UMIN000015559   Japan
   Rutgers, The State University of New Jersey
      2003   Phase 2   NCT00062738   United States
   University of Rochester
      2005   Phase 3   NCT00086190   Canada;Puerto Rico;United States
Part 1, JM-010 component group A
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Part 1, JM-010 component group B
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Part 1, JM-010 component group C
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Part 2, JM-010 combination group A
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Part 2, JM-010 combination group B
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Part 2, JM-010 component group C
   Bukwang Pharmaceutical
      2021   Phase 2   NCT04377945   United States
Participant OPEN-response writing
   Sage Bionetworks
      2015   -   NCT02696603   United States
Participant SELF-assessment surveys
   Sage Bionetworks
      2015   -   NCT02696603   United States
PBF-509
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2014   Phase 1   NCT02111330   Spain
      2012   Phase 1   NCT01691924   Spain
PCA
   The First Affiliated Hospital of Xi'an Jiaotong University
      2025   -   ChiCTR2500098893   China
PD exercise intervention
   New York Institute of Technology
      2008   -   NCT01238926   United States
PD patients H&Y=1.5-2 medications OFF
   Giovanni Mirabella
      2020   -   NCT03665493   Italy
PD patients H&Y=1.5-2 medications ON
   Giovanni Mirabella
      2020   -   NCT03665493   Italy
PD patients H&Y=3 medications OFF
   Giovanni Mirabella
      2020   -   NCT03665493   Italy
PD patients H&Y=3 medications ON
   Giovanni Mirabella
      2020   -   NCT03665493   Italy
PD vitamin + exercise
   New York Institute of Technology
      2008   -   NCT01238926   United States
PD vitamin supplementation
   New York Institute of Technology
      2008   -   NCT01238926   United States
PD-RBD
   Beijing Friendship Hospital
      2022   Phase 4   NCT06710574   China
PDM608
   Calibr, a division of Scripps Research
      2023   Phase 1   NCT05950906   United States
PEG
   AbbVie (prior sponsor, Abbott)
      2013   Phase 3   NCT01736176   United States
   The 988th Hospitail of Joint Logistic Support Force
      2021   Phase 4   ChiCTR2100043303   China
PEG tube
   AbbVie
      2013   Phase 3   NCT01960842   Japan;Korea, Republic of;Taiwan
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00660387   New Zealand;United States
      2009   Phase 3   NCT00360568   Germany;New Zealand;United States
      2009   Phase 3   NCT00357994   Germany;United States
      2008   Phase 3   NCT00335153   Australia;Canada;Czech Republic;Finland;Germany;Greece;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2006   Phase 4   NCT00141518   Norway;Sweden
Pelvic floor muscle exercise-based behavioral therapy
   VA Office of Research and Development
      2018   Phase 3   NCT03149809   United States
Pending
   Voyager Therapeutics, Inc.
      2019   Phase 2   EUCTR2017-004685-10-PL   Poland;United States
Pentoxifylline 400 MG
   Mostafa Bahaa
      2023   Phase 2   NCT05962957   Egypt
Perampanel
   Eisai Inc.
      2007   Phase 2   NCT00566462   United States
      2004   Phase 2   NCT01634360   -
   Eisai Limited
      2007   Phase 3   NCT00505622   France
Percutaneous endoscopic gastrostomy tube
   AbbVie
      2017   Phase 3   NCT02799381   Finland;Greece;Hungary;Italy;Slovakia;Spain;United States
   AbbVie (prior sponsor, Abbott)
      2006   Phase 4   NCT00141518   Norway;Sweden
Percutaneous endoscopic gastrostomy with A jejunal (PEG-J) tube
   AbbVie
      2015   Phase 3   NCT02549092   Australia;Canada;Germany;Greece;Italy;Korea, Republic of;Spain;Sweden;United States
Pergolide
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Valeant Pharmaceuticals International, Inc.
      2008   -   NCT00624741   -
PET/CT
   Asan Medical Center
      2006   Phase 3   NCT00468078   Korea, Republic of
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University
      2020   Phase 0   ChiCTR2000036137   China
   The First Affiliated Hospital of Air Force Military Medical University
      2023   -   ChiCTR2300070966   China
   The First Affiliated Hospital of Sun Yat-sen University
      2017   Phase 0   ChiCTR2200061295   China
   Tokyo Metropolitan Institute of Gerontology
      2014   -   JPRN-UMIN000014709   Japan
   University of Saskatchewan
      2016   -   NCT02538315   Canada
PET/MR with [11C]PBR28
   University of Exeter
      2022   -   NCT05205291   United Kingdom
PF-06412562
   Milton S. Hershey Medical Center
      2018   Phase 1   NCT03665454   United States
   Pfizer
      2014   Phase 1   NCT02006290   United States
PF-06649751
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002952-17-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002952-17-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002951-40-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002949-38-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002952-17-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002952-17-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-PL   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
   Pfizer
      2016   Phase 2   NCT02847650   France;Germany;Israel;United States
      2016   Phase 2   NCT02687542   Canada;France;Germany;Japan;Spain;United States
      2015   Phase 1   NCT02373072   Belgium;United States
      2014   Phase 1   NCT02224664   Belgium;United States
   Pfizer, Inc.
      2017   Phase 2   EUCTR2016-001575-71-ES   France;Germany;Israel;Spain;United States
      2016   Phase 2   EUCTR2016-001575-71-DE   France;Germany;Israel;Spain;United States
      2016   Phase 2   EUCTR2015-004912-39-ES   France;Germany;Japan;Spain;United Kingdom;United States
      2016   Phase 2   EUCTR2015-004912-39-DE   France;Germany;Japan;Spain;United Kingdom;United States
PF-06649751 - 15MG
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 2   EUCTR2017-000128-81-ES   Canada;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000128-81-DE   Canada;France;Germany;Spain;United States
PF-06649751 - 1MG
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 2   EUCTR2017-000128-81-ES   Canada;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000128-81-DE   Canada;France;Germany;Spain;United States
PF-06649751 - 5MG
   Pfizer Inc., 235 East 42nd Street, New York, New York
      2017   Phase 2   EUCTR2017-000128-81-ES   Canada;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000128-81-DE   Canada;France;Germany;Spain;United States
PF-06669571
   Pfizer
      2015   Phase 1   NCT02565628   United States
PG203
   Celon Pharma S.A.
      2021   Phase 2   EUCTR2020-006004-16-PL   Poland;Ukraine
Phenlarmide tablets
   Yiling Pharmaceutical Inc.
      2019   Phase 1   NCT04164121   China
Phenserine
   Annovis Bio, Inc.
      2023   Phase 3   EUCTR2022-001542-38-PL   France;Germany;Hungary;Italy;Poland;Spain;United States
      2023   Phase 3   EUCTR2022-001542-38-IT   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-HU   France;Germany;Hungary;Italy;Poland;Spain;United States
      2022   Phase 3   EUCTR2022-001542-38-ES   France;Germany;Hungary;Italy;Poland;Spain;United States
Phonation
   Sage Bionetworks
      2015   -   NCT02696603   United States
Physical function performance test
   University of Florida
      2016   Phase 2   NCT02789020   United States
Physical therapy
   Department of Neurology, Fukuoka university
      2022   -   JPRN-UMIN000047341   Japan
   Hubert Fernandez
      2016   Early Phase 1   NCT02879136   United States
   US WorldMeds LLC
      2016   Phase 4   NCT02549573   United States
Piclozotan
   Asubio Pharmaceuticals, Inc.
      2007   Phase 2   NCT00623363   Guatemala;Romania;United States
Pilocarpine
   Nagoya University
      2017   -   JPRN-UMIN000026128   Japan
   katsuno Masahisa
      2017   Phase 2   JPRN-jRCTs041180018   -
Pimavanserin
   ACADIA Pharmaceuticals Inc.
      2020   Phase 4   NCT04292223   United States
      2019   Phase 2   NCT04164758   United States
      2018   Phase 2   NCT03482882   United States
   Hôpitaux Universitaires de Strasbourg
      2019   Phase 2   EUCTR2016-001229-15-FR   France
   State University of New York - Downstate Medical Center
      2023   Early Phase 1   NCT05796167   United States
   The University of Texas Health Science Center at San Antonio
      2022   Phase 4   NCT05590637   United States
   University Hospital, Strasbourg, France
      2020   Phase 2   NCT03947216   France
   VA Office of Research and Development
      2022   Phase 4   NCT04373317   United States
   Vanderbilt University Medical Center
      2023   Phase 4   NCT05357612   United States
Pimavanserin 34 MG
   Humanis Saglik Anonim Sirketi
      2024   Phase 1   NCT06450184   India
Pimavanserin tartrate
   ACADIA Pharmaceuticals Inc
      2009   Phase 3   EUCTR2007-003035-22-PT   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States
   ACADIA Pharmaceuticals Inc.
      2017   Phase 3   EUCTR2016-003512-12-FR   France;Portugal;Russian Federation;Serbia
      2016   -   NCT02762591   -
      2010   Phase 3   NCT01174004   Canada;United States
      2008   Phase 3   NCT00658567   Austria;Belgium;Italy;Poland;Portugal;Serbia;Spain;Sweden;United States
      2008   Phase 3   EUCTR2007-003035-22-GB   Austria;Belgium;Canada;European Union;France;India;Italy;Portugal;Russian Federation;Sweden;Ukraine;United Kingdom;United States
      2007   Phase 3   NCT00550238   Austria;Belgium;Canada;France;India;Italy;Poland;Portugal;Russian Federation;Serbia;Sweden;Ukraine;United Kingdom;United States
      2007   Phase 3   NCT00477672   Bulgaria;France;India;Russian Federation;Ukraine;United Kingdom;United States
      2004   Phase 2   NCT01518309   United States
   Acadia Pharmaceuticals Inc
      2009   Phase 2;Phase 3   EUCTR2007-003035-22-AT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   -   EUCTR2007-003051-36-SE   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-PT   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-ES   Austria;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-BE   Austria;Belgium;Portugal;Spain;Sweden
      2008   -   EUCTR2007-003051-36-AT   Austria;Portugal;Spain;Sweden
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-SE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-FR   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   Phase 2;Phase 3   EUCTR2007-003035-22-BE   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
      2008   -   EUCTR2007-002906-23-BG   Bulgaria;France;United Kingdom
      2007   -   EUCTR2007-002906-23-GB   Bulgaria;France;United Kingdom
      2007   Phase 2;Phase 3   EUCTR2007-002906-23-FR   Bulgaria;France;United Kingdom
   Tasly Pharmaceutical Group Co., Ltd
      2024   Phase 3   NCT06068465   China
Pioglitazone
   University of Rochester
      2011   Phase 2   NCT01280123   United States
Pirepemat
   Integrative Research Laboratories AB
      2022   Phase 2   NCT05258071   France;Germany;Netherlands;Poland;Spain;Sweden
Pirepemat X fumarate
   Integrative Research Laboratories Sweden AB (IRLAB)
      2023   Phase 2   EUCTR2019-002627-16-NL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-PL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-FR   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-ES   France;Germany;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-DE   France;Germany;Netherlands;Poland;Spain;Sweden
Pirepemat, 100 MG
   Integrative Research Laboratories Sweden AB (IRLAB)
      2023   Phase 2   EUCTR2019-002627-16-NL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-PL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-FR   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-ES   France;Germany;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-DE   France;Germany;Netherlands;Poland;Spain;Sweden
Pirepemat, 50 MG
   Integrative Research Laboratories Sweden AB (IRLAB)
      2023   Phase 2   EUCTR2019-002627-16-NL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-PL   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-FR   France;Germany;Netherlands;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-ES   France;Germany;Poland;Spain;Sweden
      2022   Phase 2   EUCTR2019-002627-16-DE   France;Germany;Netherlands;Poland;Spain;Sweden
Piribedil
   Desitin Arzneimittel GmbH
      2010   Phase 3   NCT01007864   Germany
      2009   -   NCT01519856   Germany
      2009   -   EUCTR2009-012419-16-DE   Germany
      2008   -   NCT00727727   Germany
      2008   -   NCT00725478   -
   Henan University of Traditional Chinese Medicine
      2009   -   ChiCTR-TRC-12002150   China
   Institut de Recherches Internationales Servier
      2006   Phase 2   EUCTR2005-000314-12-DE   Germany;Spain
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain
   Institut de Recherches Internationales Servier (I.R.I.S.)
      2005   -   EUCTR2005-002010-38-DE   Germany
Pitolisant
   BIOPROJET
      2010   -   EUCTR2009-013886-24-SE   Czech Republic;Germany;Sweden
      2010   -   EUCTR2009-013886-24-DE   Czech Republic;Germany;Sweden
      2009   -   EUCTR2009-013886-24-CZ   Czech Republic;Germany;Sweden
      2009   Phase 3   EUCTR2009-013885-14-FR   France;Spain
      2009   Phase 3   EUCTR2009-013885-14-ES   France;Spain
   Bioprojet
      2010   Phase 3   NCT01066442   Germany
      2009   Phase 3   NCT01036139   France
Pittsburgh compound B [11C]-PIB
   Sunnybrook Health Sciences Centre
      2016   -   NCT02524405   Canada
PK-merz® 200MG/500ML INJ(amantadine) , normal saline 500ML INJ
   Seoul National University Hospital
      2011   Phase 4   NCT01313819   Korea, Republic of
PKD patients
   GlaxoSmithKline
      2011   Phase 1   NCT01424475   United Kingdom
Plantago ovata husk
   Rottapharm Spain
      2006   Phase 1   NCT00507715   Spain
Polar H10 heart sensor
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
Polysomnogram
   Douglas Scharre
      2018   -   NCT03019757   United States
Posiphen
   Annovis Bio Inc.
      2020   Phase 1/Phase 2   NCT04524351   United States
PR oxycodone
   University Hospital, Toulouse
      2016   Phase 2/Phase 3   NCT02601586   France
Pramipexol
   Axxonis Pharma GmbH
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-DE   Austria;Czech Republic;Germany;Italy
      2006   Phase 2;Phase 3   EUCTR2005-001006-12-CZ   Austria;Czech Republic;Germany;Italy
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
   Shanghai General Hospital
      2020   Phase 0   ChiCTR2000037624   China
Pramipexol extended release
   Boehringer Ingelheim
      2007   Phase 3   NCT00479401   Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States
      2007   Phase 3   NCT00466167   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom
Pramipexol immediate release
   Boehringer Ingelheim
      2007   Phase 3   NCT00479401   Argentina;Austria;Brazil;Czech Republic;Finland;Germany;Hungary;India;Japan;Malaysia;Russian Federation;Slovakia;Taiwan;Ukraine;United States
      2007   Phase 3   NCT00466167   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom
Pramipexole
      2006   -   EUCTR2005-003788-22-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Abbott Products
      2009   Phase 2   NCT00903838   Germany;Italy;Portugal
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   Boehringer Ingelheim
      2011   -   NCT01361009   China
      2008   -   NCT02236728   -
      2008   Phase 3   NCT00601523   Argentina;Austria;Czech Republic;Finland;France;Germany;Hungary;India;Japan;Malaysia;Netherlands;Russian Federation;Slovakia;Taiwan;Ukraine;United States
      2007   Phase 3   NCT00577460   Austria;Czech Republic;Hungary;India;Italy;Korea, Republic of;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Ukraine;United Kingdom
      2006   Phase 4   NCT00402233   United States
      2006   -   NCT00349310   Austria;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom
      2006   Phase 4   NCT00321854   Austria;Finland;France;Germany;Italy;Japan;Spain;Sweden;United Kingdom;United States
      2006   Phase 4   NCT00297778   Austria;Finland;France;Germany;Italy;Netherlands;Norway;Romania;Russian Federation;South Africa;Spain;Sweden;Ukraine;United Kingdom
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2004   -   NCT02248181   -
      2003   -   NCT02248207   -
      2003   Phase 3   NCT00240409   China
      2002   -   NCT02248168   -
      1999   Phase 3   NCT02172573   -
      1998   -   NCT02248220   -
      1998   Phase 4   NCT02233023   -
      1998   Phase 3   NCT02177357   -
   Boehringer Ingelheim AB
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España, S.A.
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2006   -   EUCTR2005-004949-34-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Department of Neurology, Brain Hospital Affiliated to Nanjing Medical University
      2019   Phase 0   ChiCTR1900021708   China
   First Affiliated Hospital of Zhejiang University
      2020   -   NCT04275492   China
   Geriatric Hospital of Hainan
      2019   -   ChiCTR1900022534   China
   Huashan Hospital
      2011   -   NCT01470859   China
   Institute for Neurodegenerative Disorders
      2004   Phase 2   NCT00096720   United States
   Institute of Clinical Pharmacology, Central South University
      2012   Phase 1 study   ChiCTR-TTRCC-12002751   China
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China
   Kissei Pharmaceutical Co., Ltd.
      2019   Phase 2   NCT03845387   Japan
   NEUROBIOTEC GMBH
      2007   -   EUCTR2006-003732-30-IT   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
   Oregon Health and Science University
      2003   Phase 1   NCT00666653   United States
   Qualissima
      2008   Phase 4   NCT01048229   -
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal
      2006   -   EUCTR2006-000678-57-IT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
   Sandoz
      2012   Phase 4   NCT01673724   Korea, Republic of
   Solvay Pharmaceuticals
      2006   Phase 3   NCT00335166   Australia;Czech Republic;Estonia;France;Germany;India;Italy;Lithuania;Malaysia;Netherlands;Poland;Portugal;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
   The Affiliated Brain Hospital of Nanjing Medical University (Nanjing Brain Hospital)
      2020   Phase 4   ChiCTR2000039050   China
   The Affiliated Brain Hospital of Nanjing Medical University( Nanjing Brain Hospital)
      2018   -   ChiCTR1800019942   China
   University of Toronto
      2015   Phase 2   NCT02347059   Canada
   Vanderbilt University Medical Center
      2019   Phase 1   NCT04249544   United States
   West China Hospital of Sichuan University
      2020   Phase 1   ChiCTR2000035564   China
   Xuanwu Hospital of Capital Medical University
      2024   -   ChiCTR2400087756   China
Pramipexole 0.125 MG tablets
   Boehringer Ingelheim
      1998   Phase 3   NCT00274131   -
Pramipexole 0.5 MG tablets
   Boehringer Ingelheim
      1998   Phase 3   NCT00274131   -
Pramipexole 0.6 MG
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States
      2013   Phase 2/Phase 3   NCT01968460   Israel;United States
Pramipexole dihydrochloride extended-release tablets
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States
Pramipexole dihydrochloride monohydrate
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal
Pramipexole dihydrochloride monohydrate extended release
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom
Pramipexole ER
   BOEHRINGER ING.
      2008   -   EUCTR2007-004235-37-IT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   BOEHRINGER INGELHEIM
      2008   Phase 3   EUCTR2007-004234-16-FR   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia
      2007   Phase 3   EUCTR2007-003353-90-FR   France;Germany;Netherlands
   Boehringer Ingelheim
      2008   -   EUCTR2007-004235-37-GB   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-003353-90-NL   France;Germany;Netherlands
   Boehringer Ingelheim AB
      2008   -   EUCTR2007-004235-37-SE   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España, S.A.
      2008   Phase 3   EUCTR2007-004235-37-ES   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-000074-23-ES   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Finland Ky
      2008   -   EUCTR2007-004234-16-FI   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma Ges mbH
      2008   -   EUCTR2007-004235-37-PL   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004235-37-HU   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004235-37-CZ   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004234-16-HU   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary
   Boehringer Ingelheim RCV GmbH & Co KG
      2009   -   EUCTR2007-004235-37-AT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004234-16-AT   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2008   Phase 3   EUCTR2007-004235-37-SK   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004234-16-SK   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia
      2008   -   EUCTR2007-004234-16-CZ   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim bv
      2007   -   EUCTR2007-004234-16-NL   Austria;Czech Republic;Finland;France;Hungary;Netherlands
   Department of Neurology, Juntendo University
      2011   -   JPRN-UMIN000006521   Japan
Pramipexole extended release
   Boehringer Ingelheim
      2010   -   NCT01097421   Sweden
      2007   Phase 2/Phase 3   NCT00560508   Japan
      2007   Phase 3   NCT00558025   France;Germany;Netherlands
Pramipexole extended release tablet
   Boehringer Ingelheim
      2010   Phase 3   NCT01191944   China
Pramipexole immediate release
   Boehringer Ingelheim
      2008   -   NCT00651183   Austria
      2007   Phase 2/Phase 3   NCT00560508   Japan
      2007   Phase 3   NCT00558025   France;Germany;Netherlands
Pramipexole immediate release tablet
   Boehringer Ingelheim
      2010   Phase 3   NCT01191944   China
Pramipexole IR
   Boehringer Ingelheim
      2018   Phase 4   NCT03521635   China
Pramipexole or ropinirole
   Desitin Arzneimittel GmbH
      2010   Phase 3   NCT01007864   Germany
Pramipexole SR
   Boehringer Ingelheim
      2018   Phase 4   NCT03521635   China
Prasinezumab
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2020-004997-23-LU   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-PL   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   Hoffmann-La Roche
      2021   Phase 2   NCT04777331   Austria;Canada;France;Germany;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States
Preladenant
   Merck Sharp & Dohme Corp.
      2011   Phase 1   NCT01323855   Germany
      2011   Phase 2   NCT01294800   Japan
      2010   Phase 3   NCT01227265   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
      2010   Phase 3   NCT01215227   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States
      2007   Phase 2   NCT00537017   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Singapore;Spain;United States
      2006   Phase 2   NCT00406029   Argentina;Australia;Canada;Chile;Colombia;France;Guatemala;Hong Kong;Italy;New Zealand;Peru;Singapore;South Africa;Spain;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2010-020112-11-LV   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
      2011   -   EUCTR2010-020112-11-LT   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Tokyo Metropolitan Institute of Gerontology
      2016   -   JPRN-UMIN000025638   Japan
Preladenant 10 MG tablet
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Preladenant 2 MG tablet
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Preladenant 5 MG tablet
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Pridia (donepezil hydrochloride) 5MG
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 3   EUCTR2009-015170-35-GB   United Kingdom
Pridia 10MG
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 3   EUCTR2009-015170-35-GB   United Kingdom
Pridia 5MG
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 3   EUCTR2009-015170-35-GB   United Kingdom
Pridopidine
   Prilenia
      2019   Phase 2   NCT03922711   United States
PRIM-DJ2727
   The University of Texas Health Science Center, Houston
      2019   Phase 1   NCT03671785   United States
      2017   Phase 1/Phase 2   NCT03026231   United States
Primavanserin tartrate
   ACADIA PHARMACEUTICALS INC.
      2009   -   EUCTR2007-003035-22-IT   Austria;Belgium;France;Italy;Portugal;Sweden;United Kingdom
Prior donepezil 5MG
   Eisai Inc.
      2003   Phase 3   NCT01327859   United Kingdom
Prior donzepezil 10MG
   Eisai Inc.
      2003   Phase 3   NCT01327859   United Kingdom
Probiotic
   University of British Columbia
      2022   Phase 2   NCT05568498   -
      2020   Phase 2   NCT03968133   Canada
   Yancheng Tinghu District People's Hospital
      2022   -   ChiCTR2300077412   China
Probiotic capsule
   University of Malaya
      2017   -   NCT03377322   Malaysia
Probiotic K10
   Deivis de Oliveira guimaraes
      2023   -   NCT06019117   Brazil
Probiotic supplement
   University Rovira i Virgili
      2021   -   NCT05943925   Spain
Probiotics
   Beijing Friendship Hospital, Capital Medical University
      2017   Phase 0   ChiCTR2200066482   China
   Changhua Christian Hospital
      2023   -   NCT06118294   Taiwan
   Franca Marino
      2021   -   NCT05173701   Italy
   Yancheng Tinghu District People's Hospital
      2022   -   ChiCTR2300077412   China
Probiotics with prebiotic
   National University of Malaysia
      2018   Phase 3   NCT04451096   Malaysia
Prolonged release tablet
   Boehringer Ingelheim Finland Ky
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary
Promethazine
   The first hospital of Yichang
      2023   Phase 4   ChiCTR2300069580   China
Propanoic acid
   AbbVie Inc
      2011   Phase 3   EUCTR2008-001329-33-GB   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2010   Phase 3   EUCTR2008-001329-33-CZ   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
      2009   Phase 3   EUCTR2008-001329-33-PT   Australia;Czech Republic;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Thailand;United Kingdom
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2006-005186-18-CZ   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-PT   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-GB   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
      2008   -   EUCTR2006-005186-18-DE   Australia;Canada;Czech Republic;Finland;Germany;Israel;Italy;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Spain;Thailand;United Kingdom;United States
   Abbott Laboratories
      2009   -   EUCTR2006-000578-53-DE   Germany;New Zealand;United States
   Solvay Pharmaceuticals B.V.
      2009   -   EUCTR2006-005186-18-NL   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2008   Phase 3   EUCTR2006-005186-18-ES   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
      2007   -   EUCTR2006-005186-18-FI   Czech Republic;Finland;Germany;Italy;Netherlands;Portugal;Spain;United Kingdom
Propofol
   Beijing Tiantan Hospital
      2023   -   NCT05895019   China
   Clinica Universidad de Navarra, Universidad de Navarra
      2014   Phase 4   NCT02256319   Spain
   Columbia University
      2003   -   NCT00615472   United States
   Department of Anesthesiology, the First Affiliated Hospital of Sun Yat-Sen University
      2020   Phase 4   ChiCTR2000039697   China
   First Affiliated Hospital of Sun Yat-sen University
      2023   -   ChiCTR2400087001   China
      2021   -   ChiCTR2400092724   China
   The First Affiliated Hospital of Sun Yat-sen University
      2024   -   ChiCTR2400091683   China
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900021760   China
   University of Texas Southwestern Medical Center
      2020   -   NCT04502550   United States
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China
   Xuanwu Hospital of CCMU
      2018   -   ChiCTR1800014542   China
Propofol-lipuro
   Clínica Universidad de Navarra/Universidad de Navarra
      2014   -   EUCTR2014-000868-17-ES   Spain
Propranolol HCL CF 40 MG tablet
   Radboud University Nijmegen
      2017   Phase 3   EUCTR2016-004629-18-NL   Netherlands
Prosavin
   Axovant Sciences Ltd.
      2011   Phase 1/Phase 2   NCT01856439   France;United Kingdom
   Oxford BioMedica
      2008   Phase 1/Phase 2   NCT00627588   France;United Kingdom
   Oxford BioMedica (UK) Ltd
      2010   -   EUCTR2009-017253-35-GB   United Kingdom
      2010   Phase 1;Phase 2   EUCTR2007-001109-26-GB   United Kingdom
Proscar*30CPR RIV 5MG
   AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI
      2011   -   EUCTR2011-000612-26-IT   Italy
PRP and PBD-vsel stem cell therapy
   Fatima Jinnah Medical University
      2019   -   NCT06142981   Pakistan
PRX002
   Prothena Biosciences Limited
      2014   Phase 1   NCT02157714   United States
      2014   Phase 1   NCT02095171   United States
PRX002, ELT2, ANTI-alpha-synuclein monoclonal antibody
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2020-004997-23-LU   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-PL   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States
PS128
   Professor Lu Neurological Clinic
      2020   -   NCT04722211   Taiwan
      2020   -   NCT04722198   Taiwan
Psilocybin
   Joshua Woolley, MD, PhD
      2024   Phase 2   NCT06455293   United States
   Maastricht University
      2022   Phase 2   EUCTR2021-000041-40-NL   Netherlands
Psilocybin therapy
   Joshua Woolley, MD, PhD
      2021   Phase 2   NCT04932434   United States
   University Medical Center Groningen
      2025   Phase 2   NCT06782724   -
Psilocybine
   Maastricht University
      2022   Phase 2   EUCTR2021-000041-40-NL   Netherlands
Psychosocial intervention
   Ralph H. Johnson VA Medical Center
      2024   Phase 2   NCT05669170   -
Psyllium
   University of Florida
      2021   -   NCT04829760   United States
PT320 2.0 MG
   Peptron, Inc.
      2020   Phase 2   NCT04269642   Korea, Republic of
PT320 2.5 MG
   Peptron, Inc.
      2020   Phase 2   NCT04269642   Korea, Republic of
PXT002331
   PREXTON THERAPEUTICS B.V.
      2017   Phase 2   EUCTR2017-000135-14-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Prexton Therapeutics
      2016   Phase 1   NCT02639221   United Kingdom
   Prexton Therapeutics B.V.
      2017   Phase 2   EUCTR2017-000135-14-GB   Austria;Germany;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-ES   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-DE   Austria;Germany;Italy;Spain;United Kingdom
      2017   Phase 2   EUCTR2017-000135-14-AT   Austria;Germany;Spain;United Kingdom
PXT002331 - 20MG
   Prexton Therapeutics
      2018   Phase 2   NCT03331848   -
PXT002331 - dose 1
   Prexton Therapeutics
      2017   Phase 2   NCT03162874   Austria;France;Germany;Italy;Spain;United Kingdom
PXT002331 - dose 2
   Prexton Therapeutics
      2017   Phase 2   NCT03162874   Austria;France;Germany;Italy;Spain;United Kingdom
PYM50028
   Phytopharm
      2010   Phase 2   NCT01060878   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2009   Phase 1   NCT00875316   United Kingdom
   Phytopharm plc
      2011   -   EUCTR2010-018534-44-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2011   -   EUCTR2010-018534-44-DE   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2011   -   EUCTR2010-018534-44-CZ   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2010   Phase 2   EUCTR2010-018534-44-GB   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
Pyridostigmine bromide
   Christian Baumann
      2012   Phase 2   NCT01993680   Switzerland
   Department of Neurology, Roskilde Hospital
      2012   Phase 2   EUCTR2012-000122-21-DK   Denmark
   University of Vermont Medical Center
      2022   Phase 2   NCT05603715   United States
Questionnaires
   Tools4Patient
      2018   Phase 1/Phase 2   NCT03407378   Belgium;France;United States
Questionnaires and clinical assessments
   University of Massachusetts, Worcester
      2020   -   NCT04273672   United States
Quetiapine
   ACADIA Pharmaceuticals Inc.
      2019   Phase 2   NCT04164758   United States
   Nanjing Brain Hospital
      2022   Phase 4   ChiCTR2200064086   China
   National Institute on Aging (NIA)
      2002   Phase 4   NCT00043849   United States
   The University of Texas Health Science Center at San Antonio
      2022   Phase 4   NCT05590637   United States
   VA Office of Research and Development
      2022   Phase 4   NCT04373317   United States
R-(-)-1-(benzofuran-2-YL)-2-propylaminopentane hydrochloride
   Fujimoto Pharmaceutical Corporation
      2006   Phase 2   EUCTR2006-000361-11-GB   United Kingdom
R-methugdnf
   Amgen
      2003   Phase 1   NCT00115427   United States
   North Bristol NHS Trust (NBT)
      2013   Phase 2   EUCTR2013-001881-40-GB   United Kingdom
      2012   Phase 2   EUCTR2011-003866-34-GB   United Kingdom
RAAV-GAD
   Neurologix, Inc.
      2011   -   NCT01301573   United States
Raclopride
   National Institute of Neurological Disorders and Stroke (NINDS)
      2002   -   NCT00032812   United States
   Tokyo Metropolitan Institute of Gerontology
      2014   -   JPRN-UMIN000014709   Japan
Radiosurgical thalamotomy
   Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
      2015   Phase 2   NCT02406105   Poland
Radotinib HCL 50 MG
   Il-Yang Pharm. Co., Ltd.
      2021   Phase 2   NCT04691661   France
Ramelteon
   Massachusetts General Hospital
      2009   -   NCT00907595   United States
   Southern California Institute for Research and Education
      2007   Phase 4   NCT00462254   United States
Rasagilin
   Technische Universität Dresden
      2009   -   EUCTR2008-005085-30-DE   Germany
Rasagilina mesilato
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Teva Pharmaceutical Industries Ltd
      2009   Phase 4   EUCTR2009-011541-24-ES   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
   Universita di Verona
      2018   -   NCT03648671   Italy
Rasagiline
   Beijing Hospital
      2018   -   ChiCTR1800016949   China
   Bial - Portela C S.A.
      2009   Phase 1   NCT01532141   France
      2009   Phase 1   NCT01532128   France
   Brown University
      2011   Phase 4   NCT01382342   United States
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Chongqing Fortune Pharmaceutical Co., Ltd.
      2011   Phase 3   NCT01736891   China
   Cyclotron and Radioisotope Center, Tohoku University
      2022   -   JPRN-UMIN000049442   Japan
   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
      2008   Phase 4   NCT00755027   Spain
   Georgetown University
      2012   Phase 4   NCT01497652   United States
   H. Lundbeck A/S
      2012   Phase 1   NCT01652313   China
      2012   Phase 3   NCT01556165   China
   Institut de Recerca de l'Hospital de la santa Creu i Sant Pau
      2007   -   EUCTR2007-004400-12-ES   Spain
   Istanbul University
      2007   Phase 4   NCT00696215   Turkey
   Juntendo University
      2019   -   JPRN-UMIN000053427   Japan
   Lundbeck Italia S.p.A.
      2010   Phase 4   NCT01055379   Italy
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01215227   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States
   Qualissima
      2008   Phase 4   NCT01048229   -
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom
   Schering-Plough Research Institute, a division of Schering Corporation
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2023   Phase 2/Phase 3   NCT05611372   -
   St. Josef Hospital Bochum
      2011   Phase 4   NCT01385735   Germany
   State University of New York at Buffalo
      2014   -   NCT02278588   United States
   TAKEDA PHARMACEUTICAL COMPANY LTD.
      2018   -   JPRN-jRCT1080224120   Japan
   TEVA
      2005   -   EUCTR2005-001416-42-IT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
   Takeda
      2018   -   NCT03727139   Japan
   Technische Universität Dresden
      2011   Phase 4   NCT01442610   Germany
   Teva Branded Pharmaceutical Products R&D, Inc.
      2012   Phase 4   NCT01723228   United States
   Teva Neuroscience, Inc.
      2009   Phase 4   NCT01049984   United States
   Teva Pharmaceutical Industries
      2013   Phase 1   NCT01879748   United States
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-011541-24-IT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
   The Parkinson's Institute
      2009   Phase 4   NCT01007630   United States
   UNIVERSITA` DEGLI STUDI DI PARMA
      2009   -   EUCTR2009-013004-31-IT   Italy
   University of Florida
      2016   Phase 2   NCT02789020   United States
      2009   Phase 4   NCT01168596   United States
   University of Zurich
      2011   Phase 4   NCT01178047   Switzerland
Rasagiline 0.75 MG
   Pharma Two B Ltd.
      2018   Phase 3   NCT03329508   Canada;Germany;Spain;United States
      2013   Phase 2/Phase 3   NCT01968460   Israel;United States
Rasagiline 1 MG capsule
   Merck Sharp & Dohme Corp.
      2010   Phase 3   NCT01155479   Argentina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   NCT01155466   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Japan;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
Rasagiline 1MG tablet
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
Rasagiline 2 MG tablet
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
Rasagiline mesilate
   Dresden University of Technology
      2011   -   EUCTR2010-023756-82-DE   Germany
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
   Teva Pharmaceuticals Industries LtD
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
Rasagiline mesylate
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Pharma Two B Ltd
      2018   Phase 3   EUCTR2017-001420-21-ES   Canada;France;Germany;Spain;United States
      2018   Phase 3   EUCTR2017-001420-21-DE   Canada;France;Germany;Spain;United States
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Teva Neuroscience, Inc.
      1997   Phase 3   NCT00203060   United States
   Teva Pharmaceutical Industries
      2009   -   NCT01032486   Canada
      2009   -   NCT00936676   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
      2005   Phase 3   NCT00256204   Argentina;Austria;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
      2004   Phase 3   NCT00203138   United States
      2002   Phase 3   NCT00203164   United States
      2000   Phase 3   NCT00203125   United States
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-011541-24-PT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-NL   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-HU   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-GB   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
      2009   Phase 4   EUCTR2009-011541-24-FR   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-DE   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
Rasagiline mesylate 1.0 MG
   Teva Pharmaceutical Industries
      2001   Phase 3   NCT00203177   Canada;United States
Rasagiline mesylate plus mirapex
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States
Rasagiline mesylate with levodopa
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States
Rasagiline mesylate with requip
   Teva Neuroscience, Inc.
      2006   Phase 4   NCT00399477   United States
Rasagiline tablets
   Guangzhou Henovcom Bioscience Co. Ltd.
      2025   Phase 1   NCT06798519   -
   Teva Pharmaceuticals Industries LtD
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
Recombinant human cerebral dopamine neurotrophic factor
   Herantis Pharma Plc
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-SE   Finland;Sweden
      2018   Phase 1;Phase 2   EUCTR2018-000346-19-FI   Finland;Sweden
      2017   Phase 1;Phase 2   EUCTR2015-004175-73-FI   Finland
   Renishaw Neuro Solutions Ltd.
      2019   Phase 1;Phase 2   EUCTR2017-005170-19-FI   Finland;Sweden
      2018   Phase 1;Phase 2   EUCTR2017-005170-19-SE   Finland;Sweden
Recombinant-methionyl human glial cell LINE-derived neurotrophic factor
   National Center for Research Resources (NCRR)
      2000   Phase 1   NCT00006488   United States
Recommendation with regard TO nutrition
   Saarland University
      2016   -   NCT02784145   Germany
Reduced glutathione
   University of Washington
      2014   Phase 1   NCT02324426   United States
Reduced glutathione 100MG
   Bastyr University
      2015   Phase 2   NCT02424708   United States
Reduced glutathione 200MG
   Bastyr University
      2015   Phase 2   NCT02424708   United States
Regular novolin R
   HealthPartners Institute
      2020   Phase 2   NCT04251585   United States
Rehabilitation therapy
   Copka Sonpashan
      2024   -   NCT06319625   -
   Tianjin Huanhu Hospital
      2023   -   ChiCTR2300075996   China
Remifentanil
   Columbia University
      2003   -   NCT00615472   United States
   RenJi Hospital
      2024   -   NCT06658132   China
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900021760   China
Remifentanyl
   West China Hospital, Sichuan University
      2016   -   ChiCTR-IOR-16010168   China
Remimazolam
   The First Affiliated Hospital of Sun Yat-sen University
      2024   -   ChiCTR2400091683   China
   VA Office of Research and Development
      2025   Phase 2   NCT06231563   United States
   Xiangya Hospital Central South University
      2024   Phase 4   ChiCTR2400086825   China
Reminyl
   Otto-von-Guericke University, Medical Faculty, Dpt. of Neurology
      2009   Phase 2   EUCTR2009-011093-15-DE   Germany
Reminyl retard
   UMCG
      2009   -   EUCTR2008-006278-13-NL   Netherlands
Renishaw drug delivery system
   Herantis Pharma Plc.
      2018   Phase 1/Phase 2   NCT03775538   Finland;Sweden
      2017   Phase 1/Phase 2   NCT03295786   Finland;Sweden
Repaglinide
   Bial - Portela C S.A.
      2009   Phase 1   NCT01536366   Portugal
Requip
   Boehringer Ingelheim
      2005   Phase 4   NCT00144300   United States
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy
Requip modutab, 2MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Requip modutab, 4MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Requip modutab, 8MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Requip PR
   GlaxoSmithKline
      2010   Phase 3   NCT01536574   China
      2010   Phase 3   NCT01154166   China
   Rajesh Pahwa, MD
      2006   Phase 3   NCT00275275   United States
Requip prolonged release
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom
Requip XL prolonged-release
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom
Requip*21CPR 0,25MG
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Requip*21CPR 0,5MG
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Requip*21CPR 1MG
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Requip*21CPR 5MG
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy
Requip-LP
   CHU de Toulouse
      2009   -   EUCTR2009-012529-12-FR   France
Requip-modutab
   GlaxoSmithKline Research & Development Limited
      2007   -   EUCTR2006-006209-94-DE   Germany
Requip-modutab , 2MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Requip-modutab , 4MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Requip-modutab , 8MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Requip-modutab, 2MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Requip-modutab, 4MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Requip-modutab, 8MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
Resistance training
   University of Kiel
      2011   -   NCT02253563   -
Resistant maltodextrin
   Northwestern University
      2018   Phase 2   NCT03667404   United States
Resistant starch
   Saarland University
      2016   -   NCT02784145   Germany
Resistive respiratory loads
   University of Florida
      2017   -   NCT03321019   United States
Restex tabletten
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
Rifampicin
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT04070495   Japan
Rifampin 300MG BID + istradefylline 40MG DAY 8 only
   Kyowa Kirin Co., Ltd.
      2014   Phase 1   NCT02174250   United States
Rifaximin
   Mayo Clinic
      2012   Phase 3   NCT01662791   United States
   University of California, San Francisco
      2019   Phase 1/Phase 2   NCT03575195   United States
   University of Cincinnati
      2015   Phase 2/Phase 3   NCT02470780   United States
Rifaximin 550 MG
   Taipei Medical University Shuang Ho Hospital
      2019   Phase 1/Phase 2   NCT03958708   Taiwan
Ritalin
   University Medical Center Groningen
      2010   -   EUCTR2009-012643-42-NL   Netherlands
RIV-TDS 13.3 MG/24 H
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom
Rivastigmin luye transdermal patches - 4.6MG/24H
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom
Rivastigmine
   NOVARTIS FARMA
      2008   -   EUCTR2007-000350-31-IT   France;Italy;Spain
   Novartis Farmacéutica S.A
      2008   Phase 3   EUCTR2007-000350-31-ES   France;Italy;Spain
   Novartis Pharma AG
      2008   -   EUCTR2007-000350-31-FR   France;Italy;Spain
   Research and Enterprise Department
      2012   Phase 2   EUCTR2011-003053-25-GB   United Kingdom
   University Hospital, Lille
      2009   Phase 3   NCT00767091   France
   VU University Medical Center
      2013   Phase 4   NCT01856738   Netherlands
Rivastigmine capsule
   Novartis
      2008   Phase 3   NCT00623103   Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States
Rivastigmine CF
   VU University Medical Center
      2013   Phase 4   EUCTR2013-001722-25-NL   Netherlands
Rivastigmine luye transdermal patch- 9.5MG/24H
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom
Rivastigmine patch 9.5 CM2
   University of California, San Francisco
      2010   Phase 4   NCT00988117   United States
Rivastigmine transdermal patch
   Novartis
      2008   Phase 3   NCT00623103   Argentina;Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;Turkey;United Kingdom;United States
   University of Maryland, Baltimore
      2019   Phase 4   NCT03840837   United States
Rivastigmine transdermal system
   University of Bristol
      2020   Phase 3   NCT04226248   United Kingdom
   University of Pennsylvania
      2011   Phase 4   NCT01519271   United States
Rivastigmine transdermal system 13.3 MG/24 H
   University of Bristol
      2019   Phase 3   EUCTR2018-003219-23-GB   United Kingdom
RM-131
   Motus Therapeutics, Inc.
      2013   Phase 2   NCT01955616   United States
RO7046015
   F. HOFFMANN - LA ROCHE LTD.
      2021   Phase 2   EUCTR2020-004997-23-IT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
   F. Hoffmann-La Roche Ltd
      2022   Phase 2   EUCTR2020-004997-23-LU   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-PL   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-FR   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-004997-23-AT   Austria;Canada;France;Italy;Luxembourg;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2017-000087-15-FR   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-ES   Austria;France;Germany;Spain;United States
      2017   Phase 2   EUCTR2017-000087-15-AT   Austria;France;Germany;Spain;United States
   Hoffmann-La Roche
      2017   Phase 2   NCT03100149   Austria;France;Germany;Spain;United States
   Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
      2021   Phase 2   EUCTR2020-004997-23-ES   Austria;Canada;France;Italy;Poland;Spain;United Kingdom;United States
RO7046015/prasinezumab
   F. Hoffmann-La Roche Ltd
      2017   Phase 2   EUCTR2017-000087-15-DE   Austria;France;Germany;Spain;United States
RO7486967
   Hoffmann-La Roche
      2022   Phase 1   NCT05924243   Netherlands;United Kingdom;United States
Role OF dopamine
   University Hospital, Clermont-Ferrand
      2013   Phase 4   NCT01780467   France
ROP+L-dopa
   GlaxoSmithKline
      2007   Phase 4   NCT00485069   Japan
Ropinirole
   CASA DI CURA PRIVATA S.RAFFAELE - PISANA
      2009   -   EUCTR2009-015833-66-IT   Italy
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   CHU de Toulouse
      2009   -   EUCTR2009-012529-12-FR   France
   GlaxoSmithKline
      2010   Phase 1   NCT01435915   China
      2007   Phase 2   NCT00460148   Germany;South Africa
      2003   Phase 3   NCT00381472   Belgium;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;United States
   GlaxoSmithKline Research & Development Limited
      2007   -   EUCTR2006-006209-94-DE   Germany
   Kansai Medical University
      2010   -   JPRN-UMIN000003601   Japan
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01628926   Japan
      2009   Phase 3   JPRN-jRCT2080220857   -
   Pfizer
      2001   Phase 3   NCT00036218   Argentina;Mexico;Puerto Rico;United States
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy
   UNIVERSITA` DEGLI STUDI DI PARMA
      2009   -   EUCTR2009-013004-31-IT   Italy
Ropinirole controlled-release (requip CR) FOR RLS
   GlaxoSmithKline
      2003   Phase 3   NCT00363727   United States
Ropinirole CR 2MG tablet
   GlaxoSmithKline
      2013   Phase 3   NCT01929317   Japan
Ropinirole CR 8MG tablet
   GlaxoSmithKline
      2013   Phase 3   NCT01929317   Japan
Ropinirole hydrochloride
   Agarwal, Pinky, M.D.
      2005   Phase 3   NCT00260793   United States
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
   Hisamitsu Pharmaceutical Co., Inc.
      2011   Phase 2   JPRN-jRCT2080221631   -
   Hisamitsu Pharmaceutical Co.,Inc.
      2015   Phase 3   JPRN-jRCT2080222818   -
      2014   Phase 3   JPRN-jRCT2080222696   -
      2012   Phase 2   JPRN-jRCT2080221836   -
      2012   Phase 2   JPRN-jRCT2080221835   -
   Roxane Laboratories
      2004   -   NCT00674310   -
      2004   -   NCT00673088   -
Ropinirole hydrochloride prolonged release
   University Hospital of North Staffordshire
      2013   Phase 4   EUCTR2012-000801-64-GB   United Kingdom
Ropinirole immediate release
   GlaxoSmithKline
      2006   Phase 3   NCT00331149   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
Ropinirole implant
   Titan Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03250117   United States
Ropinirole IR
   GlaxoSmithKline
      2009   Phase 3   NCT00823836   Japan
Ropinirole IR tablets
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Ropinirole monotherapy
   GlaxoSmithKline
      2012   Phase 4   NCT01485172   Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States
Ropinirole oral product
   Titan Pharmaceuticals
      2017   Phase 1/Phase 2   NCT03250117   United States
Ropinirole PR, 2MG
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
Ropinirole PR/XR
   GlaxoSmithKline
      2009   Phase 3   NCT00823836   Japan
Ropinirole PR/XR tablets
   GlaxoSmithKline
      2006   Phase 3   EUCTR2005-005423-34-ES   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2006   -   EUCTR2005-005423-34-HU   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   Phase 3   EUCTR2005-005423-34-GB   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-DE   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
      2006   -   EUCTR2005-005423-34-CZ   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Ropinirole prolonged release
   GlaxoSmithKline
      2007   Phase 2   NCT00434304   Japan
      2006   Phase 3   NCT00331149   Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom
   Seoul National University Hospital
      2009   Phase 4   NCT00986245   Korea, Republic of
Ropinirole XL
   GlaxoSmithKline
      2009   Phase 1   NCT01371682   Belgium
      2004   Phase 3   NCT00632736   Belgium;Czech Republic;France;Germany;Hungary;Italy;Philippines;Poland;Spain;United Kingdom;United States
      2002   Phase 3   NCT00650104   Belgium;France;Netherlands;Norway;United States
Ropinirole/L-dopa
   GlaxoSmithKline
      2012   Phase 4   NCT01494532   Argentina;Chile;Estonia;Korea, Republic of;Poland;Russian Federation;Slovakia;United States
Rosuvastatin
   Kyowa Kirin Co., Ltd.
      2019   Phase 1   NCT03970798   Japan
ROT-TDS 8 MG/24 H
   Luye Pharma Switzerland AG
      2021   Phase 2   EUCTR2021-000867-65-DE   Germany
Rotigotin
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
Rotigotina
   FONDAZIONE SANTA LUCIA
      2012   -   EUCTR2012-001218-40-IT   Italy
   UCB Pharma SA
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
Rotigotine
   Azienda Ospedaliera Cardinale G. Panico
      2013   Phase 2   NCT02103465   Italy
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2011   -   EUCTR2010-022363-35-DE   Germany
   Department of Neurology, Changzheng Hospital, Second Military Medical University
      2016   -   ChiCTR-CPC-15007223   China
   First Affiliated Hospital of Zhengzhou University
      2022   -   ChiCTR2200057481   China
   Luye Pharma Group Ltd.
      2020   Phase 3   NCT04571164   China
      2020   Phase 1   NCT04384666   United States
      2016   Phase 1   NCT02728947   United States
   Luye Pharma Switzerland AG
      2021   Phase 2   EUCTR2021-000867-65-DE   Germany
   Ospedale Generale Di Zona Moriggia-Pelascini
      2013   -   NCT02100176   Italy
   Peking University Third Hospital
      2018   Phase 3   NCT04455555   China
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom
   SCHWARZ BIOSCIENCES
      2005   Phase 3   EUCTR2004-002650-59-GB   United Kingdom
   SCHWARZ PHARMA
      2007   -   EUCTR2006-006907-35-IT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy
      2004   -   EUCTR2004-000148-26-IT   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
   SCHWARZ PHARMA Deutschland GmbH
      2007   -   EUCTR2006-005438-19-DE   Germany
   Sandoz
      2019   Phase 1   NCT04183634   Germany
   Schwarz BioSciences Inc.
      2008   -   EUCTR2004-000148-26-HU   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2008   -   EUCTR2004-000148-26-AT   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-SE   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-FI   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   Phase 3   EUCTR2004-000148-26-ES   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-CZ   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
   Schwarz Biosciences GmbH
      2008   -   EUCTR2006-006752-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006907-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006907-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-HU   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-FI   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-ES   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   -   EUCTR2006-006752-35-AT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2004-002641-12-GB   Austria;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2004-002641-12-ES   Austria;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002641-12-AT   Austria;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2004-002598-21-GB   Austria;United Kingdom
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy
      2004   -   EUCTR2004-002598-21-AT   Austria;United Kingdom
      -   -   EUCTR2006-006907-35-DE   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   Schwarz Biosciences GmbH, UCB Group
      2007   Phase 3   EUCTR2006-006907-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-006752-35-GB   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
   UCB BIOSCIENCES GMBH
      2013   -   EUCTR2012-002840-26-IT   Austria;Bulgaria;Hungary;Italy;Russian Federation;Slovenia;Spain;Turkey;Ukraine;United States
   UCB BIOSCIENCES GmbH
      2014   Phase 1   NCT02230904   Germany
      2013   Phase 4   NCT01782222   Austria;Hungary;Poland;Slovakia;Slovenia;Spain;United States
      2012   Phase 4   NCT01744496   Germany;Hungary;Korea, Republic of;Poland;Slovakia;United States
      2012   Phase 3   NCT01723904   Australia;Korea, Republic of;Malaysia;Singapore;Taiwan
      2012   Phase 4   NCT01711866   Korea, Republic of;Malaysia;Singapore;Taiwan;United States
   UCB Biosciences GmbH
      2013   -   EUCTR2012-002840-26-SK   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-SI   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-RO   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-HU   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-ES   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-BG   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002840-26-AT   Austria;Bulgaria;Croatia;Hungary;Italy;Poland;Romania;Serbia;Slovakia;Slovenia;Spain;Turkey;Ukraine;United States
      2013   -   EUCTR2012-002608-42-HU   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
      2013   Phase 4   EUCTR2012-002608-42-GB   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
      2013   -   EUCTR2012-002608-42-DE   Germany;Hungary;Poland;Slovakia;United Kingdom;United States
      2012   -   EUCTR2012-002608-42-SK   Argentina;France;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States
   UCB Celltech, UK - Registered Branch of UCB Pharma SA
      2011   -   EUCTR2011-000056-42-GB   United Kingdom
   UCB Korea Co., Ltd.
      2012   Phase 4   NCT01523301   Korea, Republic of
   UCB Pharma
      2012   Phase 3   NCT01646268   China
      2012   Phase 3   NCT01646255   China
      2012   Phase 3   NCT01536015   United States
      2011   Phase 4   NCT01300819   Austria;Belgium;Bulgaria;Czech Republic;France;Germany;Hungary;Italy;Romania;Slovakia;Spain;Switzerland
      2007   Phase 4   NCT00594464   Germany
      2007   Phase 3   NCT00593606   -
      2007   Phase 3   NCT00522379   Chile;India;Mexico;Peru;United States
      2007   Phase 3   NCT00519532   Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States
      2007   Phase 3   NCT00474058   Australia;Austria;Finland;Germany;Hungary;Italy;New Zealand;Poland;South Africa;Spain;United Kingdom;United States
      2006   Phase 1   NCT01964573   Korea, Republic of
      2006   Phase 1   NCT00292227   South Africa
      2005   Phase 3   NCT00505687   Austria;Germany;Israel;Italy;South Africa;Spain;United Kingdom;United States
      2004   Phase 3   NCT00501969   Australia;Austria;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;New Zealand;Norway;Poland;South Africa;Spain;Sweden;United Kingdom
      2004   Phase 3   NCT00243945   Germany
      2004   Phase 3   NCT00242008   United States
      2002   Phase 3   NCT00599196   Australia;Austria;Belgium;Croatia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Netherlands;New Zealand;Norway;Poland;South Africa;Spain;Sweden;Switzerland;United Kingdom
      2002   Phase 3   NCT00594386   Canada;United States
      2002   Phase 3   NCT00594165   Canada;United States
   UCB Pharma SA
      2012   Phase 4   NCT01519882   United Kingdom
      2011   Phase 4   EUCTR2010-021394-37-SK   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-IT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain
      2011   -   EUCTR2010-021394-37-HU   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-ES   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain
      2011   -   EUCTR2010-021394-37-DE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-CZ   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-BG   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
      2011   Phase 4   EUCTR2010-021394-37-BE   Austria;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Slovakia;Spain;Switzerland
      2011   -   EUCTR2010-021394-37-AT   Austria;Belgium;Czech Republic;Germany;Hungary;Italy;Spain;Switzerland
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy
   University Hospital, Grenoble
      2012   Phase 3   NCT02786667   France
Rotigotine 8MG/24HRS patch
   SocraTec R&D GmbH
      2021   Phase 2   NCT06247410   Germany
Rotigotine hydrochloride
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom
Rotigotine nasal spray
   Schwarz Biosciences GmbH
      2006   Phase 2   EUCTR2005-004290-19-GB   Austria;Germany;Spain;United Kingdom
      2006   -   EUCTR2005-004290-19-DE   Germany;Spain;United Kingdom
      2005   -   EUCTR2005-004290-19-AT   Austria;Germany;Spain;United Kingdom
   UCB Pharma
      2006   Phase 2   NCT00296192   Germany
Rotigotine transdermal patch
   Johns Hopkins University
      2016   Phase 4   NCT02365870   United States
   Schwarz Pharma Deutschland GmbH, UCB Group
      -   -   EUCTR2009-014341-84-DE   Germany
   Shandong Luye Pharmaceutical Co., Ltd./CMIC Co., Ltd.
      2019   Phase 1   JPRN-jRCT2080224689   Japan
   UCB Pharma
      2011   Phase 1   NCT01338896   Austria;Germany;United Kingdom
   Wakayama Medical University
      2018   Phase 1   JPRN-UMIN000033409   Japan
Rotigotine, extended-release microspheres
   Luye Pharma Group Ltd.
      2017   Phase 1   NCT04045678   China
      2013   Phase 1   NCT04044547   -
Rozerem
   Southern California Institute for Research and Education
      2007   Phase 4   NCT00462254   United States
RQ-00000010
   Virginia Commonwealth University
      2016   Phase 1   NCT02838797   United States
RVG 08740
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands
RVG 55618
   Radboud University Nijmegen
      2017   Phase 3   EUCTR2016-004629-18-NL   Netherlands
RVT-101 35 MG
   Axovant Sciences Ltd.
      2016   Phase 2   NCT02910102   United States
RYAH-medtech inhaler
   OMNI Medical Services, LLC
      2018   Phase 2   NCT03944447   United States
Rytary 145 MG
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States
Rytary 195 MG
   Impax Laboratories, LLC
      2015   Phase 2   NCT02271503   United States
S 90049
   Institut de Recherches Internationales Servier (I.R.I.S.)
      2005   -   EUCTR2005-002010-38-DE   Germany
S 90049 - F36
   Institut de Recherches Internationales Servier
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain
S 90049 - F38
   Institut de Recherches Internationales Servier
      2005   Phase 2   EUCTR2005-000314-12-ES   Germany;Spain
S.C. apomorphine
   SUNOVION PHARMACEUTICALS INC
      2018   Phase 3   EUCTR2016-003456-70-IT   Austria;France;Germany;Italy;Spain;United Kingdom
   Sunovion Pharmaceuticals Inc.
      2018   Phase 3   EUCTR2016-003456-70-ES   Austria;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-DE   Austria;France;Germany;Italy;Spain;United Kingdom
      2018   Phase 3   EUCTR2016-003456-70-AT   Austria;France;Germany;Italy;Spain;United Kingdom
      2017   Phase 3   EUCTR2016-003456-70-GB   Austria;France;Germany;Italy;Spain;United Kingdom
S90049
   Institut de Recherches Internationales Servier
      2006   Phase 2   EUCTR2005-000314-12-DE   Germany;Spain
Safety observation
   Amgen
      2005   -   NCT00148369   Canada;United Kingdom;United States
Saffron and chamomile
   Jinnah Postgraduate Medical Centre
      2022   -   NCT05696665   Pakistan
Safinamida
   Merck Serono S.A. - Geneva
      2010   Phase 2   EUCTR2010-020109-34-ES   Italy;Spain
Safinamide
   Alain Kaelin
      2019   Phase 4   NCT03968744   Switzerland
   Cyclotron and Radioisotope Center, Tohoku University
      2022   -   JPRN-UMIN000049442   Japan
   IRCCS San Raffaele Roma
      2018   Phase 4   NCT03843944   Italy
   Institut de Recerca Hospital de la Santa Creu i Sant Pau
      2017   Phase 4   EUCTR2017-003254-17-ES   Spain
   MERCK SERONO INTERNATIONAL SA
      2008   Phase 3   EUCTR2007-002963-28-IT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
   MERCK SERONO SA
      2010   Phase 2   EUCTR2010-020109-34-IT   Italy;Spain
      2009   Phase 3   EUCTR2008-005492-94-IT   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-004146-88-IT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2009   -   EUCTR2008-002769-30-IT   Italy
   Merck Serono International S.A.
      2008   Phase 3   EUCTR2007-002964-90-ES   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2008   Phase 3   EUCTR2007-002963-28-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2007   Phase 3   EUCTR2007-002964-90-NL   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2007   -   EUCTR2007-002964-90-FI   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Merck Serono S.A - Geneva
      2008   Phase 3   EUCTR2007-002964-90-GB   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
   Merck Serono S.A-Geneva
      2009   -   EUCTR2007-002963-28-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
   Merck Serono S.A. - Geneva
      2011   -   EUCTR2009-017174-20-AT   Austria;Canada;France;Germany;South Africa
      2010   Phase 2   EUCTR2009-017174-20-FR   Austria;France;Germany
      2010   -   EUCTR2009-017174-20-DE   Austria;Canada;France;Germany;South Africa
      2010   Phase 3   EUCTR2008-005492-94-NL   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2008-005492-94-BE   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2010   Phase 3   EUCTR2007-002964-90-CZ   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-SK   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   -   EUCTR2008-005492-94-HU   Austria;Belgium;Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-GB   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-FR   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2008-005492-94-ES   Austria;Belgium;Bulgaria;Czech Republic;Estonia;Finland;France;Germany;Hungary;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom
      2009   Phase 3   EUCTR2007-002964-90-FR   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2008   -   EUCTR2007-002964-90-DE   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
      2007   Phase 3   EUCTR2007-002964-90-SK   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Slovakia;Spain;United Kingdom
      2007   Phase 3   EUCTR2007-002963-28-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
   Merck Serono S.A.-Geneva
      2008   -   EUCTR2007-002964-90-HU   Austria;Belgium;Czech Republic;Estonia;Finland;France;Germany;Hungary;Netherlands;Spain;United Kingdom
   Merck Serono SA - Geneva
      2009   Phase 3   EUCTR2008-004146-88-SK   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2009   -   EUCTR2008-004146-88-PT   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   -   EUCTR2008-004146-88-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   Phase 3   EUCTR2008-004146-88-ES   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Slovakia;Spain
      2009   Phase 3   EUCTR2008-001966-10-SK   Austria;Estonia;Hungary;Slovakia;United Kingdom
      2009   -   EUCTR2008-001966-10-HU   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-GB   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-EE   Austria;Estonia;Hungary;United Kingdom
      2009   -   EUCTR2008-001966-10-AT   Austria;Estonia;Hungary;United Kingdom
   NEWRON PHARMACEUTICALS
      2007   -   EUCTR2006-005861-21-IT   Italy
      2006   -   EUCTR2006-005860-14-IT   Italy
      2004   -   EUCTR2004-000835-27-IT   Italy;Spain
      2004   -   EUCTR2004-000833-12-IT   Italy;Spain
   Newron
      2011   Phase 2   NCT01264861   United States
      2010   Phase 2   NCT01211587   Spain;United States
      2010   Phase 2   NCT01113320   Austria;Canada;France;Germany;South Africa
      2009   Phase 3   NCT00865579   Romania
      2007   Phase 3   NCT01286935   -
      2007   Phase 3   NCT01187966   -
      2007   Phase 3   NCT00605683   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Israel;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2005   Phase 3   NCT00642889   -
      2004   Phase 3   NCT00643045   -
   Newron Pharmaceuticals
      2011   -   EUCTR2008-005492-94-PT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-FI   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-CZ   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2011   -   EUCTR2008-005492-94-BG   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2010   -   EUCTR2008-004146-88-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   -   EUCTR2008-005492-94-EE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2008-005492-94-AT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2008-004146-88-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   -   EUCTR2008-004146-88-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      2009   Phase 3   EUCTR2008-004146-88-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;Slovakia;South Africa;Spain;United States
      -   -   EUCTR2008-005492-94-DE   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Slovakia;South Africa;Spain;Taiwan;Thailand;United Kingdom;United States
   Newron Pharmaceuticals S.P.A
      2005   Phase 3   EUCTR2004-000835-27-ES   Italy;Spain
   Newron Pharmaceuticals S.p.A.
      2004   Phase 3   EUCTR2004-000833-12-ES   Italy;Spain
   Newron Pharmaceuticals SpA
      2011   Phase 3   EUCTR2007-002964-90-BE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2010   -   EUCTR2007-002963-28-DE   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2009   -   EUCTR2007-002964-90-AT   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2009   -   EUCTR2007-002963-28-PL   Bulgaria;Czech Republic;Finland;Germany;Italy;Poland;Portugal;Spain
      2009   -   EUCTR2007-002963-28-CZ   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2009   -   EUCTR2007-002963-28-BG   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Peru;Poland;Portugal;South Africa;Spain;United States
      2008   -   EUCTR2007-002964-90-EE   Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Finland;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
      2007   -   EUCTR2007-002963-28-FI   Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;Germany;India;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States
   Supernus Pharmaceuticals, Inc.
      2017   -   NCT03944785   United States
   Zambon S.P.A.
      2015   Phase 3   EUCTR2014-002600-24-SE   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-GB   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-ES   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-AT   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
   Zambon SpA
      2019   Phase 3   NCT03881371   China
Safinamide + levodopa
   Newron
      2009   Phase 1/Phase 2   NCT01026428   Italy
Safinamide mesilate
   Eisai Korea Inc.
      2022   Phase 4   NCT05312632   Korea, Republic of
   Meiji Seika Pharma Co., Ltd.
      2015   Phase 3   JPRN-jRCT2080223003   Japan
      2015   Phase 2-3   JPRN-jRCT2080223002   Japan
Safinamide metansolfonato
   I.R.C.C.S. FONDAZIONE S.LUCIA
      2018   Phase 4   EUCTR2017-002239-41-IT   Italy
   OSPEDALE SANTA MARIA DELLA MISERICORDIA
      2021   Phase 3   EUCTR2018-004892-11-IT   Italy
   Universita di Verona
      2018   -   NCT03648671   Italy
   ZAMBON SPA
      2019   Phase 4   EUCTR2017-002426-20-IT   Austria;France;Germany;Italy;Spain
      2015   Phase 3   EUCTR2014-002600-24-IT   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
Safinamide methanesulfonate
   ZAMBON SPA
      2019   Phase 4   EUCTR2017-002426-20-IT   Austria;France;Germany;Italy;Spain
   Zambon SpA
      2019   Phase 4   NCT03841604   Austria;France;Germany;Italy;Spain
      2019   Phase 4   EUCTR2017-002426-20-FR   Austria;France;Spain
      2019   Phase 4   EUCTR2017-002426-20-AT   Austria;Spain
      2018   Phase 4   EUCTR2017-002426-20-ES   Austria;France;Italy;Spain
Safinamide methanesulfonate 100MG
   Zambon SpA
      2019   Phase 3   NCT03987750   -
Safinamide methanesulfonate 150MG
   Zambon SpA
      2019   Phase 3   NCT03987750   -
Safinamide methansulfonate
   Zambon SpA
      2019   Phase 4   EUCTR2017-002426-20-FR   Austria;France;Spain
      2019   Phase 4   EUCTR2017-002426-20-AT   Austria;Spain
      2018   Phase 4   EUCTR2017-002426-20-ES   Austria;France;Italy;Spain
Safinamide, MAO-B inhibitor
   Newron
      2009   Phase 3   NCT01028586   Switzerland
Safinimide 50-100 MG/DAY
   Newron
      2009   Phase 3   NCT00627640   Australia;Austria;Belgium;Canada;Estonia;France;Germany;Hungary;India;Israel;Korea, Republic of;Malaysia;Netherlands;New Zealand;Slovakia;Spain;Switzerland;Taiwan;Thailand;United Kingdom;United States
Sage leaf
   Newcastle Upon tyne Hospitals NHS Foundation Trust
      2007   -   EUCTR2007-002899-34-GB   United Kingdom
SAGE-217
   Biogen
      2016   Phase 2   NCT03000569   United States
SAGE-718
   Sage Therapeutics
      2022   Phase 2   NCT05318937   United States
      2020   Phase 2   NCT04476017   United States
Saline
   NeuroDerm Ltd.
      2011   Phase 1/Phase 2   NCT01229332   Israel
   Shanghai East Hospital
      2022   Early Phase 1   NCT05435755   China
   The Neurology Center
      2018   Early Phase 1   NCT04202757   United States
   Utano National Hospital, National Hospital Organization
      2013   -   JPRN-UMIN000017695   Japan
   Yale University
      2021   Phase 2   NCT04944017   United States
      2012   Phase 2   NCT02419313   United States
   Yancheng Third People's Hospital
      2024   -   ChiCTR2500098063   China
Saline intranasal delivery
   Bastyr University
      2012   Phase 1   NCT01398748   United States
SAM-E
   New York University School of Medicine
      2003   Phase 2/Phase 3   NCT00070941   United States
SAR402671, GZ402671 or GZ/SAR402671
   Genzyme Corporation
      2019   Phase 2   EUCTR2016-000657-12-GR   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2018   Phase 2   EUCTR2016-000657-12-AT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-PT   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-IT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-DE   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000657-12-SE   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000657-12-ES   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Saracatinib
   King's College London
      2019   Early Phase 1   NCT03661125   United Kingdom
Sarcosine capsule
   China Medical University Hospital
      2010   -   NCT01785628   Taiwan
Sargramostim
   University of Nebraska
      2023   Phase 1   NCT05677633   United States
      2019   Phase 1   NCT03790670   United States
      2013   Phase 1   NCT01882010   United States
Sarizotan
   EMD Serono
      2004   Phase 3   NCT00105508   United States
   Merck KGaA
      2005   Phase 3   EUCTR2004-001593-10-GB   Italy;United Kingdom
Sarizotan HC1
   EMD Serono
      2004   Phase 3   NCT00105521   United States
Sarizotan HCL
   EMD Serono
      2002   Phase 2   NCT00314288   Belgium;Bulgaria;Canada;France;Germany;Hungary;Portugal;Romania;South Africa;United Kingdom;United States
Sarizotan hydrochloride
   MERCK KGaA
      2004   Phase 3   EUCTR2004-001594-25-ES   Austria;Finland;Spain
   MERCK S.P.A.
      2004   -   EUCTR2004-001593-10-IT   Italy;United Kingdom
   Merck KGaA
      2005   Phase 3   EUCTR2005-000444-84-GB   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000444-84-FI   Finland;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-000444-84-ES   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2005-000444-84-AT   Austria;Finland;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-001594-25-AT   Austria;Finland;Spain
      2004   -   EUCTR2004-001594-25-FI   Finland;Spain
SCH 420814
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc.
      2011   -   EUCTR2009-015161-31-DE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
      2011   -   EUCTR2009-015162-57-PT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
      2011   Phase 3   EUCTR2009-015162-57-GB   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015161-31-GB   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-BG   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-BG   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      -   -   EUCTR2009-013552-72-DE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
   Merck Sharp & Dohme corp.
      2011   Phase 3   EUCTR2009-015162-57-NL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
   Schering Corporation, división Schering-Plough Research
      2010   Phase 3   EUCTR2009-013552-72-ES   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Schering Plough Research Institute
      2007   Phase 2   EUCTR2007-001717-42-FR   France;Spain
      2006   -   EUCTR2005-005146-39-IT   Italy
   Schering-Plough Research Institute, a division of Schering Corporation
      2011   -   EUCTR2010-020112-11-LV   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
      2011   -   EUCTR2010-020112-11-LT   Argentina;Chile;Colombia;Croatia;Latvia;Lithuania;Mexico;Russian Federation;Serbia;South Africa;Ukraine;United States
      2011   -   EUCTR2009-015162-57-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LV   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-LT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   Phase 3   EUCTR2009-015162-57-ES   Austria;Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2011   Phase 3   EUCTR2009-015162-57-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015162-57-AT   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Finland;France;Germany;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-PL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-015161-31-CZ   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   -   EUCTR2009-013552-72-PL   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2011   Phase 3   EUCTR2009-013552-72-CZ   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-SE   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-NL   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   EUCTR2009-015161-31-FR   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   -   EUCTR2009-015161-31-FI   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-015161-31-AT   Austria;Brazil;Bulgaria;Canada;Czech Republic;Finland;France;Germany;India;Israel;Italy;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   -   EUCTR2009-013552-72-SE   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
      2010   Phase 3   EUCTR2009-013552-72-HU   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2010   Phase 3   EUCTR2009-013552-72-FI   Argentina;Austria;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Peru;Poland;Portugal;Russian Federation;Spain;Sweden;Turkey;United Kingdom;United States
SCH 420814 10 MG
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States
SCH 420814 100 MG
   Merck Sharp & Dohme Corp.
      2009   Phase 1   NCT00845000   United States
SCH 900800
   Merck Sharp & Dohme Corp.
      2013   Phase 1   NCT01500707   -
SCH420814
   Schering-Plough Research Institute, a division of Schering Corporation
      2010   Phase 3   EUCTR2009-015161-31-IT   Austria;Bulgaria;Czech Republic;Finland;France;Germany;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
      2010   -   EUCTR2009-013552-72-IT   Bulgaria;Czech Republic;Finland;Germany;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
   Schering-Plough Research Institute, division of Schering Corporation
      2011   -   EUCTR2009-015162-57-IT   Bulgaria;Czech Republic;Finland;Italy;Latvia;Lithuania;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom
Screening TO prevent falls
   University of Sao Paulo General Hospital
      2015   -   NCT02488265   Brazil
Sedation with IV propofol
   Hadassah Medical Organization
      2006   -   NCT00355927   Israel
Selegiline
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Cyclotron and Radioisotope Center, Tohoku University
      2022   -   JPRN-UMIN000049442   Japan
   Department of Neurology, Juntendo Koshigaya Hospital
      2012   -   JPRN-UMIN000008477   Japan
   FP Pharmaceutical Corp.
      2012   Phase 2   JPRN-jRCT2080221954   -
      2012   Phase 3   JPRN-jRCT2080221909   -
      2010   Phase 2   JPRN-jRCT2080220987   -
   Institute of Psychology, Chinese Academy of Sciences
      2018   -   ChiCTR1800015331   China
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   -
   Longhua Hospital Shanghai University of Traditional Chinese Medicine
      2018   -   ChiCTR1800018017   China
      2018   -   ChiCTR1800017949   China
   Osaka Redcross Hospital Wakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan
   Parkinson's Disease and Movement Disorder Center of Boca Raton
      2007   Phase 4   NCT00443872   United States
   Research and Development University Hospital of North Staffordshire
      2014   -   EUCTR2014-000335-17-GB   United Kingdom
   Second Affiliated Hospital of Soochow University
      2020   Phase 4   NCT04870372   China
   The Second Affiliated Hospital of Soochow University
      2020   Phase 4   ChiCTR2100045946   China
   Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology
      2020   Phase 0   ChiCTR2000037828   China
   University of South Florida
      2014   Phase 4   NCT02225548   United States
Selegiline HCL 5 PCH
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
Semaglutide
   Kimura Yasuyoshi
      2023   Phase 2   JPRN-jRCT2051230090   -
   Oslo University Hospital
      2019   Phase 2   NCT03659682   -
Semi continuous intra-oral administration OF LD/CD
   IRCCS San Raffaele Roma
      2014   Phase 2   NCT02763137   Italy
Senfrol monotherapy
   Peking University Third Hospital
      2018   Phase 4   NCT04968613   China
SEP-363856
   Otsuka Pharmaceutical Development & Commercialization, Inc.
      2016   Phase 2   NCT02969369   United States
SER-214
   Serina Therapeutics
      2016   Phase 1   NCT02579473   United States
Seroquel
   King’s College London & King’s College Hospital
      2005   Phase 4   EUCTR2004-002608-13-GB   United Kingdom
Sertraline
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
   Zhejiang University
      2011   -   NCT01437189   China
Sevoflurane
   The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
      2019   -   ChiCTR1900026956   China
Sham compression
   Vanderbilt University Medical Center
      2020   Early Phase 1   NCT04620382   United States
Sham DBS
   Emory University
      2021   Phase 4   NCT06234995   United States
Sham surgery
   BlueRock Therapeutics
      2025   Phase 3   NCT06944522   United States
   Living Cell Technologies
      2016   Phase 2   NCT02683629   New Zealand
   MeiraGTx, LLC
      2022   Phase 1/Phase 2   NCT05603312   United States
   Sangamo Therapeutics
      2009   Phase 1/Phase 2   NCT00985517   United States
      2006   Phase 2   NCT00400634   United States
Sham tdcs
   National Cheng-Kung University Hospital
      2015   Phase 1/Phase 2   NCT02917122   -
Sham tpcs
   Western University, Canada
      2019   -   NCT04054960   Canada
Sham transcranial direct current stimulation
   Universidad Francisco de Vitoria
      2023   -   NCT06214377   Spain
SHMT1 polymorphism
   Assiut University
      2021   -   NCT04706065   Egypt
Sifol
      2006   -   EUCTR2005-003788-22-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim AB
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Limited
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
Sifrol
      2006   -   EUCTR2005-003788-22-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   BOEHRINGER ING.
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2004   Phase 4   NCT02231905   -
      2002   -   NCT02231255   -
      2000   -   NCT02231294   -
   Boehringer Ingelheim AB
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004949-34-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom
Sifrol 0,088
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
Sifrol 0,18
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
Sifrol 0,35
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
Sifrol 0,7
   Axxonis Pharma AG
      2007   -   EUCTR2006-003732-30-DE   Germany;Italy;Poland
   NeuroBiotec Pharma AG
      2008   -   EUCTR2006-003732-30-PL   Germany;Italy;Poland
Sifrol, 0,35 MG tablette
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Sifrol, 0,70 MG tablette
   Axxonis Pharma GmbH
      2006   -   EUCTR2005-001006-12-AT   Austria;Czech Republic;Germany;Italy
Sifrol, mirapexin
   Boehringer Ingelheim España, S.A.
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
Sildenafil
   Bispebjerg Hospital
      2003   Phase 4   NCT01941732   Denmark
   Loma Linda University
      2002   Phase 2   NCT02162979   United States
Silodosin
   Juntendo University School of Medicine
      2012   -   JPRN-UMIN000008138   Japan
Simvastatin
   Plymouth Hospitals NHS Trust
      2015   Phase 3   EUCTR2015-000148-40-GB   United Kingdom
   University Hospital Plymouth NHS Trust
      2016   Phase 2   NCT02787590   United Kingdom
Simvastatine
   CHU de Bordeaux
      2009   -   EUCTR2009-011736-35-FR   France
Sinemet
   Acorda Therapeutics
      2019   Phase 1   NCT03887884   United States
      2016   Phase 1   NCT02812394   United States
      2012   Phase 2   NCT01617135   Israel;Serbia;United Kingdom
   Bial - Portela C S.A.
      2005   Phase 2   NCT02834507   -
      2005   Phase 1   NCT02774564   Portugal
   Bristol-Myers Squibb
      2007   -   NCT00460954   Canada
   DR. REDDY’S LABORATORIES LIMITED
      2017   Phase 2   EUCTR2017-000262-30-IT   Italy
   EISAI LTD UK
      2007   -   EUCTR2006-005714-12-IT   Italy
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-GB   Spain;United Kingdom
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
      2005   Phase 4   EUCTR2004-001485-41-AT   Austria;Spain;United Kingdom
   Intec Pharma Ltd.
      2016   Phase 3   NCT02605434   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT06976346   China
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom
   NeuroDerm Ltd.
      2015   Phase 1   NCT02486432   -
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom
   Orion Corporation, Orion Pharma
      2009   Phase 1   NCT01070628   Finland
   XenoPort, Inc.
      2010   Phase 2   NCT01171313   United States
Sinemet - 100 MG + 25 MG compresse 50 compresse divisibili
   INTEC PHARMA LTD
      2018   Phase 2   EUCTR2018-001209-95-IT   Italy;Spain
Sinemet 10-100
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Sinemet 100 MG + 25 MG compresse
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   SynAgile Corporation
      2014   Phase 2   EUCTR2014-002295-87-IT   Italy
Sinemet 100 MG + 25 MG tablets
   BIAL-Portela & Ca, S.A.
      2021   Phase 4   EUCTR2020-002754-24-IT   Germany;Italy;Portugal;Spain;United Kingdom
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-PT   Germany;Italy;Portugal;Spain;United Kingdom
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
      2021   Phase 4   EUCTR2020-002754-24-ES   Germany;Italy;Portugal;Spain;United Kingdom
Sinemet 125
   Centre for Human Drug Research
      2020   Phase 2   EUCTR2020-000686-16-NL   Netherlands
Sinemet 125 MG
   UMCG
      2009   -   EUCTR2008-006278-13-NL   Netherlands
Sinemet 200MG/50MG
   Orion Corporation, Orion Pharma
      2008   Phase 2   NCT00562198   Finland
Sinemet 25-100
   INTEC PHARMA LTD
      2016   Phase 3   EUCTR2015-003512-20-IT   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
   Intec Pharma, Ltd.
      2016   Phase 3   EUCTR2015-003512-20-SK   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-PL   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-HU   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-GB   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
      2016   Phase 3   EUCTR2015-003512-20-ES   Bulgaria;Germany;Hungary;Israel;Italy;Poland;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;United States
Sinemet 25-100 oral tablet
   XenoPort, Inc.
      2009   Phase 1/Phase 2   NCT00914602   United States
Sinemet 25/100
   BIAL-Portela & Ca, SA
      2009   -   EUCTR2009-012897-12-RO   Romania
   Bial - Portela & Cª, S.A.
      2008   -   EUCTR2008-003869-72-PT   Portugal
   Bial - Portela C S.A.
      2001   Phase 1   NCT02763839   Portugal
Sinemet CR
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany
   Huashan Hospital
      2011   -   NCT01470859   China
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2017   Phase 4   NCT03111485   Canada
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal
Sinemet CR 25MG-100MG extended-release tablet
   Intec Pharma Ltd.
      2018   Phase 2   NCT03576638   -
Sinemet IR
   Depomed
      2012   Phase 2   NCT01515410   United States
Sinemet plus
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2015   Phase 4   EUCTR2015-002631-17-ES   Spain
   NEURODERM LTD.
      2018   Phase 3   EUCTR2017-002780-17-IT   Austria;France;Italy;Netherlands;Spain;United States
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain
   NeuroDerm Ltd.
      2018   Phase 3   EUCTR2017-002780-17-FR   Austria;France;Italy;Netherlands;Spain;United States
      2018   Phase 3   EUCTR2017-002780-17-ES   Austria;France;Italy;Netherlands;Spain;United States
Sinemet plus 25 MG/ 100 MG tablets
   Bial - Portela & Ca, S.A.
      2022   Phase 4   EUCTR2020-002754-24-DE   Germany;Italy;Portugal;Spain;United Kingdom
Sinemet*50CPR 100MG+25MG
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy
Sinemet-plus tablets
   Impax Laboratories, Inc.
      2009   -   EUCTR2009-014688-37-ES   France;Germany;Poland;Spain
Sinemet® 100/25
   Bial - Portela C S.A.
      2008   Phase 1   NCT02169479   Canada
      2004   Phase 1   NCT03091868   Portugal
Sinemet® 100/25 MG
   Bial - Portela C S.A.
      2009   Phase 1   NCT01533077   Canada
Sinemet® CR
   CombinatoRx, Inc
      2008   -   EUCTR2007-005033-11-DE   Germany
Sinemet® CR 100/25
   Bial - Portela C S.A.
      2008   Phase 1   NCT02169453   Canada
Sinemet® plus 25 MG/100 MG tablets
   Civitas Therapeutics, Inc.
      2012   -   EUCTR2012-000181-37-GB   Israel;Serbia;United Kingdom
Sinemet®-plus tablets
   Impax Laboratories, Inc.
      2010   -   EUCTR2009-014688-37-PL   France;Germany;Poland;Spain
      2009   Phase 3   EUCTR2009-014688-37-FR   France;Germany;Poland;Spain
      2009   -   EUCTR2009-014688-37-DE   France;Germany;Poland;Spain
Sinemet®25-100
   Abbott Products, Inc (Abbott Products Inc. is part of the parent company, Abbott Laboratories)
      2007   -   EUCTR2006-000577-29-DE   Germany;United States
Sirio*30CPR EFF 25MG+100MG
   VERNALIS DEVELOPMENT LIMITED
      2006   -   EUCTR2006-004112-51-IT   Italy
Sirolimus
   Prevail Therapeutics
      2020   Phase 1/Phase 2   NCT04127578   Israel;Netherlands;United States
Sitagliptin
   Mayo Clinic
      2024   Phase 4   NCT06263673   United States
   Peking Union Medical College Hospital
      2020   Phase 4   ChiCTR2000029465   China
SK&F101468
   GlaxoSmithKline Research & Development Limited
      2013   -   EUCTR2011-002828-41-SK   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
      2013   -   EUCTR2011-002828-41-EE   Argentina;Chile;Estonia;Korea, Republic of;Russian Federation;Slovakia;Taiwan;United States
      2013   -   EUCTR2011-002827-17-SK   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
      2013   -   EUCTR2011-002827-17-EE   Estonia;Korea, Republic of;Russian Federation;Slovakia;United States
      2007   -   EUCTR2006-006209-94-DE   Germany
SKF-101468A
   GlaxoSmithKline R D
      2006   -   EUCTR2005-005423-34-IT   Czech Republic;Germany;Hungary;Italy;Spain;United Kingdom
Skin biopsy
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2016   -   NCT02767037   -
SLV308
   SOLVAY PHARMACEUTICALS B.V.
      2009   -   EUCTR2008-000400-81-IT   Germany;Italy;Portugal
   Solvay Pharmaceuticals
      2005   Phase 3   NCT00134251   Bulgaria;Former Serbia and Montenegro;Malta;Serbia
SLV308 (mono) hydro
   Solvay pharmaceuticals
      2006   Phase 3   EUCTR2006-000678-57-GB   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
SLV308 (mono) hydrochlo
   Solvay Pharmaceuticals
      2006   Phase 3   EUCTR2006-000858-45-SK   Finland;Slovakia;Sweden
SLV308 (mono) hydrochlori
   Solvay Pharmaceuticals
      2006   -   EUCTR2006-000859-18-CZ   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
   Solvay pharmaceuticals
      2007   -   EUCTR2006-000859-18-PT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2007   -   EUCTR2006-000859-18-NL   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2007   -   EUCTR2006-000678-57-CZ   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000859-18-LT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2006   -   EUCTR2006-000859-18-EE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2006   -   EUCTR2006-000678-57-NL   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-LT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-EE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-DE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
   Solvay pharmaceuticals B.V.
      2006   -   EUCTR2006-000678-57-PT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
SLV308 (mono) hydrochloride
   Solvay Pharmaceuticals
      2007   -   EUCTR2006-000858-45-SE   Finland;Sweden
      2006   -   EUCTR2006-000859-18-CZ   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2006   Phase 3   EUCTR2006-000858-45-SK   Finland;Slovakia;Sweden
      2006   -   EUCTR2006-000858-45-FI   Finland;Sweden
      2006   -   EUCTR2005-006033-32-SK   Finland;Slovakia;Sweden
      2006   -   EUCTR2005-006033-32-SE   Finland;Slovakia;Sweden
      2006   -   EUCTR2005-006033-32-FI   Finland;Slovakia;Sweden
      2005   -   EUCTR2005-002432-10-MT   Malta
   Solvay pharmaceuticals
      2007   -   EUCTR2006-000859-18-PT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2007   -   EUCTR2006-000859-18-NL   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2007   -   EUCTR2006-000859-18-DE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2007   Phase 3   EUCTR2006-000678-57-FR   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2007   -   EUCTR2006-000678-57-CZ   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000859-18-LT   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2006   -   EUCTR2006-000859-18-EE   Czech Republic;Estonia;Germany;Italy;Lithuania;Netherlands;Portugal
      2006   -   EUCTR2006-000678-57-NL   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-LT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   Phase 3   EUCTR2006-000678-57-GB   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-EE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
      2006   -   EUCTR2006-000678-57-DE   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
   Solvay pharmaceuticals B.V.
      2006   -   EUCTR2006-000678-57-PT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
SLV308 (mono)hydrochloride
   SOLVAY PHARMACEUTICALS B.V.
      2006   -   EUCTR2006-000678-57-IT   Czech Republic;Estonia;France;Germany;Italy;Lithuania;Netherlands;Portugal;United Kingdom
   Solvay Pharmaceuticals
      2005   -   EUCTR2005-002432-10-MT   Malta
SLV308 hydrochloride
   Abbott Healthcare Products B.V.
      2009   -   EUCTR2008-000400-81-DE   Germany;Italy;Portugal
   Solvay Pharmaceuticals
      2009   Phase 3   EUCTR2007-001095-36-SK   Hungary;Slovakia
      2008   Phase 3   EUCTR2007-001096-10-SK   Hungary;Slovakia
      2008   -   EUCTR2007-001096-10-HU   Hungary
      2008   -   EUCTR2007-001095-36-HU   Hungary
   Solvay Pharmaceuticals B.V.
      2008   Phase 2   EUCTR2008-004943-12-SK   Slovakia
   Solvay Pharmaceuticals BV
      2009   -   EUCTR2008-000400-81-PT   Germany;Italy;Portugal
SLV308(mono)hydrochloride
   Solvay Pharmaceuticals
      2007   -   EUCTR2006-005183-91-LV   Latvia;Lithuania
      2007   -   EUCTR2006-005183-91-LT   Latvia;Lithuania
      2007   -   EUCTR2006-005182-20-LV   Latvia;Lithuania
      2007   -   EUCTR2006-005182-20-LT   Latvia;Lithuania
Smartphone-based balance exercises
   University of Houston
      2019   -   NCT04146454   United States
Smilagenin
   Phytopharm plc
      2011   -   EUCTR2010-018534-44-HU   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2011   -   EUCTR2010-018534-44-DE   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2011   -   EUCTR2010-018534-44-CZ   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
      2010   Phase 2   EUCTR2010-018534-44-GB   Canada;Czech Republic;France;Germany;Hungary;Poland;Romania;Serbia;United Kingdom;United States
SND 919 CL2 Y
      2006   -   EUCTR2005-003788-22-FI   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   BOEHRINGER INGELHEIM
      2008   Phase 3   EUCTR2007-004234-16-FR   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia
      2007   Phase 3   EUCTR2007-003353-90-FR   France;Germany;Netherlands
   Boehringer Ingelheim
      2008   -   EUCTR2007-004235-37-GB   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-003353-90-NL   France;Germany;Netherlands
      2006   Phase 4   EUCTR2005-004949-34-FI   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim AB
      2008   -   EUCTR2007-004235-37-SE   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2006   Phase 4   EUCTR2005-004949-34-SE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-SE   Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Austria GmbH
      2006   -   EUCTR2005-004949-34-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-AT   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España S.A.
      2006   Phase 4   EUCTR2005-003788-22-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España, S.A.
      2008   Phase 3   EUCTR2007-004235-37-ES   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-000074-23-ES   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-004949-34-ES   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Finland Ky
      2008   -   EUCTR2007-004234-16-FI   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   -   EUCTR2007-000073-39-FI   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2006   Phase 4   EUCTR2005-003788-22-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Ltd
      2006   Phase 4   EUCTR2005-004949-34-GB   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma Ges mbH
      2008   -   EUCTR2007-004235-37-PL   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004235-37-HU   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004235-37-CZ   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004234-16-HU   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   Phase 3   EUCTR2007-000073-39-SK   Austria;Czech Republic;Finland;Germany;Hungary;Slovakia
      2007   -   EUCTR2007-000073-39-HU   Austria;Czech Republic;Finland;Hungary
      2007   -   EUCTR2007-000073-39-AT   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-003353-90-DE   France;Germany;Netherlands
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000073-39-DE   Austria;Czech Republic;Finland;Germany;Hungary
      2006   -   EUCTR2005-004949-34-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
      2006   -   EUCTR2005-003788-22-DE   Austria;Finland;Germany;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim RCV GmbH & Co KG
      2009   -   EUCTR2007-004235-37-AT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004234-16-AT   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2008   Phase 3   EUCTR2007-004235-37-SK   Austria;Czech Republic;Hungary;Italy;Poland;Slovakia;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004234-16-SK   Austria;Czech Republic;Finland;France;Hungary;Netherlands;Slovakia
      2008   -   EUCTR2007-004234-16-CZ   Austria;Czech Republic;Finland;France;Hungary;Netherlands
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000073-39-CZ   Austria;Czech Republic;Finland;Hungary
   Boehringer Ingelheim bv
      2007   -   EUCTR2007-004234-16-NL   Austria;Czech Republic;Finland;France;Hungary;Netherlands
SND 919 CL2Y
   BOEHRINGER ING.
      2008   -   EUCTR2007-004235-37-IT   Austria;Czech Republic;Hungary;Italy;Poland;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-IT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim AB
      2007   -   EUCTR2007-000074-23-SE   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim España, S.A.
      2007   Phase 3   EUCTR2007-000074-23-ES   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Limited
      2007   -   EUCTR2007-000074-23-GB   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma Ges mbH
      2007   Phase 3   EUCTR2007-000074-23-SK   Austria;Czech Republic;Hungary;Italy;Slovakia;Spain;Sweden;United Kingdom
      2007   -   EUCTR2007-000074-23-HU   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim Pharma GmbH & Co. KG
      2007   -   EUCTR2007-000074-23-AT   Austria;Hungary;Italy;Spain;Sweden;United Kingdom
   Boehringer Ingelheim RCV GmbH & Co KG
      2007   Phase 3   EUCTR2007-000074-23-CZ   Austria;Czech Republic;Hungary;Italy;Spain;Sweden;United Kingdom
SNN0031
   NeuroNova AB
      2009   -   EUCTR2007-007853-30-SE   Sweden
   Newron Sweden AB
      2013   Phase 1   NCT01829867   Sweden
      2009   Phase 1/Phase 2   NCT00866502   Sweden
Sodium oxybate
   Baylor College of Medicine
      2004   Phase 2   NCT00641186   -
   Christian Baumann
      2014   Phase 2   NCT02111122   Switzerland
   Stanford University
      2019   Phase 4   NCT04006925   United States
Sodium phosphate enema, oral rifaximin and polyethylene glycol
   Torre Médica Santé
      2018   Phase 1   NCT04730245   Mexico
Solifenacin
   University of South Florida
      2010   Phase 4   NCT01018264   United States
      2007   Phase 4   NCT00584090   United States
   VA Office of Research and Development
      2018   Phase 3   NCT03149809   United States
Soligen
   Institute for Neurodegenerative Disorders
      2005   -   EUCTR2004-001485-41-ES   Spain;United Kingdom
SOLU-cortef
   University Medical Center Groningen
      2015   Phase 2   EUCTR2014-000657-36-NL   Netherlands
Solution DE chlorhydrate DE dopamine ANAérobie
   InBrain Pharma SAS
      2020   Phase 1;Phase 2   EUCTR2020-000155-12-FR   France
Soluzione DI levodopa/carbidopa
   NEURODERM LTD.
      2016   Phase 2   EUCTR2015-005814-31-IT   Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;United States
      2016   Phase 2   EUCTR2015-005078-39-IT   Austria;Germany;Israel;Italy;United States
SOY protein
   Chulalongkorn University
      2011   Phase 4   NCT01662414   Thailand
Specific SL-therapy
   University Hospital, Basel, Switzerland
      2016   -   NCT02935842   Switzerland
Spect
   Zionexa
      2021   Phase 3   NCT04265209   France
Spect imaging
   Institute for Neurodegenerative Disorders
      2007   Phase 0   NCT00556764   United States
      2007   Phase 1   NCT00427674   United States
      2006   Phase 2   NCT00387075   United States
      2004   Phase 2   NCT00096720   United States
      2001   Phase 2   NCT00117819   United States
      2000   Phase 2   NCT00134784   -
      1992   Phase 2   NCT00132626   -
   Tel-Aviv Sourasky Medical Center
      2013   Phase 2   NCT01931488   Israel
Spheramine
   Bayer
      2003   Phase 2   NCT00206687   Austria;France;Germany;Spain;United States
      2000   Phase 2   NCT00761436   United States
Spiropent
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
      -   Phase 2   EUCTR2020-006067-28-BE   Australia;Belgium;New Zealand;United Kingdom
Split-belt treadmill training
   KU Leuven
      2022   -   NCT05511597   Belgium
SPM 926
   SCHWARZ PHARMA
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy
SPM 962
   Otsuka Pharmaceutical Co., Ltd.
      2009   Phase 3   NCT01631825   Japan
      2009   Phase 3   NCT01628926   Japan
      2009   Phase 3   JPRN-jRCT2080220857   -
      2008   Phase 2/Phase 3   NCT01628965   Japan
      2007   Phase 2/Phase 3   NCT00537485   Japan
      2006   Phase 2   NCT01631812   Japan
      2006   Phase 2   NCT01628848   Japan
      2005   Phase 2   NCT01634243   Japan
   SCHWARZ BIOSCIENCES
      2005   Phase 3   EUCTR2004-002650-59-GB   United Kingdom
   SCHWARZ PHARMA
      2007   -   EUCTR2006-006907-35-IT   Austria;Finland;Germany;Hungary;Italy;Spain;United Kingdom
      2004   -   EUCTR2004-002609-66-IT   Germany;Italy
   Schwarz BioSciences Inc.
      2008   -   EUCTR2004-000148-26-HU   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2008   -   EUCTR2004-000148-26-AT   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-SE   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-FI   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   Phase 3   EUCTR2004-000148-26-ES   Austria;Czech Republic;Finland;Hungary;Italy;Spain;Sweden
      2004   -   EUCTR2004-000148-26-CZ   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
   Schwarz Biosciences GmbH
      2005   Phase 3   EUCTR2004-002641-12-GB   Austria;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2004-002641-12-ES   Austria;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002641-12-AT   Austria;Italy;Spain;United Kingdom
      2005   Phase 3   EUCTR2004-002598-21-GB   Austria;United Kingdom
      2004   -   EUCTR2004-002598-21-AT   Austria;United Kingdom
   UCB Pharma
      2004   Phase 3   NCT00244387   Germany
      2004   Phase 3   NCT00243971   Germany
SPM962
   SCHWARZ PHARMA
      2004   -   EUCTR2004-000148-26-IT   Czech Republic;Finland;Hungary;Italy;Spain;Sweden
   Schwarz Biosciences GmbH
      2004   -   EUCTR2004-002609-66-DE   Germany;Italy
   Unità Malattie Neurodegenerative, Ospedale Cardinale Giovanni Panico, Tricase
      2013   -   EUCTR2013-000827-15-IT   Italy
Spoton balance glasses
   SpotOn Therapeutics Ltd.
      2018   -   NCT03942172   Israel
Sqjz herbal mixtures
   Dongzhimen Hospital, Beijing
      2015   Phase 2   NCT02616120   China
SR57667B
   Sanofi
      2004   Phase 2   NCT00220272   Canada;Finland;France;Netherlands;Spain;Switzerland;United Kingdom
      2003   Phase 2   NCT00228150   Austria;Canada;Denmark;France;Germany;Morocco;Netherlands;Portugal;South Africa;Spain;Sweden;Tunisia;United Kingdom
ST 36
   Beijing Hospital of Traditional Chinese Medicine
      2024   Phase 0   ChiCTR2400087389   CHINA
ST36
   Binzhou Medical University Hospital
      2022   Phase 0   ChiCTR2100049704   China
Stalevo
   Asan Medical Center
      2015   -   NCT02452606   Korea, Republic of
   Molecular NeuroImaging
      2004   Phase 2   NCT00200447   -
   NOVARTIS FARMA
      2005   -   EUCTR2005-001032-72-IT   Czech Republic;Italy;Portugal
      2004   -   EUCTR2004-000185-12-IT   Finland;Italy;Sweden;United Kingdom
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-PT   Czech Republic;Italy;Portugal
   Orion Corporation Orion Pharma
      2007   -   EUCTR2007-002496-14-FI   Finland
      2006   Phase 4   EUCTR2006-001755-36-GB   Germany;Sweden;United Kingdom
      -   -   EUCTR2006-001755-36-DE   Germany;Sweden;United Kingdom
   Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
      2006   -   EUCTR2006-001755-36-SE   Germany;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA
      2005   -   EUCTR2004-005234-39-FI   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-FI   Finland;Italy;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, Finland
      2005   Phase 4   EUCTR2004-005234-39-GB   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
   Orion Corporation, ORION PHARMA, 02200 Espoo, Finland
      2008   -   EUCTR2004-005234-39-DE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2007   Phase 3   EUCTR2004-000185-12-GB   Austria;Finland;Italy;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LV   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2006   -   EUCTR2004-005234-39-LT   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-SE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   Phase 4   EUCTR2004-005234-39-IE   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2005   -   EUCTR2004-005234-39-DK   Denmark;Finland;Germany;Ireland;Latvia;Lithuania;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-SE   Finland;Italy;Sweden;United Kingdom
      2004   -   EUCTR2004-000185-12-AT   Austria;Finland;Italy;Sweden;United Kingdom
   Orion Corporation, Orion Pharma
      2016   Phase 2   NCT02764125   Finland;Germany;Hungary;Latvia
      2011   Phase 2   NCT01766258   -
      2009   Phase 1   NCT01070628   Finland
      2006   Phase 4   NCT00462007   Germany;Sweden;United Kingdom
      2005   Phase 4   NCT00125567   Denmark;Finland;Germany;Ireland;Sweden;United Kingdom
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2022   Phase 4   NCT04952194   China
Stalevo 100
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain
Stalevo 100 MG/ 25 MG/ 200 MG filmtabletten
   Novartis Pharma Services AG
      2008   -   EUCTR2007-003134-42-DE   Germany
Stalevo 100 MG/25 MG / 200 MG
   Novartis Pharma AG
      2006   -   EUCTR2005-001032-72-CZ   Czech Republic;Italy;Portugal
Stalevo 100/25/200 MG
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
Stalevo 150
   Institut de Recerca del Hospital de la Santa Creu i Sant Pau
      2007   -   EUCTR2006-002408-32-ES   Spain
   NOVARTIS FARMACEUTICA, S.A
      2006   -   EUCTR2006-000680-28-ES   Spain
Stalevo 150/37.5/200 MG
   Orion Corporation
      2011   -   EUCTR2010-022915-21-SE   Finland;Sweden
      2011   -   EUCTR2010-022915-21-FI   Finland;Sweden
Stalevo*100CPR 100/25/200MG
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
Stalevo*100CPR 50/12,5/200MG
   AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE
      2010   -   EUCTR2010-019396-29-IT   Italy
Standard LD/CD
   IRCCS San Raffaele Roma
      2014   Phase 2   NCT02763137   Italy
Standard treatment
   Ain Shams University
      2024   Phase 2   NCT06612593   Egypt
   The No.1 People's Hospital of Xiangyang, Affiliated to Hubei University of Medicine
      2024   -   ChiCTR2400085736   China
Standardized scales: MDS-updrs (part II TO IV) and rdrs
   Institut de Myologie, France
      2016   -   NCT02785978   France
Static balance exercise
   KU Leuven
      2022   -   NCT05511597   Belgium
Static, dynamic and functional balance exercises with dual task
   Istanbul University-Cerrahpasa
      2019   -   NCT03939559   -
Stellate ganglion block
   Copka Sonpashan
      2024   -   NCT06319625   -
STEM-PD
   Region Skane
      2022   Phase 1   NCT05635409   Sweden;United Kingdom
STEM-PD product
   Region Skåne – Skåne University Hospital
      2022   Phase 1;Phase 2   EUCTR2021-001366-38-SE   Sweden;United Kingdom
Stemregen product
   Sociedad Española de Medicina Regenerativa y Terapia Celular
      2023   -   NCT05699694   Spain
Stilnoct
   Aston University
      2018   Phase 2   EUCTR2017-004297-34-GB   United Kingdom
Stim ON plus
   IRCCS Istituto delle Scienze Neurologiche di Bologna
      2023   Phase 4   NCT06316232   Italy
Stimulator OFF
   Maastricht University Medical Center
      2015   -   NCT02632279   Netherlands
Stimulator ON
   Maastricht University Medical Center
      2015   -   NCT02632279   Netherlands
Stool sample
   University of Florida
      2019   -   NCT04477161   United States
Strattera
   Oregon Health and Science University
      2011   Phase 4   NCT01340885   United States
Strength training IN shallow water and DRY land
   Federal University of Health Science of Porto Alegre
      2021   -   NCT04863118   Brazil
Stretching
   Department of Neurology, Fukuoka university
      2022   -   JPRN-UMIN000047341   Japan
   Murakami Karindoh Hospital
      2023   -   JPRN-UMIN000049144   Japan
   Nagasaki Kita Hospital
      2022   -   JPRN-UMIN000049425   Japan
   Shanghai Shangti orthopedic hospital; Shanghai University of Sport
      2024   Phase 1   ChiCTR2400087568   China
   Slovak Academy of Sciences
      2017   -   NCT03330470   Slovakia;Taiwan
   Union Medical College Affiliated Hospital of Tongji Medical College, Huazhong University of science and technology
      2020   Phase 0   ChiCTR2000037828   China
Study drug
   Dokkyo Medical University
      2016   -   JPRN-UMIN000022023   Japan
      2016   -   JPRN-UMIN000022022   Japan
   Hatano Taku
      2020   -   JPRN-jRCTs031200172   -
   Kanazashi Shuichi
      2024   Phase 2   JPRN-jRCT2061230065   -
   Pfizer
      2010   -   NCT01270711   -
Subcortical stimulation
   University of Texas Southwestern Medical Center
      2022   -   NCT04957095   United States
Subcutaneous apomorphine
   Sunovion
      2018   Phase 3   NCT03391882   Austria;France;Germany;Italy;Spain;United Kingdom
   University Hospital, Toulouse
      2024   -   NCT06080399   France
Subcutaneous hydrocortisone 10MG
   University Medical Center Groningen
      2015   Phase 2   NCT02230930   Netherlands
Subject interview
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
Sudoscan and clinical assessment
   McGill University Health Centre/Research Institute of the McGill University Health Centre
      2016   -   NCT02767037   -
Sugar pill
   Henry Ford Health System
      2015   Phase 2   NCT02066571   United States
   New York Institute of Technology
      2014   Phase 0   NCT02259049   United States
      2012   Phase 1/Phase 2   NCT01676103   United States
   Oregon Health and Science University
      2009   -   NCT00794313   United States
      2005   -   NCT00912808   -
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States
      2010   Phase 2   NCT01341080   United States
Sulforaphane
   Central South University
      2021   Phase 2   NCT05084365   China
Sumanirole
   Pfizer
      2003   Phase 3   NCT00058838   Argentina;Australia;Austria;Belgium;Colombia;France;Germany;Greece;Italy;Mexico;Peru;Puerto Rico;Spain;United States
      2001   Phase 3   NCT00036218   Argentina;Mexico;Puerto Rico;United States
      2000   Phase 3   NCT00036205   Argentina;Colombia;Puerto Rico;United States
Supressi. T-diet plus range
   Vegenat, S.A.
      2010   -   NCT01192529   Spain
Surgical infusion OF AAV-GAD into THE subthalamic nucleus
   Neurologix, Inc.
      2003   Phase 1   NCT00195143   United States
Sustained-release carbidopa/levodopa
   Jiangsu HengRui Medicine Co., Ltd.
      2024   Phase 3   NCT06596876   China
      2023   Phase 2   NCT06614153   China
Suvecaltamide
   Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
      2023   Phase 2   EUCTR2022-001063-27-PL   Germany;Poland;Spain;United States
      2023   Phase 2   EUCTR2022-001063-27-DE   Germany;Poland;Spain;United States
   Jazz Pharmaceuticals
      2022   Phase 2   NCT05642442   Germany;Poland;Spain;United States
Suvorexant
   Burdick, Daniel, M.D.
      2016   Phase 4   NCT02729714   United States
SYN115
   BIOTIE THERAPIES INC.
      2015   Phase 3   EUCTR2014-005630-60-IT   Austria;Canada;Czech Republic;Germany;Italy;Spain;United States
   Biotie Therapies Inc.
      2015   Phase 3   EUCTR2014-005630-60-ES   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
   Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2015   Phase 3   EUCTR2014-005630-60-CZ   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
   Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2016   Phase 3   EUCTR2014-005630-60-AT   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-005630-60-DE   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
SYN115 tablets, 60 MG
   Biotie Therapies Inc.
      2012   -   EUCTR2011-005054-59-RO   Argentina;Canada;Chile;Romania;Ukraine;United States
SYN120
   Biotie Therapies Inc.
      2014   Phase 2   NCT02258152   United States
Synthetic oxytocin
   Abteilung für Neurologie der Medizinischen Universität Innsbruck
      2019   Phase 2   EUCTR2018-002877-23-AT   Austria
Tacrolimus
   Kyoto University Hospital
      2018   Phase 3   JPRN-jRCT2091220385   Japan
      2018   Phase 3   JPRN-UMIN000033565   Japan
      2018   Phase 1,2   JPRN-UMIN000033564   Japan
Tadalafil
   University of South Florida
      2014   Phase 4   NCT02225548   United States
TAK-071
   Takeda
      2020   Phase 2   NCT04334317   United States
Talampanel
   National Institute of Neurological Disorders and Stroke (NINDS)
      2005   Phase 2   NCT00108667   United States
   Teva Pharmaceutical Industries
      2006   Phase 1/Phase 2   NCT00036296   Canada;United States
Talineuren
   InnoMedica Schweiz AG
      2024   Phase 2   NCT06431971   Switzerland
      2021   Phase 1   NCT04976127   Switzerland
Tampa kinesiophobia scale, BERG-balance test, international physical activity questionnaire-short form, falls efficacy scale
   Istanbul Kültür University
      2018   -   NCT03827746   Turkey
Targinact 10 MG/5 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Targinact 20 MG/10 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Targinact 5 MG/2.5 MG prolonged-release tablets
   Mundipharma Research GmbH & Co. KG
      2012   -   EUCTR2011-002901-31-DE   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-HU   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-GB   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   Phase 3   EUCTR2011-002901-31-ES   Czech Republic;Germany;Hungary;Spain;United Kingdom
      2011   -   EUCTR2011-002901-31-CZ   Czech Republic;Germany;Hungary;Spain;United Kingdom
Tasmar
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
Taste tests
   Centre Hospitalier Universitaire Dijon
      2024   -   NCT06439355   France
Tavapadon
   AbbVie
      2021   Phase 3   NCT04760769   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   NCT04542499   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   NCT04223193   Australia;France;Germany;Hungary;Italy;Korea, Republic of;Poland;Serbia;Spain;Taiwan;Thailand;Ukraine;United States
   Cerevel Therapeutics, LLC
      2022   Phase 1   NCT05610189   United States
      2022   Phase 1   NCT05581823   United States
      2021   Phase 3   EUCTR2019-002952-17-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002952-17-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002951-40-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2021   Phase 3   EUCTR2019-002949-38-BG   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002952-17-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002952-17-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-HU   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-PL   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-DE   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-CZ   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Spain;Ukraine;United States
      2019   Phase 3   NCT04201093   Australia;Bulgaria;Canada;Czechia;France;Germany;Israel;Italy;Poland;Spain;Ukraine;United States
Tavapadon 0.25 MG
   Cerevel Therapeutics LLC
      2021   Phase 3   EUCTR2019-002952-17-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
Tavapadon 0.25MG
   Cerevel Therapeutics LLC
      2020   Phase 3   EUCTR2019-002951-40-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-IT   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
Tavapadon 1MG
   Cerevel Therapeutics LLC
      2021   Phase 3   EUCTR2019-002952-17-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-IT   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
Tavapadon 5 MG
   Cerevel Therapeutics LLC
      2021   Phase 3   EUCTR2019-002952-17-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
Tavapadon 5MG
   Cerevel Therapeutics LLC
      2020   Phase 3   EUCTR2019-002951-40-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-IT   Australia;Bulgaria;Canada;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-IT   Australia;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
   Cerevel Therapeutics, LLC
      2021   Phase 3   EUCTR2019-002952-17-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002951-40-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002950-22-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-HU   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-FR   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
      2020   Phase 3   EUCTR2019-002949-38-ES   Australia;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Poland;Serbia;Spain;Sweden;Ukraine;United States
TB006
   TrueBinding, Inc.
      2025   Phase 2   NCT06773962   United States
TD-9855
   THERAVANCE BIOPHARMA ANTIBIOTICS, INC.
      2019   Phase 3   EUCTR2018-003289-15-IT   Austria;Bulgaria;Canada;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
   Theravance Biopharma
      2016   Phase 2   NCT02705755   United States
   Theravance Biopharma Ireland Limited
      2020   Phase 3   EUCTR2018-003941-41-PT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003941-41-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-PT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2020   Phase 3   EUCTR2018-003289-15-DE   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-IT   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-HU   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-ES   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-EE   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003941-41-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-PL   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-HU   Austria;Bulgaria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-GB   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-ES   Austria;Canada;Czech Republic;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-EE   Australia;Austria;Bulgaria;Canada;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;New Zealand;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-DK   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-BG   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-003289-15-AT   Argentina;Australia;Austria;Bulgaria;Canada;Chile;Czechia;Denmark;Estonia;France;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Poland;Portugal;Russian Federation;Spain;Ukraine;United Kingdom;United States
Technetium (99MTC) exametazime
   IDIBAPS
      2016   Phase 2   EUCTR2015-004238-85-ES   Spain
Telerehabilitation based functional balance and mobility exercise
   Yeditepe University
      2021   -   NCT04694872   Turkey
Telerehabilitation based lsvt BIG exercise protocol
   Yeditepe University
      2021   -   NCT04694872   Turkey
Tenapanor
   Cedar Valley Digestive Health Center
      2025   Phase 2   NCT06460038   United States
Tenofovir disoproxil fumarate
   The Fourth Affiliated Hospital of Zhejiang University School of Medicine
      2024   Phase 1   NCT06356662   China
   The Fourth Affiliated Hospital, Zhejiang University School of Medicine
      2024   -   ChiCTR2500098658   China
Terazosin
   Cedars-Sinai Medical Center
      2020   Phase 2   NCT04386317   United States
   I.R.C.C.S. Fondazione Santa Lucia
      2023   Phase 4   NCT05855577   -
Terazosin 5 MG
   Jordan Schultz
      2019   Phase 1/Phase 2   NCT03905811   United States
Terazosin therapy
   Cedars-Sinai Medical Center
      2022   Phase 2   NCT05109364   United States
Tesofensine
   Boehringer Ingelheim
      2003   Phase 2   NCT00148512   Austria;El Salvador;France;Germany;Netherlands;Spain;United Kingdom
THE conventional balance exercise program
   Kirsehir Ahi Evran Universitesi
      2024   -   NCT06272838   Turkey
THE timed 360° turn test
   Gazi University
      2018   -   NCT03587168   Turkey
THK-5351
   Kagawa University
      2021   -   JPRN-UMIN000043737   Japan
   Nagoya University Department of Neurology
      2015   -   JPRN-UMIN000018496   Japan
THK5351
   Nagoya City Rehabilitation Agency
      2019   -   JPRN-UMIN000036956   Japan
THN02
   Theranexus S.A.
      2018   Phase 2   EUCTR2017-004475-31-HU   Czech Republic;France;Germany;Hungary;United States
      2018   Phase 2   EUCTR2017-004475-31-CZ   Czech Republic;France;Germany;Hungary;United States
THN102 dosage A
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States
THN102 dosage B
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States
THN102 dosage C
   Theranexus
      2018   Phase 2   NCT03624920   Czechia;France;Germany;Hungary;United States
Timed UP and GO test
   Gazi University
      2018   -   NCT03587168   Turkey
Tissue samplings
   Michael J. Fox Foundation for Parkinson's Research
      2015   -   NCT02572713   Canada;United States
TJ0113
   Second Affiliated Hospital, School of Medicine, Zhejiang University
      2024   Phase 2   NCT06596005   China
Tolcapon
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
Tolcapone
   CHU de Poitiers
      2010   -   EUCTR2010-020769-25-FR   France
   Clinical research lab for neurodegeneration, Dept. of Neurology, St. Josef-Hospital, Ruhr-University
      2010   -   EUCTR2009-017416-33-DE   Germany
   Dept of Neuroscience, Uppsala University
      2008   Phase 4   EUCTR2008-003581-26-SE   Sweden
   Uppsala University
      2008   Phase 4   NCT00906828   Sweden
Tolubuterol hydrochloride
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
Topiramate
   Oregon Health and Science University
      2009   -   NCT00794313   United States
   Rush University Medical Center
      2013   Phase 2   NCT01789047   United States
   Salford Royal NHS Foundation Trust
      2008   -   EUCTR2007-002467-27-GB   United Kingdom
   University Health Network, Toronto
      2004   Phase 2   NCT00296959   Canada
TOZ
   Biotie Therapies
      2017   Phase 3   EUCTR2016-003961-25-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
Tozadenant
   BIOTIE THERAPIES INC.
      2015   Phase 3   EUCTR2014-005630-60-IT   Austria;Canada;Czech Republic;Germany;Italy;Spain;United States
   Biotie Therapies
      2017   Phase 3   EUCTR2016-003961-25-HU   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-GB   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-ES   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-DE   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
      2017   Phase 3   EUCTR2016-003961-25-CZ   Australia;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Spain;United Kingdom;United States
   Biotie Therapies Inc.
      2017   Phase 3   NCT03051607   Canada;United Kingdom;United States
      2015   Phase 3   NCT02453386   Austria;Canada;Czech Republic;Czechia;Germany;Italy;Spain;United States
      2015   Phase 3   EUCTR2014-005630-60-ES   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
      2012   -   EUCTR2011-005054-59-RO   Argentina;Canada;Chile;Romania;Ukraine;United States
      2008   Phase 2   NCT00605553   United States
   Biotie Therapies Inc. (a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2015   Phase 3   EUCTR2014-005630-60-CZ   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
   Biotie Therapies Inc.(a wholly owned subsidiary of Acorda Therapeutics Inc.)
      2016   Phase 3   EUCTR2014-005630-60-AT   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
      2015   Phase 3   EUCTR2014-005630-60-DE   Austria;Canada;Czech Republic;European Union;Germany;Spain;United States
Tozadenant (SYN115) 120 MG BID
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
Tozadenant (SYN115) 180 MG BID
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
Tozadenant (SYN115) 240 MG BID
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
Tozadenant (SYN115) 60 MG BID
   Biotie Therapies Inc.
      2011   Phase 2/Phase 3   NCT01283594   Argentina;Canada;Chile;Romania;Ukraine;United States
TR-012001
   Kanazashi Shuichi
      2024   Phase 2   JPRN-jRCT2061230065   -
   SNLD, Ltd.
      2023   Phase 2   NCT06212089   Japan
Transcranial magnetic stimulation
   Anhui Medical University
      2020   -   NCT06365190   China
   Gansu Provincial Hospital
      2020   Phase 0   ChiCTR2000035872   China
Transdermal nicotine
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT00873392   France
Traxoprodil
   Pfizer
      2005   Phase 2   NCT00163085   United States
Trehalose
   Neuromed IRCCS
      2022   Phase 4   NCT05355064   -
Tributyrin
   Nicolaas Bohnen, MD, PhD
      2022   Phase 1   NCT05446168   United States
Trigel
   LobSor Pharmaceuticals AB
      2015   Phase 1   NCT02448914   Sweden
Trihexyphenidyl
   University of Florida
      2014   -   NCT02046447   United States
Trimethobenzamide
   MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
      2012   Phase 4   NCT01770145   United States
Trimethobenzamide hydrochloride
   Pfizer
      2015   Phase 1   NCT02373072   Belgium;United States
Trivastal
   Institut de Recherches Internationales Servier (I.R.I.S.)
      2005   -   EUCTR2005-002010-38-DE   Germany
TRN501 - dose 1
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 2
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 3
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 4
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 5
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 6
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 7
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
TRN501 - dose 8
   SNLD, Ltd.
      2024   Phase 1   NCT06453551   Japan
Trunk impairment scale
   Gazi University
      2018   -   NCT03587168   Turkey
Tryptophan (TRP) depletion
   Maastricht University Medical Center
      2015   -   NCT02632279   Netherlands
Tulobuterol hydrochloride
   CuraSen Therapeutics, Inc.
      2020   Phase 2   EUCTR2020-003796-17-GB   United Kingdom
TVP-1012
   TEVA
      2005   -   EUCTR2005-001416-42-IT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
   TEVA Pharmaceuticals Industries Ltd
      2006   Phase 4   EUCTR2006-005140-89-NL   Netherlands
   Takeda
      2015   Phase 3   NCT02337725   Japan
   Takeda Pharmaceutical Company Limited
      2015   Phase 3   JPRN-jRCT2080222710   Japan
   Teva Pharmaceutical Industries Ltd
      2009   -   EUCTR2009-011541-24-PT   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-NL   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-HU   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   Phase 4   EUCTR2009-011541-24-GB   Argentina;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Portugal;Romania;Spain;United Kingdom;United States
      2009   Phase 4   EUCTR2009-011541-24-FR   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
      2009   -   EUCTR2009-011541-24-DE   France;Germany;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom
   Teva Pharmaceuticals Industries LtD
      2005   -   EUCTR2005-001416-42-PT   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-HU   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-GB   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   Phase 3   EUCTR2005-001416-42-ES   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-DE   Germany;Hungary;Italy;Portugal;Spain;United Kingdom
      2005   -   EUCTR2005-001416-42-AT   Austria;Germany;Hungary;Italy;Portugal;Spain;United Kingdom
TVP-1012 0.5MG
   Takeda
      2015   Phase 2/Phase 3   NCT02337738   Japan
TVP-1012 1MG
   Takeda
      2015   Phase 3   NCT02337764   Japan
      2015   Phase 3   NCT02337751   Japan
      2015   Phase 2/Phase 3   NCT02337738   Japan
Tyramine
   Teva Pharmaceutical Industries
      2000   Phase 3   NCT00203125   United States
Tyrosine
   New York Institute of Technology
      2012   Phase 1/Phase 2   NCT01676103   United States
UB-312
   United Neuroscience Ltd.
      2019   Phase 1   NCT04075318   Netherlands
UB-312 injection
   NYU Langone Health
      2023   Phase 1/Phase 2   NCT05634876   United States
Ubiquinol
   Weill Medical College of Cornell University
      2012   Phase 2   NCT03061513   -
UCB0022
   UCB Biopharma SRL
      2023   Phase 2   NCT06055985   United States
      2021   Phase 1   NCT04867642   United Kingdom
UCB0599
   UCB Biopharma S.P.R.L.
      2019   Phase 1   NCT04875962   United States
   UCB Biopharma SRL
      2022   Phase 2   NCT05543252   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-PL   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-NL   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-IT   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-FR   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-ES   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003265-19-DE   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
      2020   Phase 2   NCT04658186   Canada;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
UCB7853
   UCB Biopharma SRL
      2020   Phase 1   NCT04651153   Netherlands;United Kingdom
Umbilical cord blood therapy
   MinYoung Kim, M.D.
      2014   -   NCT02236065   Korea, Republic of
Unified parkinson'S disease rating scale
   Gazi University
      2018   -   NCT03587168   Turkey
Upper limb exercise
   The Hong Kong Polytechnic University
      2018   -   NCT04048291   Hong Kong
Urate
   Ehime University Graduate School of Medicine
      2016   Phase 2   JPRN-UMIN000020527   Japan
   Nagai Masahiro
      2016   Phase 2   JPRN-jRCTs061180060   -
Ursodeoxycholic acid
   Sheffield Teaching Hospitals NHS Foundation Trust
      2018   Phase 2   EUCTR2018-001887-46-GB   United Kingdom
   University of Minnesota
      2020   Phase 1   NCT02967250   United States
Ursonorm
   Sheffield Teaching Hospitals NHS Foundation Trust
      2018   Phase 2   NCT03840005   United Kingdom
      2018   Phase 2   EUCTR2018-001887-46-GB   United Kingdom
Usual care ARM exercise
   University of Nevada, Las Vegas
      2014   Phase 2   NCT02230267   United States
Usual dopaminergic PER OS treatment
   Rennes University Hospital
      2009   Phase 3   NCT01039090   France
Usual drug treatment OF parkinson'S disease
   Assistance Publique - Hôpitaux de Paris
      2009   Phase 2   NCT00873392   France
UX-DA001
   Shanghai UniXell Biotechnology Co., Ltd
      2025   Phase 1   NCT06778265   China
V1512 and entacapone
   Vernalis (R&D) Ltd
      2006   Phase 1/Phase 2   NCT00491998   Italy
V81444
   Vernalis (R&D) Ltd
      2012   Phase 1   NCT02764892   -
      2011   Phase 1   NCT01634568   United Kingdom
Valerian
   National Center for Complementary and Integrative Health (NCCIH)
      2000   Phase 2   NCT00070928   United States
Valiloxybate
   XWPharma
      2021   Phase 2   NCT05056194   -
Varenicline
   Rush University Medical Center
      2010   Phase 2   NCT01341080   United States
   University of Michigan
      2017   Phase 2   NCT04403399   United States
      2015   Phase 2   NCT02933372   -
   VU University Medical Center
      2013   Phase 4   NCT02473562   Netherlands
   Vikas Kotagal
      2025   Phase 2   NCT06679374   United States
Varenicline tartrate
   VU University Medical Center
      2012   Phase 3   EUCTR2012-001530-34-NL   Netherlands
Variation OF behaviors OF parkinson'S disease
   Centre Hospitalier Universitaire, Amiens
      2018   Phase 3   NCT03146130   France
Vehicle
   Neuraly, Inc.
      2020   Phase 2   NCT04154072   Canada;United States
Venglustat GZ/SAR402671
   Genzyme, a Sanofi Company
      2016   Phase 2   NCT02906020   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Venglustat malate
   Genzyme Corporation
      2018   Phase 2   EUCTR2016-000657-12-AT   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-PT   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2017   Phase 2   EUCTR2016-000657-12-DE   Australia;Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
      2016   Phase 2   EUCTR2016-000657-12-SE   Austria;Canada;France;Germany;Greece;Israel;Italy;Japan;Norway;Portugal;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States
Venlafaxine
   The Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine
      2014   Phase 2 study   ChiCTR-TRC-14005143   China
   University of Rochester
      2005   Phase 3   NCT00086190   Canada;Puerto Rico;United States
VENT-02
   Ventus Therapeutics U.S., Inc.
      2025   Phase 1/Phase 2   NCT06822517   United States
VGN-R09B
   Shanghai Vitalgen BioPharma Co., Ltd.
      2024   Phase 1/Phase 2   NCT06480461   -
Videofluoroscopic swallow evaluation
   University of Florida
      2015   Phase 1   NCT02390089   United States
Vildagliptin 50 MG BID
   First Affiliated Hospital, Sun Yat-Sen University
      2025   -   NCT06951334   -
Vineuro
   Hospital Authority, Hong Kong
      2005   -   NCT00517842   China
Virtual reality
   Ahram Canadian University
      2023   -   NCT05931692   Egypt
   The Second Hospital of Dalian Medical University
      2023   -   ChiCTR2300067399   China
Visual biofeedback therapy
   Ziauddin University
      2022   -   NCT05325541   Pakistan
Vitamin B12
   Oregon Health and Science University
      2024   -   NCT06772220   United States
Vitamin B12 supplementation
   Emory University
      2006   Phase 2/Phase 3   NCT00208611   United States
Vitamin B6 25 MG
   Oregon Health and Science University
      2024   -   NCT06772220   United States
Vitamin D
   Suzhou Municipal Hospital of Anhui Province
      2023   Early Phase 1   NCT06539260   China
Vitamin D3
   Jikei University School of Medicine
      2009   -   JPRN-UMIN000001841   Japan
   Memorial Medical Center
      2009   Phase 2   NCT00907972   United States
   VA Office of Research and Development
      2011   Phase 2   NCT01119131   United States
Vitamin D3 - high dose
   Emory University
      2007   Phase 4   NCT00571285   United States
Viusid/alzer
   Catalysis SL
      2009   Phase 3   NCT01016470   Cuba
Voice, speech and language analysis
   University of Massachusetts, Worcester
      2020   -   NCT04273672   United States
Voluntary cough test
   University of Florida
      2014   Phase 1/Phase 2   NCT02183519   United States
Vortioxetina bromidrato
   IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
      -   Phase 4   EUCTR2018-004112-21-IT   Italy
Vortioxetine
   IRCCS San Raffaele Roma
      2019   Phase 4   NCT04301492   Italy
   Marianna Amboni
      2025   Phase 4   NCT06805266   -
VR040
   Vectura Group plc
      2006   Phase 2   EUCTR2006-005509-79-GB   United Kingdom
      2006   Phase 2   EUCTR2006-004582-33-GB   United Kingdom
      2005   Phase 2   EUCTR2005-005120-13-GB   United Kingdom
   Vectura Limited
      2009   -   EUCTR2008-004447-11-GB   Germany;Italy;United Kingdom
      -   -   EUCTR2008-004447-11-DE   Germany;Italy;United Kingdom
VR040/aspirair® inhaler
   South Glasgow University Hospitals NHS Trust
      2007   Phase 2   NCT01693081   Serbia;United Kingdom
VTX3232
   Zomagen Biosciences Ltd.
      2024   Phase 2   NCT06556173   United States
Vutiglabridin
   Glaceum
      2024   Phase 2   NCT06329141   Korea, Republic of
VY-AADC01
   Neurocrine Biosciences
      2017   Phase 1   NCT03065192   United States
      2013   Phase 1   NCT01973543   United States
VY-AADC02
   Neurocrine Biosciences
      2018   Phase 1   NCT03562494   United States
   Voyager Therapeutics, Inc.
      2019   Phase 2   EUCTR2017-004685-10-PL   Poland;United States
Warfarin
   Bial - Portela C S.A.
      2014   Phase 1   NCT02305030   -
      2009   Phase 1   NCT02169440   Portugal
Water
   Beijing Luhe Hospital Affiliated to Capital Medical University
      2024   Phase 0   ChiCTR2400092087   China
   Chengdu Sport University
      2024   -   ChiCTR2400088282   China
   Department of Neurology, Juntendo University School of Medicine
      2010   -   JPRN-UMIN000007497   Japan
   Juntendo University Koshigaya Hospital
      2015   -   JPRN-UMIN000019090   Japan
   Juntendo University School of Medicine, Neurology
      2013   -   JPRN-UMIN000010014   Japan
   Kaida Wang
      2019   Phase 0   ChiCTR1900025894   China
   Nagoya graduate school of medicine university
      2015   -   JPRN-UMIN000019654   Japan
   National Center of Neurology and Psychiatry
      2023   -   JPRN-UMIN000051942   Japan
      2023   -   JPRN-UMIN000051163   Japan
   the Affiliated Hospital of Hangzhou Normal University
      2024   Phase 0   ChiCTR2400084209   China
WD-1603
   Hong Kong WD Pharmaceutical Co., Limited
      2020   Phase 1   NCT04553978   -
WD-1603 carbidopa and levodopa extended-release tablets
   Hong Kong WD Pharmaceutical Co., Limited
      2020   Phase 1   NCT04513340   India
WD-1603 carbidopa-levodopa extended-release tablets
   Shanghai WD Pharmaceutical Co., Ltd.
      2021   Phase 1   NCT05128175   India
      2021   Phase 2   NCT05036473   China
WD-1603 carbidopa/levodopa extended-release tablets
   Hong Kong WD Pharmaceutical Co., Limited
      2020   Phase 1   NCT04591535   India
Weancare-domus
   Milko Zanini
      2021   -   NCT04983290   Italy
Whey protein
   Chulalongkorn University
      2011   Phase 4   NCT01662414   Thailand
Whey protein supplement
   UConn Health
      2025   Early Phase 1   NCT06954662   United States
Whole exome sequencing
   Neuromed IRCCS
      2025   -   NCT06803784   Italy
Whole genome sequencing
   Neuromed IRCCS
      2025   -   NCT06803784   Italy
      2023   -   NCT05721911   Italy
WIN-1001X
   Medi Help Line
      2020   Phase 2   NCT04220762   Korea, Republic of
Wuling powder
   Beijing Hospital
      2017   Phase 4   NCT03195231   -
Xadago
   Institut de Recerca Hospital de la Santa Creu i Sant Pau
      2017   Phase 4   EUCTR2017-003254-17-ES   Spain
   Supernus Pharmaceuticals, Inc.
      2017   -   NCT03944785   United States
   ZAMBON SPA
      2019   Phase 4   EUCTR2017-002426-20-IT   Austria;France;Germany;Italy;Spain
      2015   Phase 3   EUCTR2014-002600-24-IT   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
   Zambon S.P.A.
      2015   Phase 3   EUCTR2014-002600-24-SE   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-GB   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-ES   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
      2015   Phase 3   EUCTR2014-002600-24-AT   Austria;France;Germany;Italy;Russian Federation;Spain;Sweden;Switzerland;United Kingdom
   Zambon SpA
      2019   Phase 4   EUCTR2017-002426-20-FR   Austria;France;Spain
      2019   Phase 4   EUCTR2017-002426-20-AT   Austria;Spain
      2018   Phase 4   EUCTR2017-002426-20-ES   Austria;France;Italy;Spain
Xadago - 100 MG- compressa rivestita CON FILM- USO orale- blister (PVC/pvdc/alluminio)- 30 compresse
   OSPEDALE SANTA MARIA DELLA MISERICORDIA
      2021   Phase 3   EUCTR2018-004892-11-IT   Italy
Xadago - 50 MG- compressa rivestita CON FILM- USO orale- blister (PVC/pvdc/alluminio)- 30 compresse
   I.R.C.C.S. FONDAZIONE S.LUCIA
      2018   Phase 4   EUCTR2017-002239-41-IT   Italy
   IRCCS SAN RAFFAELE PISANA GESTITO DA SAN RAFFAELE ROMA SRL
      -   Phase 4   EUCTR2016-000973-19-IT   Italy
   OSPEDALE SANTA MARIA DELLA MISERICORDIA
      2021   Phase 3   EUCTR2018-004892-11-IT   Italy
Xadago 50MG
   I.R.C.C.S. FONDAZIONE S.LUCIA
      2018   Phase 4   EUCTR2017-002239-41-IT   Italy
XC130-A10H
   Xoc Pharmaceuticals
      2019   Phase 1   NCT04043338   United States
Xeomin
   Merz Pharmaceuticals GmbH
      2014   Phase 3   EUCTR2012-005539-10-DE   Germany;Poland;United States
Xiaoyao pill
   Xuanwu Hospital, Beijing
      2008   Phase 2   NCT01416818   China
XP21279
   XenoPort, Inc.
      2010   Phase 2   NCT01171313   United States
      2009   Phase 1/Phase 2   NCT00914602   United States
Yohimbine HCL
   Nathaniel M. Robbins
      2021   Early Phase 1   NCT04346394   United States
Zelapar
   Baylor College of Medicine
      2007   Phase 4   NCT00640159   United States
   Parkinson's Disease and Movement Disorder Center of Boca Raton
      2007   Phase 4   NCT00443872   United States
Zoledronic acid
   Department of Orthopaedic Surgery, Niigata University Medical and Dental Hospital
      2018   -   JPRN-UMIN000033285   Japan
Zoledronic acid 5MG/BAG 100ML INJ
   California Pacific Medical Center Research Institute
      2019   Phase 4   NCT03924414   United States
Zolmitriptan
   Contera Pharma
      2023   Phase 2   EUCTR2022-002818-16-IT   France;Germany;Italy;Korea, Republic of;Spain
      2020   Phase 2   EUCTR2017-003415-19-IT   France;Germany;Italy;Spain
      2018   Phase 2   EUCTR2017-003415-19-ES   France;Germany;Spain
   Contera Pharma A/S
      2023   Phase 2   EUCTR2017-003415-19-SK   France;Germany;Italy;Korea, Republic of;Slovakia;Spain
      2022   Phase 2   EUCTR2022-002818-16-FR   France;Germany;Italy;Korea, Republic of;Spain
Zolpidem
   Aston University
      2018   Phase 2   NCT03621046   United Kingdom
Zolpidem first dose
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States
Zolpidem second dose
   Rush University Medical Center
      2011   Phase 2   NCT01351168   United States
Zolpidem tartrate
   Aston University
      2018   Phase 2   EUCTR2017-004297-34-GB   United Kingdom
Zonegran
   The Cooper Health System
      2016   Phase 4   NCT03034538   United States
Zonisamide
   Dainippon Sumitomo Pharma Co., Ltd.
      2010   Phase 3   JPRN-jRCT2080221162   -
      2007   Phase 3   JPRN-jRCT2080220368   -
      2005   -   JPRN-jRCT2080220097   -
   Department of Neurology, University of Yamanashi
      2013   -   JPRN-UMIN000010371   Japan
   Hamamatsu University School of Medicine
      2015   -   JPRN-UMIN000019524   Japan
   Hiroshi Kataoka
      2021   Phase 2-3   JPRN-jRCTs051200160   -
   Ito Hidefumi
      2016   Phase 2   JPRN-jRCTs051180098   -
   Katsuno Masahisa
      2021   Phase 2   JPRN-jRCTs041190126   -
   Mazandaran University of Medical Sciences
      2013   Phase 2/Phase 3   NCT01766128   -
   Medical Corporation Abe Neurology Clinic
      2016   -   JPRN-UMIN000024859   Japan
   Osaka Redcross Hospital Wakayama Prefectural Medical College
      2016   Phase 2   JPRN-UMIN000022533   Japan
   Ouchi Yasuomi
      2015   -   JPRN-jRCTs041180070   -
Zonisamide capsules
   Ain Shams University
      2020   -   NCT04182399   Egypt